var title_f7_62_8160="Posterior vaginal wall prolapse 9";
var content_f7_62_8160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 346px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFaAbwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKQD1paACiiigAooooAKKxv7cid7iOJd8sTFSoNZUniG/WZkazQMo3bQ2TigDrqK5rR/FlreTC3uY5bW4zjbKMAn2NdLQAyeVYYZJXzsRSxx6CsSTxXpcenreNJJ5BG7OznH0rXvhusrgesbD9K8mugH8DzM3VAVGPrQB65bzJcQRzRHKSKGU+xqSsnwo5k8N6ax6mFf5VrUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFV0vIHmkiDjzE+8pp91L5FtJKRkIMkV5HrXiV/wDhMpRCPLQxDPvQB60LqHzli8xd7DIGetT147beIiNa06UtnbMF69jXsIIIBHIoAWiiigAooooAKKKzdb1zTtFt/N1K6jhB+6pOWb2A6mgDSrJ8Qam2mQK6ruLZ4rn/APhJdb1cMPD2iyRxcYub4+WuPUL1Nc/r9lrt8sh1HXUVY22tFaRYGcepoA56w8Sma9v5iNheUkiuh8J6tb3PiCU3MqKrQYBZsDivHF09Xnuy8k7bZSv38Z/Kp7Sxb+0rWK2VjuySruTu9qAPeNXisrhCjXVtg8qRKMg+tW/CniEPcPpl/NGZ4h8km8fOvY1x3gnR9C1gSJc6cFuYjtkQyHKmrfiDwZpUO5ra1dHQ7gVlYEj0oA9Nu5YzaT4dT8jdD7V5Nc5TwHcFhwWb+dbdp4O0a+0F7y1n1GJvKY4F0xwQOlcPq2kS2vgsSQateAN1jbBU80Aez+EePDOm8Y/cLxWvmvPdD0/xhZ6LaNZalY3MflKVjnjKkDHTIq83iHxFp0anVPDzzDu9nKH/APHetAHaUVi2/iTT5bk28rvb3AiEzJMpXap9T0rXiljlQNE6upGQVOcigB9FFFABWVJrNuuptZhstGuXbsCego8UaxFoeiXN9MQNi/KPVuwrxbTdekaV5ZXJlmcu5z3NAHuxvIBszIuXOFGetWK8r8B6pHqviK4luZSVtl2xqTxmvUxyAR0oAWiiigAooNFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJ0EkLowyCCK+fPiFCbbXLO4GUGTExFfQ1eL/F6xYJLJjHlyiQEehoA8/klm3bkY7lIYH6V9J+Fr9dS8P2F2pz5kS5+vSvBbex8+JJQuA4r1f4U3DDRprFxhraQ4/wB08igDuKKKKACiikdgiMzHCqMk+1AHMeL/ABDNp8kGm6PCLnWbviKPtGO7t7CmeH/B9vaT/b9YkOpas/LTzchT6KOwqn8PoRqN5qfiKf5prqZoos/wRqcAD+ddjczLBEzscAUAZPiTVRp9sI4Bm4kOyNB61zV/btBp0KudzMxLn1Y1LZCTWNZkvZAfLQ7IQfTuan8TSKPIgXs3NAHjWl2hnutRGM4mNbmh2Ah1+xd1+XcV59xUng218/U9SXH8Zz+dbmu232CzjulHMcqmgCvHJ9g8WfabXKl12uB3x3r0G7ljvbOK4hwwZc15No10NQ8aOBJ+6hiKjB4JPWu38KSS20txZTPuRW3KD6GgBst0+habfBWLQTowx/cY8DH51heJ4vL8Lafak4aUoprc8YJttVtl63Eqov55rI8RA3viLRLCIFsSqxHsOtAHrOnoIrC2jH8Maj9KsUgGAAOgpaAK91Z291G8dxDHIrjawYdR6Vlt4eiinaaxnltnbYpCn5dq9gO1blFACAYApSR3orn/ABjqb2OnGC25u7j5IwO3qaAPMfinrb61qv2K2Y/YrQ4JHR3/APrVwUzPbRMy5MjfKg9zXcz6R5aYOTjkse57msDSbAap4i6ZtrXr6E0Ad38LvD/kQReYPmP72U+p7CvVsVleHLH7Fp6hgBI/zN/hWrQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVzvibWWtIjDZFTdn7uegPvQB0VFc14T8TLqwa1vU+zalF9+In73uvqK6WgAooooAKKKKACiiigArz74n2TTW0xwCHhP5ivQa53xpbCayjY9m2/gRQB5p4Ji+26MpZMNEdn1rsPDif2d4hiOGCXMZQ46bh0rmfhxPHFBe20nBjc9frXSalfRRJDNG4DwyqwPt0NAHf0UyGQSRI6nKsAQafQAVW1QFtMuwv3jC4H/fJqzQQCMHkGgDkvhcynwXZ46ruDfXPNL4lvjMfssJJZ+OPSsrwtdjSBrujy4VrSdpUz/EjHOam0VTdzvezDC5+UH0oA2LNU06wBIG/HArjNRvjc6vEuf4jmui1OV5kdlyEWuRVQLtZSehJoAqfDx1j1XVDIcAu+Pzro/F3kXPhy9jJz8ucA+9ec6PeSRLPPGT+8lfH0zVnUNWnNjMDkjbQBUnIsL6zubSHyeRuA53CvQvPEN1a3qco6gNjuDXL6k9vdaPCxwsgQOC3Fauk3KTaLEc5Qcj2FAHQeICt3rukxIwKwoZ2/pWBot2lx8SY5cZigUgn0zxTLW/ZNNvtUlbiX9zBnso71V8MRPa+H77V5hj7VL+7f0AoA9vqnPNhsA1V0rUku9Ht7gMCWQZ+tQ7zJLQBsQMWTmpKjtxiMVJQA2WRY42dzhFBJPoK4lG/tO7m1CQ5D/JCp/hT1/GoPif4i+xwx6VbMfOn+aUj+FP8A69czpXiHYFQ8KOAKALnjqddN0dyn+tl+VcCpvhnoPlxQ+agyf30p/kK53U7o+IfEtvD1t4B5j46cdB+NeweHLIWenqSMSSfMf6CgDVAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAZOrPC6xtscjAb0NeS61e3ej6rLFrMJBkP7u4H3WH9K9dqlq+l2urWT2t9EskTjHI5HuKAPA9Z1R/tKzQyNHMhykinBFdx4H+JK3DR2PiDEc33UuR91/r6GuQ8Y+ELvQLhigaewJyrjlkFY9haLKB0dDQB9LI6yIHRgynkEHINOryfwpqeo6MqpGWubIdYWPzL/un+lel6VqdtqcAktnyf4kPDKfQigC7RRRQAUUUUAFZniSIy6TNjgrhh+dadVdVXfp1wv8AsGgDwCC6ew1nV4Y+02fwNPub+4nideTkYrQtNMN34i1LC5DMpPHtW9B4cPGUoA7rwPf/ANo+GLKbGGCbGHuOK3q5HwNAdOlvNPYnGRKgPYGuuoAKDRUc0qRRlnYKB6nFAHmPxHKaf4isNUDFYn/0e9A/55k8MfpXT2EH2zalvxaLjDj+P6e1cxdy2Ou6xfSahcRLpwBiKlvv0eEfGFnoizaFdvJcvan/AEOSNc+dF2H1HSgDqPE222tREgxx2rgb6QxuABkiNnIB5HFHi7xTealIQiDT7cDq3MjfQVznh20n1PWVWBpQuQsrs2Wb2oA3PD/h1m0qJ9p+bmrlz4aYwSjafunt7V6lZ2Vtb2sUI2/IoWpWtoGUgbeQRQB5O2kmTRrYuq7tgAdecfWsSO6uYQ2kCPF7O22MqONp6tS2000F9c2Yu5LTEzhC/wA0bc9Parltpeqrey3iz2kszJ5auQfkHtQBQ8X3McaWuk2zfJGFiJHqepr06e1sf+EXg06Iq0KwhOO/HWvK10nUba/muLq0NzMRiMowKjPU1uaONbYbJPKtYkGAXO44/CgC5oF7caNIunSktAD+7Y+npXo+lqsqLKWXB9688bSIrlt2oT3Fw45UINoFOi09Vc7PPSMd3uCoFAHrCkEfKQaraleR2NlLcSnhBwPU9hXk9xfrpGXj1iSJh2WXzP0rZ8H6xc+JbvN7cxz6fbHIbbtLv6Ee1AGTquj3N5cS3t2Cbic7iD/COwrnLzTpLYM/3QvOa90uLOG4BIwc1xHj/S44dIc4ALtigDn/AIV6UbqQ3MqnM8hck/3F6V7IBgADtXM+A9PSz0hGTBBAVT7CunoAKKKKACiiigAooooAKKKKACg1m6xrdhpEJe9nVT2Qcsfwryjxf8QtTvd0GkqbK2PBkbmRh7elAHp2ueJdO0gbJpg854WFDliaNC1htQXdMixM33UByQPevnzTrl1uvMd3klY5Z3OSfxrrNP8AFbQXEVtYfvbliBkcgUAe5UVS0jz/ALFG11IJJWGSR0FXaACiiigAooooAKKKKACiiigCve2kV5btDcKGRh3ryvxH4Tl0i8Nzp4GxjnZ/C3+Br1yobq3juoGimUMjdqAPNfDk0F6mE+SZOHjPUGte6hWAi5t5Tb3S9HXo3sR3rJ8TaFdaVei908nzF5BH/LQeh96xr7xKL213D5JBw6ehoA77w94utr64+xXzLBfDgAn5ZPdTXRX97bWFu013MkUY7scV8/LG97cBjuyDlSOoPtXSNFqXk/ab9JtUijHy5OWj/DvQB2tx4zDhjp1lLLGOkr/Kp/Osifxnqe7aFs4s/wC0SRXFpcz6ruM90Y41OBFHxj60DS7bOd0jN6ljQB1y+ItZlbFvdxMfdMCpJtd1owPHJdWxYghgR0FcTParGp278ezmsGS4thdxpO8kSFxudmOKAPVPhlpjZvbq7l813O0se/piu9CW0fUrXkVt4507T7NYI7yIY5ODVSX4gwzEiCV5D/sKTQB6B4u1KXS7qyvtLjhlct5Mgc44PSs0+I9cuFYl7e3PYIN1cBe6zqerhYreCWFA4bzpRjGPQU+W/wBTaTa98+30QAUAdzNeanNGBLf3BY/3V2isa8jhYN/aGpylTxtabP6VjR75MG5nuJB/tOcVajihQ7kiTPqRmgBC2k2xC2Fu9x9FP9apawLu/ihNpax2V1bt5kE7H5gfT6GtNmPBXgGmThtuR1oA5uCT+0baadi39oqSsok6o/sPSk0TxhaeHkWGeGaKZerlcgnuatazYy25Go2X/H2q4lj7TL6fX0rOhezvYEm2B0bqCOVPoaAOjT4n2JH/AB94+oIqX/hZlkmGa8UjrxzXMSWGnOD/AKKh/Cqb6dYo2Ut0B/3aANnRtQXV57yaRN0MshZQw7etaaWUseTYXU0B9M7l/KsjSGVJFRRtBHSuvsY9yZIoAzEutbiGPtsLAdmSkm1HVjjzbqAY9Fq9qKbFzjFYdzk/jQBNJrGogEHUmA/2FxWTdXT3Dfvp5pvZm4pLiNu3FPtbJ5GGRgUAVyrGNgiDJHpR4e8TTaCBZ3cbRxqxKyqODn1roIrVY0wBzUTW1nOSlwgx03GgDstC8aJKikSq6+xq340v4dW8POqsN4B4zXk2p+G5LdvN0m4KseflOKbpt/4iiVoLmKKdOxbg0AdL4X8T6jaW8cC6n5CqNqxyplePQ13Nt4n1gRhvLs7pfVHwTXlVnE1pa+VchZHckkEZAq5ZmeOUf2bO0LH+BuVNAHrNv40+YC8025h9WA3D9K0LXxdo87hPtQjb0kG3+deXx6vqsICXVpHLjq0TYNStrmnSrsukliJ6iVNw/OgD2eGaOZA8Tq6noVOafXj1heW0Y36Xqn2Z/RX4/I1v2PjW6sXRNXiS4tzx9pg7fUUAehUVnwaxp89kLuK6iaDGdwauV8Q+MblI2TR7Ukf895RgfgO9AHX6jqNrp0Pm3cyxr2yeT9BXPXesX+oIfsK/Zbc/8tXHzH6CvLBqV1Pqf2jUp3uJs8F+i/Qdq73S9Tie13zyBUA5JoAydS01QzOxeWU9XkOSa4jXjBbE+Y2WPRRyTXQeIPEc2pXTWOhRFz0aQdvxqbwz4JknuBPdD7TcE5LN9xP8aAOP0vQdQ1hlYg2lmT/wJq9V8J+B4bOFCI/JXu7D52/wrrdJ0O3sVVmUSSj+IjgfQVr0ARW8CW8Sxx/dUYqWiigAooooAKKKKACiiigAooooAKKKKAIrq3juYGimUMjCvFPiNo6aJqMdzG2ZJTgxr/Gv94+hFe4V5X4q26j4kvmmTcLdBFGD0z1NAGf4TsUvEWWPBHevTtJsVgjBIxxXkfw81Q6d4gNrKweKTt6ew+lesa5qsdlbsFIzigDivH2iWId7vTStvedWUcLJ/ga4rS74zxgsDjO0+xFR+NfEk1zcmysm3XMnH+4PU1Jp1kLDT4Yz8zEfNn1oA1T93nkVSuNPtbgNvjU565FXYBtGOqmnSwkfMnSgDn4vDmnCbc9upHpitO1NnZtsgt0X0+WraLxmmz2quNwFAFmaY3MWCAPpVKKyQyc9TUtpmM+W/I7GrXlncMUAVhDs3Rn0yKIuRitCSEsqv3HBqKODa/45oASC3Mij2NXIbPd9/tU8e2M0k94qIzCgDE1+JVSIqcFmIx7VxepJ9hvTewqfIcgXKDp/viut1NmecbznaucelYtxt2sjLuDcMD3FACBVKjYQQRkEdxUDx8k/hVbR2aCWawcn9380JPdD/hWkYmPA7UAVISYplOehru9Fm8+2aMEfJ831ri5YvlPrV7Q71o5ghbBHFAHT6pHujBHpWFJFlgK3XmEsI7msyQBST3oAoi3EkmCOFq9BAFGe5p1vHlRjvyauLFwKAKxj3DHrUNxaLIAoGFHWtDZjJxVacnG1enc0AZzAxtshPHc1FM5XgHLVbdRGnuegqGOEs2AOT1PpQBQMRLF35NVZW2txxWvdIEQ4Hyj9ayZY2BLuOT0FADor2eJg6yMCPU5p0uoSTOWcKc9scVU8tnPtS4C8Dk0AXUaGQgSQRk/SopAsmoQWVoWikkGS284UeuO9MjbaQT1qj4ghntzb6pZ5LwNlgO47igD2vwV4b0y1txIWa5uWHzs/3SfUL0q34j00SKxC/lXJeAvEiXEULo+UYfl7V6NqNzbrpr3MzDy1GT7+1AHiuvWq2jtI52qOcmqWlW+oa9tWMvBp+cb8fNJ/uiti2t/+Ev8AEksTqTbxHKxL0f6+wr1vRNDt9NjUhVaUDGccL7CgDC8M+D4LO2QPH5UfXYPvN/vGuxhijhQJEgRB0AFPooAKKKKACiiigAooooAKKKKACiikDA9CDQAtFFFABRRRQAV5ZqZxq2qMeAt0ufpivU6858U2/k65fxYwLmITJ/vL1oA8y1RpNI8XrLFgQCba5/uhu9afi3xVLKotbE+fc42lhyq+9EqLd6pfhk3LhS4aiPTIYObZVjPXGODQBneGdCMYN5eMWlbkk9Sa2n3LIT95fSq0xmQgnJA7DpUsE24ZA+ooAvW5VhgcVOvBx2qsI8jfEefSrMDeZweHFAEgg5DAcGpvs+BjHBqWLhcGrMa5TFAGb9lOcEcjkVbRV2c4yKssnyhsVm3btHJuyAmMZPegCyJUKEDFUpHOcjtwaoW9wROyk8dqnD7t9AFl5CV69qoXbkxtg9KfLcLGpJIwBWPc6pBFE5kcYoAlmlCQFnPJ4Ge9Zu1pH55Hesy71RJAZ5ZFSNeFBPAqudXWA7ncBf7xPFAG3qVt9mFnqKg/uZBG4HdW4/nW26xo5jX5j1z61yd3rq3mnT27HaGQ8+/am2WuBIIDI+W2AZ9cUAdJcxAZ4xWNMWt5llXsefpUM+vQso3Ek/WqY1eGdioIx65oA7SxvN8Y54IptzLhyM+1cjFq/wBk4P3exqddfgmkBZx+dAHZ27/L+lXg/H6VzmnahFLgo4PetL7UNwFAG3GqupDcA9/SqVxF1x90d6WOf5QM1YjCysFJwnc0AYxiaSTJ4FW0jVI8YwP51rG0UZPbt71TmhZSWI47UAZ8sAY7m6DoKz7i2LMc8Ctlx1z1/lVC5G87V6d6AMeVAflj6DqaqyKEyT0FbUkGBgCsy8QDI6mgDO3s7Z6D0re0YxTwS2txgh1wM9jWE+UBY9KjjvGSQFM8UAKjT+E9YLkMdPkb5gP+WZ9a7fxV4l3+Go44pMrIAIyD99m6flWDJJ/a1uFutpUDBBHWs630NIp4R50jwRNujjY5CH2oA7Xwhbv/AGPbXdrJ9m1FBw/Tfj+Fh3r1Hw5qg1fTI7grslBKSp/dYda8l0m4aG7mtnckSASxfUdRXbeCbnZrN3b4wJ41mA9D0NAHcUUUUAFFFVrm/tLZSbi5hjA67nFAFmiuV1Hx94esiym+Ezj+GEbjWfF48F9xp1i+T0aVgB+VAHdUVW0+Zri1jkk27yOdvSrNABRRRQBHOQImJ9K8o8U3M0E7tbXdzCc5wj8V6XrNhJqFq0UVy8DEY3LXn+ueCNQhs5Hi1JZyBnbKvX8aAOKXxt4itJNkWo7lH/PRc1t6T4+8QtIPOa2lHoVxXG3Ok6vas7XOmmQA/ehbPH0qTTtRht5MXUU0GP8AnouKAPW7Lxbq0xXNlAynrtetpfEM6x7pdOl4/ukGuB0HXdLljUi5VfXdxXVvcwvZloZUcEcYNAFgePtJjcpeCa2Yf30NZHi3XdG1SyS7sbtGu7U7lGMFlPUVw+vzGS5K5PWtfwtaI7qWjU/UZoA559Vgi165DMAksQ61o/aIn2sjqw9jXrMGjadPaZubG3kIHUxjNeXfEbT9OtLa4ks7dYJEGVKEjmgBoCTp8pGaqPC0L5xVDT/PXT4J95JZQTn1rTtb0uNs4/SgCxauCRtPNasECthsYasoWwdg8DYPpWvYPgBX+VvegCeSP5cinWzYOGqyqhlINUpWEEoLqSvp60AW/lRHkk/1a/rXN63ceaFfAAzwB2q1qepvcRlRhVB4Udqw7qUuoB7GgBFfEhbNVrvWIrVX3MMms3WdTW0gcg/NXk+ueKna/ktonSSdwBEc8Ke+aAO317xZLuENqjTTPwEX+tYf/E6lzJcKo3dEJ+7W/wCA7DS4IFm1G9SWZhukZWBYn0FaWq6xortItogOOApOTQBwWq/bl0q5jukTyip5BrL0PVJtXkhW/tpVs4FAU44dh3NXtXnutS15YGt2jsYwDkfxGukt44/KSOGIxigCul1bEYJxk1Vtp4BbrufLAkAe2a6i20VZEDOFI+lZVhpgez3Kg5dh096AOL8T69DbS24tHLSbijL6Z71ueGdIvruFEspFKgZZy2TmtO+0S3ZAZ7aMgc5K1iT2V9Z3UVzoPmJOrcgcKw7g0AdU3g+ZsNe30rr3ROBUcvhG1SMywefGy87t2Qamh1W9ij330qoSPug96lsPG1jaeYmqSKo9OpP4UAYltczaWy3CTB7bP3weK7vTtSjubZZQw3GvIte1mJ9VMekW12NIuXEkqtH9wjrt9jXSadqELqk+nzeZbg7SOhU+4oA9Vs5vMQDPNacDlSBniuU0q8DxKynrW8twPLJ79APWgDrtLkS6jMLJuYD5W9KbPCDkEc1k6ZdvZyK6H5hya2Li5W5jWaMYkI/eD0oAxL6LaSF/E1QKbOvWtp49+apXFtgkDkmgDKmJ+6vXuaoXKLGpL1qzDyuFXLn9KrpZGVi8pzQBzM8Utw5OCqelOhstpBYdK6SW3RRhFqlJGFPNAFWMbRxVmNWLAmmHA9AKj0Fk1TVZ4ZJ3SGIhdqHBNAGldIPsglEgjmh+aNs9DWv4V8R2lprNreXku1ZYCjEDIU5rt9G8LaKLFWW0ErY+9IdxNYfibTYoUYQwxxqOgVQKAL0nxH0952isre4nI4DbcA/nVmPV9Wv7ctH5FqCeD944ryc5hu+/Wu60fV7W2swbuZUGOmaALGrm+lT99qM5x/zz+WuB1q23SMztI7HuzEmt3WPGlrI/lafbvcMcjgZrFFhrurEGRY7NCc5YbifwoA5l4jG5YKAAeTXRaDqSwyKqh5W6/IM10mi/DYTOJLzzbliclpzhfwArvtL8I2NkihkVsdFVdooAr+CdSvb2EiWzMUCnAYnrXWUyGGOFAkSBVHYCn0AFFFFABSOquCHAI9DS0UAZ82j2UoOYQhPdOKx73whazrhWVh6SID+tdRRQB5dqfw7ifeRar7GFsfoa5278KahYOGs7yaNsYCyqcfnXudNeNHGHUN9RQB833kOr2cha8tDNGDkvEc/pXYeCdWsZpFRpRG/QhuMH3FenXWhWNwCTEEY85XiuE8a+GrKwh+0oFa5Y4i2/K2fX3oA9BdxHp5ZSCNvBBrwz4oXp8kxq3zSyBBWz4X8XTRxy6ZePukUYwT94eo/wriPE7Nq/i2C3jbMVudzH/aNAHRW0DDSYAo7CrVsgCBZFANF1mKCKJGJAFRJI46jP1oA0raJN4KHBrWWIOo3Yz2NYtpKNw3Lj6VuxcoCpoAmtMiQI54HOaz9blDszDp2q1cZEY3cZ6GsS5n3MUagDMlf5z6GsXWb9bVCM/N2FaOozC2VmY9K8n8e63IsgihbEkvGfQUAVNe1WXVLo2VqxZ3O1iOgrQ0vwjo1v5Ul1aPJJGOGyeT6mk+HejrPMpypnb5ip6hfWvS9Ss4rdRGNpYCgDy7xN4etTZST6SkkVwnKiNiDmqvhbT71FiN3BIZm+8CO9ejNYpKwwAD6itKz06RMNHk49qAKlr4eWeFGZMGtCPQACM4Aq9AlwOME/Wraxz452igDOlsPItpn34CIW/Sq+gaMo0i2fcTuBf8zVnxI8kWjyoT805WFQPc81oW8TW8EMAyVjQJj6CgDOuNLD8bQwHqKz7zTJNu1PkH+ytdQrMByrUjshHIIPuKAPOLnQWmc7AxPctXMDweYdZN3MfN3Ho38Ir2WWJnHyKMGqM2lmXltqj1NAFHwfYWspNtcwIUKkDA5BrgdesY/D/ii5VUCw3HXHTNen2McVjODE26QHtXI/ESGDVZJ3tSGnj+8o6qfQ0AQeGdQUzeQTx1Fdtp58y4BY/Kg6e9eJ+HdQa3uzE/3o+VP9K9W0S8a7SNYzjd1NAHWo2Ruq7p7kyZJ+X+L3rOLBVCqeBVuxP5CgDXnYK7Bfwx2qrJwp9TVtSZYAQhJTqQKrhOd7/gKAKDwgZZhUR5HoorQmUMpJ4UfrWbNLkkKOBQBBPyDjgVi39ysQIXk+taNxvlO1eaqS6YMFpTmgDFimaaY7iayvD1zJp/jCVHJEdx0+orccRQyjbzg1neKIMxR3tsMSxkNx6igD6B8H3YntApPaq3jOa2tLZnuJFUkcDPJrjfBPiaOPREvFIJZOAegPfP0rDmu7nxG+oX1y5a1jyIwf4vegDEvr+a+u2TTYtxzw+OPwrZ0bwhd37qb55ZcnPlr/AF7Cu/8ABXhCOLS7eW8RFZlDFU7/AFNdzbW0NsgSCNUUegoA47RPBUVqq5SOBR2UZY/jXVWmmWlqB5cQLf3m5NXaKAAdKKKKACiiigAooooAKKKKACiiigAooooAiuZ47a3kmmYLHGpZiewryzxFq7Xay6jONqMpECHsg/iP1rf+IupBpLXSY2/1p82fHZB2P1NcfrWbua1sRjMxDv8A7Ea0AcW+kz3Oy6VnSdiXyOCM1raBoRt5HuJpHaZzksTyTW1NLE07kY25wPpS+fEo+9j8aAI2sWd9xZj+NPS2Kep+tRvdgNxu21JFdq/A3fiKAJ4UQsPlI5rZs4jIyJGcsxwM1lW7hmFdBo8kEcxecblVcigCp4gQ283lE8quDiuVvnOQ38QroNZvDd3bysoUHgAVzWptsRznjFAHHeLtVUMQW2qgy1ePa/eCcS3dw2HfiFPYV1PjC6aS6MeT+8fGBS6BpdveXyCaFXaMDr0UUAW/hl4l0rTonn1Hz4rqfAZinCgdAPau2/tm1vZ2ktpkntyeXU9K2bjwpZroilbSJpJEz05FeY2Phe6tPERa0EixN9+NehPrigD1nSkRwGVUYn3roYIDs+6B9KzfDuixx2sZ2Sh8c5rq7bTUCYZvzNAGSLUFuWH51KlontWymnQqeStT/ZLeNSxIwoLHj0oA4e+txfeJ7Kxj5jtENzN6ZPCitp9PYkkZOaTwVbrcwX2qup3X05K57RrwtdJ5JPAAoA5hrNh3NRSWrdwDXVtalhztqtLpu7PzflQBy5tiBxn6Cs6/tpVQsVbaPWuvfSnHOXqjeWWUZWaTH0oA83utXgt97ySpFHH95mOK4vxH4kWbUo7zwzplzeSyJ5c+E+ST0P1Fb974AkvPF9zcX8zNY4DRRE8Z78V2miaalh+7tYlUDuFoA+e45WttRVLm0mtrp3JZHHHPXmvVPBshVCQfpWZ8WtJe0u4Lgj/W/MGxT/B0xDBWPGBQB6JaMZWAHQdTWmjbcKtZFm2Cqr1brWoOOe54FAG/oU7NLJCASsi7fxpt7byWs7RTkbl64puj3EdiyyNy/XFP1W5+3XRmHG4cj0oAy7uUsMdEH61QYFzzwvpWhcJxWbPOkeR1NACvIsK5ArH1G8ZwVQ1ZkSa5OTkLTk09F5c5oA5popXfPJqb7NPLEY2Q7D610yQRjIRBxWSupSXWptZWEaMycu7dF9qAMqw0y6tbe4hWcpZffMfqf8K7eK2SHR7Kzt1xvMav7knJrJ1O2v7W3T7bZvHHI6jzU+ZMZ9e1dpoqxaj4jsobcK0VuvnOynIPGBQB6LaxiG3ijUcKoAqWiigAooooAKKKKACiiigAbJBwcGuC8W+INR029+yQTxhmGQSvIrva8a+I+ovF4kPl2/n4XGA2DQBUu/iD4htH2iS3kx/eXFXdN+KOrPhbiwt3Pqr4rjZri3n5udOuo/dWzUcVxpUb8NeRH/ajyKAPWtO8e3E5/faa2P8AYbNbcHigSLk2Nwo+leUaXrmmwdbuPg/xAiuw0zxFp8oASZGHYhhQB0d3400+zCm5jnTP+x0qtH8Q9Dl4SWUt6bDXL+J7hJoyY9xB9s1yWmEG7wOuaAOkuI7/AFjXb++S3kMczqsWRzsArFv4NVhvri5vLGeIkbEyOAgr03wr91K0vFX/AB5HIzxQB4O967syxnnvnqKSO5KH5uvrSapGH8ULGmFG3kjvV24tAJNvBoAW3vc8Y/KtK3mDgYOKz4NMLnggVei0148EOaANa09a0UfCnjI9qqWMRROTmrqhfKlJO0gfnQBk3z7WOPu1z+uyYtX5zkcVt35wDkZHrXIeJbgRWkmD0BNAHl2ryLPqbkcCHgn09a6z4epbuY5GZc3EmIwerYrhopgltcXVxyC5JA5J9BW38PrTxHDIb1dOWWNMi3EhxtU+g9aAPoa7t0CqiHBVRgA03StPt5LsM0X736V5pZePn/tRLDVraaxuWO0BhkP7g1614dlWWNXjfcSPSgDbSz4wABU6aeMcsKVFc/xYqTypT0YUAM+woO+aw/GQNj4ZvpEcq8iiJD7txW8YpsferlfHsUr2WmW55E19HkeoBoA3tI01LDSrO1U8RQqv445/Wrvljswpjhw7fIMA+tJ5jr/CKAJfJJHBpptmP8VIs0h6LUivMegoAjNo/ZjVS5sLlv8AVuB+FXy8/wDdpyPJ1agDmptAlkl3ytk+1Wk0ZYV/hX3NbckrY+UGsu6mwSGyxoA82+LunR3GhyKuXeIZU15R4fuTGYGP0NeufEXV4YNP1GElGlgh8xoj1APSvF4d1vPErjb5yCVR6E9qAPWNLmBUMOeK2bZwoaSQ9BmuR8MziW3XnkV0ceZGVD0PWgDYsm8wh279K0vMVI2GAc9aywwjQBfwq1bcglxkEcUAQ3bNIpC8Cs9YFDZ6n1Nasy/LgVUwFPqaAItjY+UUx4z3b8qmaQDqfwFV5Z1HcACgBt7tstHubljgqp61m/DHTWmiFzKv7y4cyMfbtUfjO5B8OeUjfNcOqD8TXe+AdOS1tYBIyoqKBljigDuoreKPTRHKiuhHKsMiuB1Bk0C+lu9EC28j/fjPKMB29q7fVL63S2IWaM8f3q8u8TXnmM21gR7HNAHYaB8QrC9dYNSU2dz0y3KN9DXaxSxzRh4nV0PQqcg14JoVr9on+Zdwz0Ir0OxtZrCFX0+4aB+6HlG/CgDu6K5W18WxwyCLV4vs7dBKvKH/AArpreeK4iEkEiyIehU5oAkooooAKKKKACse/wDDel38xmuLYGU9WBwa2KKAOXl8EaW3MfnJ/wADyKpXHgC0dT5dwVPvGDXa0UAecS/DdXyGktpB/tR4/lWTf/CoFCYY4C3bYzKa9dooA8HvPBmv6UFa1u76IDnGRKo/Cs2O81K3uI11Wyt7lGbHnwfu5F+or6KIyOa88+K2nRC306/EQEdvODKyjHBoAq+EPEtiZvKScSBThlPyyJ9R3/Cuu8RyJNpweJgyMOCK8K1vSIF1CWS1naKV282GVDg81r6H40ewsZLTxBMIyo4Zuj+hHvQBgyOZfF9wQchWwK13kVpzuIBrlNEvTNfXd5yd7sQfarkd07TFmU9aAOvtimB84q4p6YfNcxDfkYwhq0uotjlTQB0sczL1wabNIWB2tj2Nc+t+f9oVbhvFbq4/GgCZ5WGQfmHcVw/jJgYZ9vGEOK7eQxyqcHDD0rgfHIdbS5deSEoA4HTYw8EERUM7MOvrmvfPC2nJHo4Mr/vBgKB614l4Jg+1alalxlUYEivoiHyobK3WMBRjOKAOV1/wwmp39nLcYHktuViORXdaJbQWsKrFNuAGOlVFVJcZbNXra12gbG+WgDZRgBwc1OjEjh6zl/dLknpTftjZwMYoA02kcd81yvjqZ0j0edgdsd8g/M1s/bSo5xWJ4tDaloF1Ci7pkxNGB/eXkUAb00zCR8nue9M84/3qzNJ1KPU9LtrtFGJEBYejDgj86s+ZjoBQBdW4cdDVmK5OPmFZAlY9AKsQzhD84oA1BOWHApVkYDGMVT+1x4+UU37YpOMYNAF3zGzjdWVe3yiR4yo3A9T6VM7kjKmvOfi3FrMmkBtGSTz3YRyMnVUJ5NAHHfFKdvG2oWum+Foy11BJtuLzom3+4f7wrmPG2l6rp8UFxd/ZsW5CZhz0HHevZfBWl2+jWVvFbxgEAFmYcsfesr4paeklnclUGyVNw+tAHC+G7l4mjYHMcgBFd1ZXCs+7qQOK8u8KXW6wMZ6xNtr0TQCGK5780AdJDnG+Tlj0Fa2n52Su2AoXBzWYhzz2HemXWoFIvKVsL1wO5oAt3lwoBGfwrLkuMnr+AqDMk2SSETuxNTWthd3bAWFs8q95X+Vf1oAYnmzkrCpb6dvxpk9vGi4lu4t5/gj+dvpgVtpoIKD+074sq/8ALC24H4nvWnp0drAFGm2UUCfxSOMn8zQBw97o2rakLU2tgyRwSBw1wdoI+lX7y21qOMtcywxWfquTk/jXXy38JmW2tmfULtjxHH90fU1vaT4eeWaO61llllTmOBf9XH/iaAOAtvBWpXelrcTSXKO/ICt0XtxWNfeFdXtTtgu92OSkybc17+AAMAcUyWCKUESRq2eORQB8/adfalokq/bLFjGOSy8g11lj42066RY5T5Eh7Gu/uvDllNkopjOOg6Vyms+AIbjJ8iOT/aT5WoAxNUu454S0brIjDtyK5eDXdQ0S48zS7lolzkxMcofw7Vf1Dwbf2BP2G6kjPaOYcVzGpRX9of8AiZWciDp5sY3L9aAPWPC/xOtL1lg1mE2k3TzV5Q/4V6HbXMN1EJLeVJEPIKnNfNmgxRzyLtdHB7V654M0wxSrLE8kWOSoPyn8KAO8ooFFABRRRQAUUUUAFFFFABUN5aw3ltJb3MayQyDaysOCKmooA8o8Q+C3sBtit3u9ODZXYf3kI9B6iucu/DyXMf8AoksWo23dJBiSM+hr3nFc/q3hLTdQmacI9tct1khO0n6jvQB4zFoptUKmxnjX1C5FMFtApyY5uP8AYNeoS+FdXts/ZNSSZB0WVcH9KpPb6vbZF1pryD+9C4/kaAOAQW3YSD6oacXtEXLF1Huhrqb6+Fuf3ttfQHP/ADyDCnf2haypn7eA2PuyQYoA5ZZrE4/fqPqCKmWGJxmNkcexrpIFjuuC2mzr/dKgE1BcaVppys2myQH/AJ6W7EAUAYLxlBwCK5TxgTLZSx7TllIzXeT+HriIGXSLz7XEeTbz8MPoa5rWLbzQ9vcwyW1wRwsgxn6HvQB5FoOqQ6EyX91JtitpPmjB5cV7N4T1sanpou5LmOZZm3Rxq3MadgfevJvDvh60ufGl5b6tAJolGVRumfaug8W+HrbTrUSaSZLSZeVMLYwf60Ae16ZcQD5kb6g1p/bRjCYFeVeALy4m0S1a9YtdFfnJ7muxWaQ9M0AdFJcBh+8k4piyW4BO85rDBdvvZqYFYx85oA1HuIT05qMSZPy4rOEyE8YFTxSoTyfyFAGLHdr4Z1Zra9k2aXfSF7eQDIjkPVD7HrXVhCQCHyp5BHes7UbSO+tcDBmjO+MsuQDVHwvqDM8tlcZDjLxg9h3FAHQgY6tTXO8YyaRgc5JH41FJMU/5aCgCeJW/vGlZZCcg8VntdPnhz+VNN7KP+Wn6UAbCyOoxgk0StuT94vXtWP8A2nInJJP4VU1DxRDY20k904jjQZZm7UAalz5UUbPtYBQTgCuV12+g1fRY7iMEQuhA38EdsGsxviZp1ypeC1vLteypHjdXmsniySeS6sdVtLyy0hJnmjYqdzZ5CkjtQBn6KTb6pdxof3fmV6toEZS3DmvJdEB1e+L6ejFGfJOPSvaNFtXaGO3RDLcAcqvQfU9qAJ7q+8uI/NtX1p1lpd5eBZZ2FlbN0eQfO30Fb2m6Nb2Uiz3KreXn8K/wR/hTtR1WytGkaTN/djkhT8kfsTQBPpdhY2e1YoJLphz5kvPP0qTUpHiY/bL+C3tiOQG5HtgVjQz3+sN5bXyWsR5EMA2nH1Na9h4XtInDNEZJO7SHcf1oAoR6lGHC6NZS3RXjzZ/lU+/vVu20O/1aUNqtyxizkQRfKg/KultbO2iIRpIVI/h3CtS7tpV0u7FlgXPkt5R/2scUAQaPZadpieVC1vEw4IBGc+hrYe7tomKPNGrDkgt0+tecfD4WcHgCBddjf+1Flb7SJQS5m3HB/lUfw7WKHTNfXxSkhvzdO03nZJaP+Db7YoA9Ma9tV3ZuIht+98w4+tTqwdQykEHkEV5P4Ttnv/FvjGG2RPKdovLFwrY27RXqlrEILeOJQAEULgdKAJaMUUUAMliSVdsiK49GGax77w5Z3APlgxE9hyD+FbdFAHKTeB9JuLURyQLHOOksQ2mrfh3RrrSHaJ7j7RbnoW6iugooAKKKKACiiigAooooAKKKKACiiigAooooAKYyA0+igDH1exE0ZIHNchNaiORlaNc+616MwBGCKw9W0wSAvGPmoA5BrG0l/wBdbxt7gYqRNJRRu0+6ltpOwJ3IfqKuNCVJVxgimDdG1AGTcve6axl1K0W4hz/r7bqPqKJNQsNYg8uVI7uDv/fT+tb8coZcE1g6v4dtp5PtFtugn6+ZFwR9aAOK1zwaba8GqaM5uYF5eM/6xB/WlgW01RAko56YI5Bro0vdQ0mZRfxCSDp9piHOP9oVFrWmRX8iXNm8dvct8yzJ/q5fY+9AENhpKWagBRjtirNzPHbwtI5CIgyzHoBVeLXJrJEtNXtVR04WQdD+NV7maO+LLIwaJuCp6Ee9AEkurWyGDdOD55xFt6NV5FVxksM+5rxaXVbyx8WPpWkWh1HT7NjJCw4Ck/w59BXa6Hda9cozapp5t8jcrRnIxQB3Sqg9DT/MVfSsG1u2ZcMW49RVtJC33VYmgDVW629DWNqQ8m5+2wKRJDIsjEd1PDVOWdcbxtFRTxS3O9Fm2QSRmOTC5Yg+lAGsZt4zu4NQOVHUmkjV44o4re1cxxrtXPU+5qG5tr6ZSI7cg0AMluAqvgnIBIHrWbpmt29zpS3ty4thkhwTwuKgv/DfiS4I+xzRwDqdy5Jrz+30DW/DuoCPxkPO0x5S8Zib5EJPVhQB6pZajBqEKPY3AlR/utjg1O/hxL/AvQJIicncODVe1+zadbJJC8LoVBTZ0x7UzVPFkgtwCyoijqeAKAL93Bp2kxeXbQQhsYyFFefeKrmOdXtxGju/GMZ5q9Yz6h4huyumQvMP4pm4RfxrstI0Gx0eRWEIv9UPJkYZVD7UAcl4E8CXdva+dMVs4JOXkcYdh/siu8H2LSbMBMw25OFAGZJjSXGsEyeRbKL3UDwT/wAsofr60+ys1gm+13khub0/xt0T2UdqAI47S+1AE3TfYbM/dhQ/vGH+0e1Xzo9u1i1tDEqR9QPUj1q3bZlbJB/GtB43itpJY4jI6KWCDq3tQBk6NbJfXF5FcIrKpG0AYKcdK27RHsr2OzmZnimU+S5+8D3Brm9MjU6zNfTajJDDdxASRRjHlyDtVzVbC+e6s5bSe/NjG581wfn5HBX2oAkOnrpkU9jc2scs8znyLmRsK2f7x7EV1MSSaRoBOTcSwRk89zXM3WnWctq0Di/u1YYKPnOfr2rb8NaTfWGn28V1eyzbQQySfNhewz7UAYWjeIZru0vpr1LRGjTzRKF4T2b3qhJ4svxBFNLa2ztIAoAGSwJ4k+gr0UWVsI3jFvFsf7y7RhvrSCwtAABbQgBdo+QcD0oA47w/4olu9fgsGtEUurebcKmA7D0PpXdVHHBFGEEcaKE+6AMY+lSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJAMU+kIzQBh6lahyWUfNWPLCQMEV1ksIaqNxaAg8UAcuylDxTlmIGDWjc2mOgqg9uc0ARy7WUhgCp/GsS5sJLYvJYRiSBuZLbsfdfQ1utAcVCoeCQMn5UAYVv9m1S3ltnTzo1+9DIMSJXEeNNG1TTtDvH0cPcxMuFZPvx+uRXqt5p9nqqiTBtr1PuzJwQf61gvPdaVebdQIQNx56jMbj/aHagDgvBEtpaaXB9nRJGA/eZHzA9813Nt4ggMQSVAMe1YHjfwSl+jal4ZuDp2pMN21DmKavK7jxP4i0W5+yavbRvKvBLfLmgD32DVtLmYiWFOehHFSPHprqSbzYewFeDL45uyvOltz3VqjPjrWHBWy0zOO7HOKAPeFu9Nsm/dQG6f8AvMeKZJ4oMJ/d21vH7YFfPra94t1CZYgzRFzgLEuDVubw9ryhZrqa73N335oA9wPi27z+7jQL34p3/CZT7l3Qpx6CvDDHr9uNsd1cY9xmopNS8Qxgg3RCj1WgD3e88ZTSQlVhVSfQVyHiPUlvLOUalMiW5U8Oa8ivta1UZ8zUnBPZa6bwb8NdX8VNHea1czQ6ZnO6VjucewoAoeGPFEy2p0vTba41KdJWSHYMjbnjmvQ9D8GXl40d54ulCL1SwhP/AKEa7rSfDWj+GNKxYRwWMC9ZnxveqwmmvXxpyNDCetxL99voKAL6z2ml26RybLaEDEdrCPnb8KrubzVRiQfYrM9IYz87D/aNWLHS4LYmQqXmP3pZDljWpbwGVgFHy9zQBVsbGO3jEVrEFX2HX61p29gB80nJq5FEsQwBV62h3YLc0AQ21plskYHYVr29vjHbFPghFWlGKAIhbQ5yYoy3rtFSgYGB0paKAECgdAKWiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKa6BhTqKAM+5t+MgVnSwDOcV0DKCKp3UHBIFAGI0QqvPBgEkVelG1sUiEHg0AYxTH+IqvegSQlLhPMjPGcZroJLVHGV4NU5YNhwy49+xoA4lre40lzNp+biyP8ArbYnPHqvoaz/ABBoOmeJ9M8x082E9JAPniPoa7S4syjl4Rj1Ws9dMJme402QQXR+/GfuS/Uf1oA+dvFfhnWfDcgeyhFzadn7CsrSNdvraQs1hDIpPzgHB/Cvpe1lgjuJLS/tNpk+9bSjKt7qa87+IHw+Fsz614SjL7fmmsyOR9KAOPHilE+aPTrveRgrvGKy7HxP4gs5plgtjJayNuEbEnZWlpWri/fyTbxQXK8Mjrgg1sSJ5S5muEQeigUAc1d+IvENwhzZJEvqTWJLcazeTLAhQzSHARAWY119vHeeIr4aboUbzvn55T91B6k16r4Q8H6d4Xi8+Ropr5Rma7kHyx+y0Acj4C+Fn2Jor7xKftF6+HS3P3U+teoPerbv9l09BeXgGNo/1UI9/wDCkVLjVhuhMltYn707cSTf7o7CtWztYLOERWsYRPbqfcnvQBgppE09wJ9Um8+bOQvZfoO1bMVrtHyrirkSDdxyatqFUdKAKMNnk5k4FWxtjG1BSsxNSRR5PvQBJAmSM9a1rSHgGorO26EitJFCigBVAA4paKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACigZxz1ooAKa+Mc06mv0oAyb2MEkis0kqea3JUzms+5g70AQRTY71Z+SVMHFZsilGoScoRQBPNbYzjkVQuLXJDL8jjowrUiugeG5p0iJIMrjNAGPNFb30Qt9SiBI+644IPqDWddaVqen/vbZje2wHVf9Yo9x3rfMAORjI9Kntw8P+rcgehoA8p8Q+FtB8UCRiPseqgcTRDa2f9oVzGl/Cad7oNrGpNLag9I85YV7rqejadqpD3cHl3A6TRfK1V/+EXgEe2TU714h/BuxQBy+nwaToduunaBaeWW+8IxmR/qa1E0p7iVJtUVREnMdqp+UH1b1NbMNpZ2ERjsYFj9W7n6moZW/vUANdi5HYDgY6D6UDHSmkM3T5F9T1p8ahR8vPuaAJE+XgDAqQZY8UiKWq3BCSRgUARxwkkAVp2lpjBYVNa22ACauqoAoARFCjinUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUxuaeaTHNADBHTJIAwNT0UAZNzZnnArLntiM8V1JUGqtzbhlOBzQBy+1ozg9KkScqMZq1dxYyKoOhFAD2u9p560C+BNZzuGcofvCmbTnHQ0AbaXw7mla9UjGeKwGMqnGMikLy9kNAGtJdJ61WMpZtwUfVqqKkznONtKYwp+dmY0AW1bcfmbcfSrUbA4GOfQVmQktIFBCj25NdLpNvGoBYZPvQAlrau+CwwK1re3CAcVPGoA4FPoAAMCiiigAooooAKKKDntQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUABooooAKKKKAA1GzAHBqSmugYc0AUb22EqEr1rAuQ0ZKsK6ho2UfLyKw9XSQAkxkj1AoA5q9VJJl3Eg/3h1FY+raxNaFo5QJFH3WXg1uyRBny4YKOuBzXPa7G9wrLFDhR3agBLLxhbxxKl2iyY/iHWpj8QvDMYbe8wcfw7a4S+0sKrM8vODwK5FdCmutSKEsMfMB6+lAHr918QYZPl0yzOCPvyf4U6xvL/U33ynAPYdBXnNnDLZSbLhNr5HXvXoHhi6ldkCp8tAHbaXZOkYLck10mn2rKAWqvpZXaobqBWymMcUAOAwMUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVedC1WKbJ04oA5rWHEK4wM/SuO1aR3G0A/NwAK7jUrKe5mwoUL/eNVpdBxFuHzN3NAHnZ0tW5mXIH86xdM07PiKVgeDhQPSvSn0pzkbTnpWdp2gSR6w0hXk8fhQBnapo1rdWhjkh+f+/3FQ+GLOezuhCMtGD8rGvQhpI2jevWrtlo9vCwfaCaAGWMThVLLg1rRAheacFAxgUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACbRS4FFFAEZgQnO3mmrbIsm8DmpqKAEKg9RSgYoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Graft-augmented rectocele repair. A graft is trimmed and placed over a posterior colporrhaphy or site-specific repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8160=[""].join("\n");
var outline_f7_62_8160=null;
var title_f7_62_8161="Isoproterenol and phenylephrine: International drug information";
var content_f7_62_8161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Isoproterenol and phenylephrine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F4089263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Phenylephrine and Isoproterenol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4089264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4089265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bronchospasm associated with acute and chronic bronchial asthma, bronchitis, pulmonary emphysema, and bronchiectasis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4089267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Daily maintenance: 1-2 inhalations 4-6 times/day, no more than 2 inhalations at any one time or more than 6 in any 1 hour within 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4089268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aerosol: Each actuation releases isoproterenol hydrochloride 0.16 mg and phenylephrine bitartrate 0.24 mg (15 mL, 22.5 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10464 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8161=[""].join("\n");
var outline_f7_62_8161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089263\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089264\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089265\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089267\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821243\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089268\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10464|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8162="Patient information: Trichomoniasis (The Basics)";
var content_f7_62_8162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21906\">",
"         Patient information: Genital herpes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/13/16594\">",
"         Patient information: Genital warts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1940\">",
"         Patient information: Screening for sexually transmitted diseases (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/50/33570\">",
"         Patient information: Vaginal discharge in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/44/40641\">",
"         Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Trichomoniasis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/trichomoniasis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10516026\">",
"      <span class=\"h1\">",
"       What is trichomoniasis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Trichomoniasis is an infection that you can catch during sex. Infections that you can catch during sex are called &ldquo;sexually transmitted infections.&rdquo;",
"     </p>",
"     <p>",
"      Both women and men can get trichomoniasis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516041\">",
"      <span class=\"h1\">",
"       What are the symptoms of trichomoniasis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people with trichomoniasis have no symptoms. This is true for most men and some women.",
"     </p>",
"     <p>",
"      In",
"      <strong>",
"       women",
"      </strong>",
"      , the symptoms of the infection include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Vaginal discharge that smells bad and may be foamy and greenish-yellow (&ldquo;Vaginal discharge&rdquo; is the term doctors use to describe the small amount of fluid that comes out of the vagina.)",
"       </li>",
"       <li>",
"        Itching of the vagina or the area around the vagina",
"       </li>",
"       <li>",
"        Burning or pain during urination",
"       </li>",
"       <li>",
"        Pain during sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In",
"      <strong>",
"       men",
"      </strong>",
"      , the symptoms of the infection include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Discharge from the penis",
"       </li>",
"       <li>",
"        Burning or pain during urination",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516056\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you should see your doctor or nurse if you have any of the symptoms listed above. You should also see a doctor or nurse if any of your sexual partners have had trichomoniasis. Even if you have no symptoms, you could be infected.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516071\">",
"      <span class=\"h1\">",
"       Is there a test for trichomoniasis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. In women, the test involves doing a vaginal exam and taking a sample of vaginal discharge. In men, the doctor might test a sample of urine or of discharge from the penis.",
"     </p>",
"     <p>",
"      Your doctor might want to test you for other sexually transmitted infections, too.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516086\">",
"      <span class=\"h1\">",
"       How is trichomoniasis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Trichomoniasis is treated with medicine that comes in pills. There are 2 prescription medicines for trichomoniasis:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?38/0/38912?source=see_link\">",
"         Metronidazole",
"        </a>",
"        (brand name: Flagyl&reg;)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4581?source=see_link\">",
"         Tinidazole",
"        </a>",
"        (brand name: Tindamax&reg;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you learn that you have trichomoniasis, you should contact all the people you have had sex with recently to let them know. That&rsquo;s because they might have trichomoniasis, too. If they have trichomoniasis, they will need treatment even if they have no symptoms. If you are infected, anyone you have sex with should be treated at the same time. Otherwise, your sexual partner could infect you again after you are treated.",
"     </p>",
"     <p>",
"      While you are getting treated for trichomoniasis, you should not have sex with anyone. Wait until you have taken all your medicine and have no more symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516101\">",
"      <span class=\"h1\">",
"       What happens if I don&rsquo;t get treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you don&rsquo;t get treatment for your trichomoniasis, your symptoms can get worse. Plus, you can keep spreading the infection to your sexual partners. You might also have a higher chance of getting the virus that causes AIDS.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516118\">",
"      <span class=\"h1\">",
"       Can trichomoniasis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lower your chances of getting trichomoniasis if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Use a condom every time you have sex.",
"       </li>",
"       <li>",
"        Avoid sex when you or your partner has any symptoms that could be caused by an infection. These include itching, discharge, or pain with urination.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10516133\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=see_link\">",
"       Patient information: Vaginal discharge in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"       Patient information: Screening for sexually transmitted diseases (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       Patient information: Genital herpes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=see_link\">",
"       Patient information: Genital warts (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=see_link\">",
"       Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/62/8162?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16999 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8162=[""].join("\n");
var outline_f7_62_8162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516026\">",
"      What is trichomoniasis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516041\">",
"      What are the symptoms of trichomoniasis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516056\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516071\">",
"      Is there a test for trichomoniasis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516086\">",
"      How is trichomoniasis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516101\">",
"      What happens if I don&rsquo;t get treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516118\">",
"      Can trichomoniasis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10516133\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/13/16594?source=related_link\">",
"      Patient information: Genital warts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=related_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/44/40641?source=related_link\">",
"      Patient information: Vaginal discharge in adult women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33570?source=related_link\">",
"      Patient information: Vaginal discharge in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8163="Patient information: What to expect in the NICU (The Basics)";
var content_f7_62_8163=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/22/36194\">",
"         Patient information: Breast pumps (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/19/38194\">",
"         Patient information: Deciding to breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1732\">",
"         Patient information: Having twins (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/62/22498\">",
"         Patient information: Jaundice in babies (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/38/2659\">",
"         Patient information: When a baby is born premature (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/25/17813\">",
"         Patient information: Breast pumps (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/63/34805\">",
"         Patient information: Deciding to breastfeed (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/45/16083\">",
"         Patient information: Jaundice in newborn infants (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: What to expect in the NICU (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/what-to-expect-in-the-nicu-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H24206995\">",
"      <span class=\"h1\">",
"       What is the NICU?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;NICU&rdquo; is short for &ldquo;neonatal intensive care unit.&rdquo; It is a part of the hospital where doctors and nurses take care of babies who are sick or were born too early. The NICU is sometimes called the special care nursery, intensive care nursery, or newborn intensive care unit. (&ldquo;Neonatal&rdquo; means newborn.)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24207010\">",
"      <span class=\"h1\">",
"       Why might my baby need to go to the NICU?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your baby might need to go to the NICU if he or she:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Is born sick or premature (3 or more weeks before the due date)",
"       </li>",
"       <li>",
"        Has problems during the birth process, such as infection or trouble breathing",
"       </li>",
"       <li>",
"        Shows health problems within a few days of being born, such as jaundice (when the skin or white part of the eyes turn yellow) or problems with the heart, lungs, or intestines",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24207025\">",
"      <span class=\"h1\">",
"       Who will take care of my baby in the NICU?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The doctors and nurses in the NICU are specially trained to take care of sick and premature newborns. The NICU staff might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A neonatologist &ndash; This is the doctor in charge. Neonatologists are trained in newborn medicine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Nurses &ndash; There will be one or more nurses assigned to take care of your baby.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A respiratory therapist &ndash; This person&rsquo;s job is to give treatments that help with babies&rsquo; breathing.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A nutritionist &ndash; This person is specially trained to take care of newborns&rsquo; feeding needs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Specialists &ndash; These are doctors who are trained to treat problems with certain parts of the body, like the brain or heart.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24207040\">",
"      <span class=\"h1\">",
"       What kinds of things happen in the NICU?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lots of different things happen in the NICU. First, your baby will be placed in a special bed such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An incubator or &ldquo;isolette&rdquo; &ndash; This is a bed that is surrounded by clear plastic to help keep your baby safe and warm.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A warmer &ndash; This is an open bed with an overhead heater.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some of the things that usually happen in the NICU include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Monitoring &ndash; The doctors and nurses carefully monitor, or watch, each baby. You might see wires connecting your baby to a screen (similar to a TV screen). These wires are attached to the skin with stickers and are not painful for the baby. The screen keeps track of the baby&rsquo;s vital signs. Vital signs include temperature, pulse, breathing rate, and blood pressure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tests &ndash; The NICU doctors and nurses will probably do tests to make sure they are giving your baby the best care. These might include blood tests, urine tests, or X-rays.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines &ndash; Most babies in the NICU need to take one or more medicines. These can include antibiotics (to fight infection) or medicines to help the heart or lungs to work. Your baby might have an IV (a thin tube placed in a vein) to make it easier for the doctors and nurses to give medicine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Other treatments &ndash; Depending on the reason your baby is in the NICU, he or she might need other treatments, too. Babies with jaundice are put under a special light. Babies who are having trouble breathing might be attached to a ventilator, a machine to help them breathe.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24207055\">",
"      <span class=\"h1\">",
"       Will I be able to visit my baby in the NICU?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can and should spend time with your baby if he or she is in the NICU.",
"     </p>",
"     <p>",
"      In some cases, you will be able to hold your baby. This can help you bond with and comfort your baby. Your baby&rsquo;s doctor or nurse might suggest that you try &ldquo;skin-to-skin&rdquo; contact. This is when you hold your baby on your bare chest while he or she is wearing only a diaper (and sometimes a hat).",
"     </p>",
"     <p>",
"      It might not be possible to hold your baby if he or she is very sick or was born very early. But you might still be able to hold your baby&rsquo;s hand or stroke his or her head. Even if you cannot touch your baby at all, you can still talk or sing to him or her. The NICU doctors and nurses can help you figure out what kind of touch is safe for your baby.",
"     </p>",
"     <p>",
"      Other family members can usually visit your baby in the NICU, too. But there might be rules about when they can visit, and what they need to do (such as wash hands, or wear special hospital gowns or masks). Children might not be allowed to visit, since they are more likely to carry germs that could hurt a very small or sick newborn.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24207070\">",
"      <span class=\"h1\">",
"       How will my baby eat in the NICU?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on how sick your baby is or how premature he or she is. Your baby might be able to breastfeed, or drink breast milk or formula from a bottle. On the other hand, your baby might need a feeding tube. A feeding tube is a small tube that goes into the baby&rsquo;s mouth or nose, down his or her throat, and into the stomach. The tube can deliver breast milk or formula right into the baby&rsquo;s stomach. For babies who are too sick to be fed even through a feeding tube, nutrition is given through an IV.",
"     </p>",
"     <p>",
"      If you want to breastfeed your baby, talk to the NICU doctors and nurses. There are also breastfeeding experts, called &ldquo;lactation consultants,&rdquo; who can help. If your baby is not able to suck from the breast, you can try using a breast pump. A breast pump is a device that pumps milk from the breasts. The milk can then be fed to the baby from a bottle or through a feeding tube. If your baby can&rsquo;t yet have milk, your breast milk can be stored and fed to your baby later.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24207085\">",
"      <span class=\"h1\">",
"       When will I be able to bring my baby home?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on your baby&rsquo;s condition. For some health problems, a baby only needs to stay in the NICU for a few days. Babies who are very sick or premature might need to stay for weeks or even months.",
"     </p>",
"     <p>",
"      Your baby&rsquo;s doctors and nurses will work with you to help you understand how your baby is doing and when he or she might be able to go home. You will also get instructions on how to take care of your baby at home, and what kinds of follow-up appointments your baby will need.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24207100\">",
"      <span class=\"h1\">",
"       How can I get support while my baby is in the NICU?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Having your baby in the NICU can be hard and stressful. Social workers and hospital chaplains (spiritual counselors) can provide support during this difficult time. There are also support groups for parents of sick or premature babies. It can be helpful to talk to other people who are going through the same things. Try to get help from these sources and from relatives and friends. That way you will have support both in the hospital and at home.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H24207115\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=see_link\">",
"       Patient information: Deciding to breastfeed (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/22/36194?source=see_link\">",
"       Patient information: Breast pumps (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"       Patient information: Jaundice in babies (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=see_link\">",
"       Patient information: When a baby is born premature (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=see_link\">",
"       Patient information: Having twins (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"       Patient information: Deciding to breastfeed (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"       Patient information: Breast pumps (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=see_link\">",
"       Patient information: Jaundice in newborn infants (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/62/8163?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17208 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-7484D81656-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8163=[""].join("\n");
var outline_f7_62_8163=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24206995\">",
"      What is the NICU?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24207010\">",
"      Why might my baby need to go to the NICU?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24207025\">",
"      Who will take care of my baby in the NICU?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24207040\">",
"      What kinds of things happen in the NICU?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24207055\">",
"      Will I be able to visit my baby in the NICU?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24207070\">",
"      How will my baby eat in the NICU?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24207085\">",
"      When will I be able to bring my baby home?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24207100\">",
"      How can I get support while my baby is in the NICU?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24207115\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=related_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/22/36194?source=related_link\">",
"      Patient information: Breast pumps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/19/38194?source=related_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=related_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=related_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/45/16083?source=related_link\">",
"      Patient information: Jaundice in newborn infants (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=related_link\">",
"      Patient information: When a baby is born premature (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8164="Desflurane: Patient drug information";
var content_f7_62_8164=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Desflurane: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=see_link\">",
"     see \"Desflurane: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Suprane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Suprane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put you to sleep for surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701905",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to desflurane or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you or a family member have had malignant hyperthermia after getting an anesthetic. Signs of this health problem include a very high fever, a fast heartbeat, muscle stiffness, and trouble breathing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698063",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Good mouth care may help. Ask the doctor for a drug to help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698330",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shivering.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a liquid for breathing into the lungs by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11618 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8164=[""].join("\n");
var outline_f7_62_8164=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157562\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157563\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019153\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019155\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019154\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019158\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019159\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019161\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019157\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019162\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019163\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/44/5830?source=related_link\">",
"      Desflurane: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8165="Cilazapril: Patient drug information";
var content_f7_62_8165=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cilazapril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/7/39031?source=see_link\">",
"     see \"Cilazapril: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cilazapril&reg;;",
"     </li>",
"     <li>",
"      CO Cilazapril;",
"     </li>",
"     <li>",
"      Inhibace&reg;;",
"     </li>",
"     <li>",
"      Mylan-Cilazapril;",
"     </li>",
"     <li>",
"      Novo-Cilazapril;",
"     </li>",
"     <li>",
"      PHL-Cilazapril;",
"     </li>",
"     <li>",
"      PMS-Cilazapril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701804",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cilazapril or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703376",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries, fluid in your belly, or hyperaldosteronism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11703 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8165=[""].join("\n");
var outline_f7_62_8165=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151363\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020797\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020799\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020798\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020803\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020804\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020806\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020801\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020802\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020807\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020808\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/7/39031?source=related_link\">",
"      Cilazapril: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8166="Pathogenesis of giant cell (temporal) arteritis";
var content_f7_62_8166=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of giant cell (temporal) arteritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8166/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8166/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8166/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8166/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8166/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8166/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/62/8166/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant cell (temporal) arteritis is a chronic vasculitis of large- and medium-sized vessels, which occurs among individuals over 50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/1\">",
"     1",
"    </a>",
"    ]. Although it may be generalized, vessel inflammation most prominently involves the cranial branches of the arteries originating from the aortic arch [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis and pathology of giant cell arteritis (GCA). The clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and pathogenesis of GCA are unknown. However, the following observations suggest that increasing age, a unique genetic and ethnic background, and infection may have causative roles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GCA occurs with increased frequency among individuals older than 50 years of age. Specific age-related changes in the innate and adaptive immune systems and age-related alterations of large and medium blood vessels appear important in the development of the vasculitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Clustering of the illness may occur within families [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heavy smoking and previous atheromatous disease increase the risk of GCA in women but not in men [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High incidence rates have been reported among individuals of Northern European ancestry who live in either the United States or Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/9\">",
"       9",
"      </a>",
"      ]. GCA is probably the most common form of vasculitis among these individuals.",
"     </li>",
"     <li>",
"      A significant correlation has been observed among individuals with HLA-DR4 and the development of GCA. Additional investigations have identified a sequence polymorphism within the secondary hypervariable region of the HLA-DRB1 gene which maps to the antigen-binding cleft of the HLA-DR molecules in patients with GCA, suggesting an important role for antigen selection and presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/10\">",
"       10",
"      </a>",
"      ]. Patients with polymyalgia rheumatica (PMR) share this sequence polymorphism, suggesting it is pathogenetically related to GCA; this polymorphism is not shared by patients with rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=see_link\">",
"       \"Clinical manifestations and diagnosis of polymyalgia rheumatica\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other genetic associations have been identified [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. As an example, the inheritance of a particular polymorphism of the gene for intercellular adhesion molecule-1 (ICAM-1) enhances the risk of GCA and PMR (odds ratio [OR] of 5) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/12\">",
"       12",
"      </a>",
"      ]. Genetics may also influence the risk of complications of GCA. For example, carriage of the PIA2 allele of the platelet glycoprotein IIIa gene has been associated with an increased risk (OR 2.4) of ischemic anterior optic neuropathy (IAON) in a European population; homozygosity for the PIA2 allele confers an even higher risk of IAON in those with GCA (OR 7.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The finding of cyclic occurrences with peak incidence rates every five to seven years suggests a possible infectious cause or triggering event (",
"      <a class=\"graphic graphic_figure graphicRef77458 \" href=\"UTD.htm?31/5/31837\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/9\">",
"       9",
"      </a>",
"      ]. Additional evidence is provided by the findings that infection with gamma-herpes virus 68 results in a large-vessel arteritis in mice deficient in the interferon-gamma receptor and that the development of GCA is significantly associated with previous parainfluenza type 1 infection [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. An association has also been made between GCA and infection with parvovirus B19, with findings of parvovirus B19 DNA in 7 of 13 temporal artery biopsy specimens with histologic evidence of GCA [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/18\">",
"       18",
"      </a>",
"      ]. A suggested association with chlamydia in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/19\">",
"       19",
"      </a>",
"      ] could not be confirmed by others [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of the immune system and cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the humoral and cellular immune systems have been implicated in the pathogenesis of GCA. As an example, immune complexes have been identified in the serum of some patients with GCA; in addition, immunoglobulin deposits have been found along the internal elastic lamina of involved vessels in a minority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, experimental and clinical findings suggest that cell-mediated processes are of primary importance in GCA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/4\">",
"     4",
"    </a>",
"    ]. The inflammatory infiltrate in affected vessels is predominantly composed of lymphocytes and macrophages and also frequently contains multinucleated giant cells of the Langerhans or foreign body type (often in close proximity to the fragmented internal elastic lamina) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The majority of involved lymphocytes are CD4 positive T cells. Identical T cell clones have been isolated from multiple vasculitic sites, thereby suggesting a response to a specific antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD8 positive T cells may also be involved. One study, for example, found a restricted repertoire of J beta gene segment usage among peripheral blood CD8 cells of patients with GCA or PMR [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The production of cytokines, in particular interleukin (IL)-6, appears to closely correlate with the severity and expression of systemic symptoms. This is suggested by the response to glucocorticoid therapy. The administration of glucocorticoids is associated with both a decrease in serum levels of IL-6 and a rapid improvement in symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/25\">",
"     25",
"    </a>",
"    ]. On the other hand, both symptoms and elevated IL-6 levels rapidly return when glucocorticoids are abruptly terminated. This finding indicates that the basic disease processes in GCA remain intact for a period of time after treatment has been started despite rapid symptomatic improvement and a decrease in cytokine levels.",
"   </p>",
"   <p>",
"    Findings in an animal model of GCA in which temporal artery biopsy specimens from patients with GCA are engrafted into severe combined immunodeficiency mice may provide insight into the mechanism of ongoing disease activity despite aggressive glucocorticoid treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/26\">",
"     26",
"    </a>",
"    ]. The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in these animals resulted in abrogation of T cell-mediated function but failed to adequately suppress macrophage function (including the production of transforming growth factor-beta 1). Glucocorticoid therapy may not, therefore, be fully effective because of its inability to ameliorate tissue infiltrating macrophage function.",
"   </p>",
"   <p>",
"    Antigen-presenting dendritic cells that are present in medium-sized arteries may play a role in recruiting and activating lymphocytes in affected vessels. Segments of normal arteries from HLA-matched individuals did not accumulate or activate lymphocytes when explanted along with pieces of artery from patients with GCA in immunodeficient mice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/27\">",
"     27",
"    </a>",
"    ]. The arteries of patients with polymyalgia were able to attract and activate T cells, suggesting that alteration in dendritic cell function is an early step in the process.",
"   </p>",
"   <p>",
"    In addition to systemic complaints, the expression of certain cytokines may be associated with different manifestations of the disease, thereby suggesting that the specific type of inflammation influences the clinical expression of the disorder. One study of 23 patients with GCA, for example, found that patients in whom higher levels of interferon gamma and interleukin-1 beta mRNA were detected in involved arteries commonly had ischemic symptoms, including jaw claudication",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    visual abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/28\">",
"     28",
"    </a>",
"    ]. In comparison, those with higher levels of interleukin-2 typically had symptoms of polymyalgia rheumatica. Further study is required to assess the general applicability of these findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Possible sequential pathogenic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following hypothetical events represent one possible explanation for the sequential findings reported among patients with giant cell arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/4,23\">",
"     4,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An unknown initial factor (perhaps a viral or other infection) activates dendritic cells located in the adventitia in medium and large blood vessel walls, initiating an adaptive immune response. The location of the activation is influenced by specific toll-like receptors on the cells, which recognize the pathogenic factor. Toll-like receptors vary in different blood vessels and determine the site and extent of the inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Experimental evidence suggests that ligands to toll-like receptor 4 recruit CD4 T cells that invade deeply into the wall, causing panarteritis, while ligands to toll-like receptor 5 condition dendritic cells to support a perivascular infiltrates [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/29\">",
"       29",
"      </a>",
"      ]. The age-changed vessel also influences the inflammatory response.",
"      <br/>",
"      <br/>",
"      Activated monocytes subsequently produce inflammatory cytokines (including IL-6), which results in characteristic systemic symptoms, elevation of the erythrocyte sedimentation rate, and increased release of other acute phase proteins. The trafficking behavior of circulating leukocytes subsequently changes. Some activated monocytes, for example, infiltrate the adventitia of the walls of large arteries via the vaso vasora using adhesion molecules. Within these vessels, infiltrating macrophages encounter antigen; this results in altered macrophage function, interferon gamma production, and the recruitment of additional macrophages and lymphocytes.",
"     </li>",
"     <li>",
"      Interactions among recruited cells lead to the production of further mediators of inflammation, tissue destruction, and induction of repair mechanisms. Cytokines subsequently promote intimal proliferation, thrombosis, and, possibly, vessel occlusion. In addition, damage of the smooth muscle of the media is followed by fibrosis, scarring, and narrowing or occlusion of the arteries.",
"      <br/>",
"      <br/>",
"      At least two separate CD4 T-cell lineages participate in the vascular inflammation. In untreated patients, Th1 lymphocytes producing interferon gamma and IL-17 cells producing IL-17 coexist in vascular lesions. Glucocorticoid treatment suppresses the Th17 pathway, but Th1 cells are not affected. This response leads to an improvement in systemic symptoms but also to persistence of the vasculitis for a longer period of months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The antigen which initiates these sequential reactions could be of either exogenous or endogenous origin. This process may, therefore, begin outside of blood vessels, with subsequent extension and expansion to involved arterial walls where the antigen must be selectively localized to produce the characteristic clinical picture of GCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory infiltrations among patients with GCA are most commonly observed in the thoracic aorta, large cervical arteries, and branches of the external carotid arteries. By comparison, intracranial vessels are rarely affected. The vasculitis, however, may be more widespread in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/2,3,31\">",
"     2,3,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vasculitic lesions tend to involve arteries in a patchy fashion, but longer segments may also be involved. Histologic findings are variable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T lymphocytes and macrophages predominate with variable numbers of multinucleated giant cells and with occasional plasma cells, neutrophils, and eosinophils (",
"      <a class=\"graphic graphic_picture graphicRef57876 \" href=\"UTD.htm?16/56/17289\">",
"       picture 1",
"      </a>",
"      ). Multinucleated giant cells are found in about one-half of temporal artery biopsy specimens, frequently in close proximity to the fragmented elastic lamina (",
"      <a class=\"graphic graphic_picture graphicRef83907 \" href=\"UTD.htm?13/60/14278\">",
"       picture 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8166/abstract/23\">",
"       23",
"      </a>",
"      ]. The most marked inflammatory infiltration usually centers around the media and the fragmented internal elastic membrane (",
"      <a class=\"graphic graphic_picture graphicRef83908 \" href=\"UTD.htm?19/53/20310\">",
"       picture 3",
"      </a>",
"      ). Granulomatous or chronic inflammatory lesions involving the large arteries such as the aorta or subclavian arteries appear similar to those involving smaller arteries such as the superficial temporal artery (",
"      <a class=\"graphic graphic_picture graphicRef83912 \" href=\"UTD.htm?29/44/30406\">",
"       picture 4",
"      </a>",
"      ). Among some arterial segments with minimal involvement, collections of lymphocytes may be confined to the adventitia or external internal elastic laminal area.",
"     </li>",
"     <li>",
"      Intimal thickening is usually present. All arterial layers are affected with more extensive disease.",
"     </li>",
"     <li>",
"      Thrombosis may develop at sites of active inflammation (",
"      <a class=\"graphic graphic_picture graphicRef83910 \" href=\"UTD.htm?1/44/1735\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The elastic lamina becomes fragmented (",
"      <a class=\"graphic graphic_picture graphicRef57876 \" href=\"UTD.htm?16/56/17289\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The symptomatic response to therapy appears to be partly independent of continued inflammation. Histologic evidence of ongoing inflammation, for example, appears to persist for several weeks or more after therapy has been started and after the patient&rsquo;s symptoms have improved or resolved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662208\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Giant cell (temporal) arteritis is a chronic vasculitis of large- and medium-sized vessels, which occurs among individuals over 50 years of age. Vessel inflammation most prominently involves the cranial branches of the arteries originating from the aortic arch but may be more generalized. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology and pathogenesis of GCA are unknown. However, increasing age, genetic factors, and infection may have causative roles. Both the humoral and cellular immune systems have been implicated in the pathogenesis (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Role of the immune system and cytokines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is hypothesized that a viral infection or other factor first triggers monocyte activation in a susceptible host, with resultant systemic symptoms in association with an acute phase response. Some activated monocytes then infiltrate the adventitia of large arteries, encounter antigen, and recruit further macrophages and lymphocytes. The cellular response results in the production of inflammatory mediators, tissue injury, and the stimulation of repair mechanisms in the media that may lead to fibrosis, scarring, and narrowing or occlusion of the arteries. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Possible sequential pathogenic events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inflammatory changes are most commonly found in the thoracic aorta, large cervical arteries, and branches of the external carotid arteries, while intracranial vessels are rarely affected. Vasculitic lesions tend to involve arteries in a patchy fashion, but longer segments may also be involved. The most marked inflammatory infiltration is usually in the media and the fragmented internal elastic membrane. Histologic findings are variable; T lymphocytes and macrophages predominate with variable numbers of multinucleated giant cells and with occasional plasma cells, neutrophils, and eosinophils. Multinucleated giant cells are found in about one-half of temporal artery biopsy specimens, frequently in close proximity to the fragmented elastic lamina. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hellmann DB, Hunder GG. Giant cell arteritis and polymyalgia rheumatica. In: Kelley's Textbook of Rheumatology, 7th, Harris ED, Budd RC, Firestein GS, Genovese MC, et al (Eds), WB Saunders Company, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/2\">",
"      Evans JM, Bowles CA, Bjornsson J, et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994; 37:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/3\">",
"      Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/4\">",
"      Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/5\">",
"      Kaiser M, Weyand CM, Bj&ouml;rnsson J, Goronzy JJ. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998; 41:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/6\">",
"      Mohan SV, Liao YJ, Kim JW, et al. Giant cell arteritis: immune and vascular aging as disease risk factors. Arthritis Res Ther 2011; 13:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/7\">",
"      Mathewson JA, Hunder GG. Giant cell arteritis in two brothers. J Rheumatol 1986; 13:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/8\">",
"      Duhaut P, Pinede L, Demolombe-Rague S, et al. Giant cell arteritis and cardiovascular risk factors: a multicenter, prospective case-control study. Groupe de Recherche sur l'Art&eacute;rite &agrave; Cellules G&eacute;antes. Arthritis Rheum 1998; 41:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/9\">",
"      Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/10\">",
"      Weyand CM, Hicok KC, Hunder GG, Goronzy JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992; 90:2355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/11\">",
"      Weyand CM, Hunder NN, Hicok KC, et al. HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. Arthritis Rheum 1994; 37:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/12\">",
"      Salvarani C, Casali B, Boiardi L, et al. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2000; 27:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/13\">",
"      Mattey DL, Hajeer AH, Dababneh A, et al. Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000; 43:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/14\">",
"      Boiardi L, Casali B, Nicoli D, et al. Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. J Rheumatol 2003; 30:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/15\">",
"      Salvarani C, Casali B, Farnetti E, et al. PlA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2007; 56:3502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/16\">",
"      Weck KE, Dal Canto AJ, Gould JD, et al. Murine gamma-herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon-gamma responsiveness: a new model for virus-induced vascular disease. Nat Med 1997; 3:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/17\">",
"      Duhaut P, Bosshard S, Calvet A, et al. Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l'Art&eacute;rite &agrave; Cellules G&eacute;antes. J Rheumatol 1999; 26:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/18\">",
"      Gabriel SE, Espy M, Erdman DD, et al. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: a preliminary evaluation. Arthritis Rheum 1999; 42:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/19\">",
"      Wagner AD, G&eacute;rard HC, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum 2000; 43:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/20\">",
"      Regan MJ, Wood BJ, Hsieh YH, et al. Temporal arteritis and Chlamydia pneumoniae: failure to detect the organism by polymerase chain reaction in ninety cases and ninety controls. Arthritis Rheum 2002; 46:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/21\">",
"      Papaioannou CC, Gupta RC, Hunder GG, McDuffie FC. Circulating immune complexes in giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 1980; 23:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/22\">",
"      Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/23\">",
"      Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum 1999; 42:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/24\">",
"      Martinez-Taboada VM, Goronzy JJ, Weyand CM. Clonally expanded CD8 T cells in patients with polymyalgia rheumatica and giant cell arteritis. Clin Immunol Immunopathol 1996; 79:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/25\">",
"      Roche NE, Fulbright JW, Wagner AD, et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993; 36:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/26\">",
"      Brack A, Rittner HL, Younge BR, et al. Glucocorticoid-mediated repression of cytokine gene transcription in human arteritis-SCID chimeras. J Clin Invest 1997; 99:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/27\">",
"      Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/28\">",
"      Weyand CM, Tetzlaff N, Bj&ouml;rnsson J, et al. Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 1997; 40:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/29\">",
"      Piggott K, Biousse V, Newman NJ, et al. Vascular damage in giant cell arteritis. Autoimmunity 2009; 42:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/30\">",
"      Weyand CM, Younge BR, Goronzy JJ. IFN-&gamma; and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 2011; 23:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8166/abstract/31\">",
"      Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995; 24:422.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8234 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8166=[""].join("\n");
var outline_f7_62_8166=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H662208\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of the immune system and cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Possible sequential pathogenic events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H662208\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/8234\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8234|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/5/31837\" title=\"figure 1\">",
"      Cyclic incidence of GCA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/8234|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/56/17289\" title=\"picture 1\">",
"      Giant cell arteritis light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/60/14278\" title=\"picture 2\">",
"      Giant cell arteritis multinuc giant cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/53/20310\" title=\"picture 3\">",
"      Giant cell arteritis inflam infiltrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/44/30406\" title=\"picture 4\">",
"      Thoracic aorta in giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/44/1735\" title=\"picture 5\">",
"      Thrombosed artery in giant cell arteritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13832?source=related_link\">",
"      Clinical manifestations and diagnosis of polymyalgia rheumatica",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8167="Hydrocodone, chlorpheniramine, and pseudoephedrine: Drug information";
var content_f7_62_8167=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocodone, chlorpheniramine, and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/48/12037?source=see_link\">",
"    see \"Hydrocodone, chlorpheniramine, and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13159414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zutripro&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cough and congestion:",
"     </b>",
"     Oral: 5 mL every 4-6 hours as needed; do not exceed 4 doses/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13159415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zutripro&trade;: Hydrocodone bitartrate 5 mg, chlorpheniramine maleate 4 mg, and pseudoephedrine hydrochloride 60 mg per 5 mL (480 mL) [contains propylene glycol; grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F215558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of cough and nasal congestion due to colds or upper respiratory allergies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14199155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also refer to the Chlorpheniramine and Pseudoephedrine individual monographs. Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Bradycardia, hyper-/hypotension, orthostatic hypotension, palpitation, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Agitation, anxiety, confusion, dizziness, dysphoria, euphoria, fear, headache, insomnia, irritability, lethargy, lightheadedness, mental impairment, mood changes, nervousness, restlessness, sedation, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Erythema, hyperhidrosis, rash, pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine: Gynecomastia, hypoglycemia, lactation decreased, libido increased, menstrual irregularities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, appetite changes, constipation, dyspepsia, epigastric distress, nausea, pancreatitis (acute), vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Dysuria, glycosuria, ureteral spasm, urinary frequency, urinary hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Facial dyskinesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ocular: Hypermetropia, lacrimation increased, mydriasis, photophobia, visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Otic: Labyrinthitis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Dyspnea, respiratory dryness, laryngismus, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pseudoephedrine, hydrocodone, chlorpheniramine, or any component of the formulation; narrow-angle glaucoma; severe hypertension, severe coronary artery disease; with or within 14 days of MAO inhibitor therapy; urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydromorphone, levorphanol, morphine, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: May cause dose-related respiratory depression, risk increased in children, elderly, patients with pulmonary disease, and when used postoperatively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions. Concurrent use of hydrocodone and other anticholinergics may cause paralytic ileus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease); contraindicated with severe coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pulmonary disease (eg, asthma) or decreased ventilatory function; dose-related respiratory depression occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with seizure disorder; may produce CNS stimulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;poor metabolizers&rdquo;: Due to the role of CYP2D6 in the metabolism of hydrocodone to hydromorphone (an active metabolite with higher binding affinity to mu-opioid receptors compared to hydrocodone), patients with genetic variations of CYP2D6, including &ldquo;poor metabolizers&rdquo; or &ldquo;extensive metabolizers,&rdquo; may have decreased or increased hydromorphone formation, respectively. Variable effects in positive and negative opioid effects have been reported in these patients; however, limited data exists to determine if clinically significant differences of analgesia and toxicity can be predicted based on CYP2D6 phenotype (Hutchinson, 2004; Otton, 1993; Zhou, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Measuring device: Appropriate use: Accurate measuring devices should be used to measure solution doses. Calibrated oral syringes are most accurate. Household teaspoons are not recommended for measurement.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F215551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F215537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F215520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F215531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination product. In humans, birth defects, including some heart defects, have been associated with maternal use of opioid analgesics, including hydrocodone, during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery.  Also refer to the chlorpheniramine and pseudoephedrine monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F215546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F215532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrocodone and pseudoephedrine are excreted in breast milk. In one study, the calculated dose of hydrocodone to a nursing infant was 0.2% to 9% (mean: 2.4%) of the weight-adjusted maternal dose. Hydromorphone was also measurable in 12 cases; the total opioid dose to a nursing infant was calculated to be 0.1% to 9.9% (mean; 1.5%) of the weight-adjusted maternal dose. Concentrations may be increased in women who are extensive metabolizers of CYP2D6. Caution should be used since most persons are not aware of their CYP2D6 genotype status. When hydrocodone is used in breast-feeding women, it is recommended to use the lowest dose for the shortest duration of time and observe the infant for adverse events. Some clinicians recommend limiting the dose to hydrocodone bitartrate 30 mg/day (Sauberan, 2011). The manufacturer recommends discontinuing the medication or to discontinue nursing during therapy. Also refer to the chlorpheniramine and the pseudoephedrine individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Zutripro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60-4-5 mg/5 mL (480 mL): $382.80",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pseudoephedrine: Directly stimulates alpha-adrenergic receptors of respiratory mucosa causing vasoconstriction; directly stimulates beta-adrenergic receptors causing bronchial relaxation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydrocodone: Binds to opiate receptors in the CNS; suppresses cough in medullary center; produces generalized CNS depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chlorpheniramine: Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hydrocodone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Narcotic analgesic: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic; O-demethylation via primarily CYP2D6 to hydromorphone (major, active metabolite with ~10- to 33-fold higher or as much as a &gt;100-fold higher binding affinity for the mu-opioid receptor than hydrocodone); N-demethylation via CYP3A4 to norhydrocodone (major metabolite); and ~40% of metabolism/clearance occurs via other non-CYP pathways, including 6-ketosteroid reduction to 6-alpha-hydrocol and 6-beta-hydrocol, and other elimination pathways (eg, fecal, biliary, intestinal, renal) (Hutchinson, 2004; Volpe, 2011; Zhou, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 3.3-4.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Time to peak: 1.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (26% of single dose in 72 hours, with ~12% as unchanged drug, 5% as norhydrocodone, 4% as conjugated hydrocodone, 3% as 6-hydrocodol, and 0.21% as conjugated 6-hydromorphol (Zhou, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chlorpheniramine:",
"     </b>",
"     See Chlorpheniramine monograph",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pseudoephedrine:",
"     </b>",
"     See Pseudoephedrine (Systemic) monograph",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo;",
"      <i>",
"       Breastfeed Med",
"      </i>",
"      , 2007, 2(1):10-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/17661614/pubmed\" id=\"17661614\" target=\"_blank\">",
"        17661614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"National Birth Defects Prevention Study: Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson MR, Menelaou A, Foster DJ, et al, &ldquo;CYP2D6 and CYP3A4 Involvement in the Primary Oxidative Metabolism of Hydrocodone by Human Liver Microsomes,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2004, 57(3):287-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/14998425/pubmed\" id=\"14998425\" target=\"_blank\">",
"        14998425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina DK and Hargrove VM, &ldquo;What Is the Lethal Concentration of Hydrocodone?,&rdquo;",
"      <i>",
"       Am J Forensic Med Pathol",
"      </i>",
"      , 32(2):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/20407360/pubmed\" id=\"20407360\" target=\"_blank\">",
"        20407360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Otton SV, Schadel M, Cheung SW, et al, &ldquo;CYP2D6 Phenotype Determines the Metabolic Conversion of Hydrocodone to Hydromorphone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 54(5):463-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/7693389/pubmed\" id=\"7693389\" target=\"_blank\">",
"        7693389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, &ldquo;Management of Nonobstetric Pain During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sauberan JB, Anderson PO, Lane JR, et al, \"Breast Milk Hydrocodone and Hydromorphone Levels in Mothers Using Hydrocodone for Postpartum Pain,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):611-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/21343764/pubmed\" id=\"21343764\" target=\"_blank\">",
"        21343764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Volpe DA, McMahon Tobin GA, Mellon RD, et al, &ldquo;Uniform Assessment and Ranking of Opioid Mu Receptor Binding Constants for Selected Opioid Drugs,&rdquo;",
"      <i>",
"       Regul Toxicol Pharmacol",
"      </i>",
"      , 2011, 59(3):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/21215785 /pubmed\" id=\"21215785 \" target=\"_blank\">",
"        21215785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhou SF, &ldquo;Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2009, 48(12):761-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/62/8167/abstract-text/19902987/pubmed\" id=\"19902987\" target=\"_blank\">",
"        19902987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16772 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8167=[""].join("\n");
var outline_f7_62_8167=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13159414\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215556\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215544\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062219\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13159415\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215511\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215558\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215525\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14199155\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215554\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215528\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215514\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215551\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215518\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215537\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215520\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215531\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215546\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215532\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323757\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215513\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215527\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16772|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/48/12037?source=related_link\">",
"      Hydrocodone, chlorpheniramine, and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8168="Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults";
var content_f7_62_8168=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8168/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8168/contributors\">",
"     Edward D Chan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8168/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8168/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8168/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8168/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8168/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/62/8168/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary alveolar proteinosis (PAP), also known as pulmonary alveolar phospholipoproteinosis, is a diffuse lung disease characterized by the accumulation of amorphous, periodic acid-Schiff (PAS)-positive lipoproteinaceous material in the distal air spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. There is little or no lung inflammation, and the underlying lung architecture is preserved. The lipoproteinaceous material is composed principally of the phospholipid surfactant and surfactant apoproteins.",
"   </p>",
"   <p>",
"    The etiology, pathogenesis, and clinical manifestations of PAP in adults will be reviewed here. The presentation and management of PAP in children and the diagnosis, treatment, and prognosis of PAP in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/360?source=see_link\">",
"     \"Pulmonary alveolar proteinosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=see_link\">",
"     \"Diagnosis and treatment of pulmonary alveolar proteinosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three forms of PAP are recognized: congenital, secondary, and acquired (",
"    <a class=\"graphic graphic_table graphicRef77313 \" href=\"UTD.htm?14/8/14475\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The congenital form often presents in the neonatal period and is likely related to mutations in the genes for surfactant, the granulocyte macrophage-colony stimulating factor (GM-CSF) receptor, or a defect in the plasma membrane transport of cationic amino acids (known as lysinuric protein intolerance). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/360?source=see_link\">",
"       \"Pulmonary alveolar proteinosis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The acquired form of PAP is the most common; it is associated with a high prevalence of anti-GM-CSF antibodies that are believed to contribute to macrophage dysfunction and impaired processing of surfactant.",
"     </li>",
"     <li>",
"      The secondary form develops in adulthood and is found in association with high level dust exposures (eg, silica, aluminum, titanium, indium-tin oxide), hematologic malignancies, and after allogeneic bone marrow transplantation for myeloid malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/5-13\">",
"       5-13",
"      </a>",
"      ]. In most cases, secondary PAP is likely related to a relative deficiency of GM-CSF and related macrophage dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/5-11\">",
"       5-11",
"      </a>",
"      ]. However, in one patient with PAP related to indium-tin oxide exposure, elevated levels of antibodies to GM-CSF were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/12\">",
"       12",
"      </a>",
"      ]. This observation suggests that certain inhalational exposures may result in PAP through autoimmune mechanisms, rather than via a direct toxic effect on macrophages. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33145?source=see_link\">",
"       \"Silicosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=see_link\">",
"       \"Pulmonary complications after allogeneic hematopoietic cell transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Role of GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several lines of evidence suggest that diminished GM-CSF protein or function plays a key role in PAP and is responsible for the observed impairments in surfactant processing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/4\">",
"     4",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetically-engineered mice that lack the gene for GM-CSF have an accumulation of surfactant and surfactant apoprotein in the alveolar spaces similar to that seen in patients with PAP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/14\">",
"       14",
"      </a>",
"      ]. Reconstitution with the GM-CSF gene completely corrects the alveolar proteinosis in these GM-CSF knockout mice, as does treatment with aerosolized GM-CSF [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GM-CSF binds to cells via the heterodimeric GM-CSF receptor, which is composed of the ligand-binding alpha-chain (encoded by the CSF2RA gene) and the signal-transducing beta-chain (encoded by the CSF2RB gene). Mice that lack the GM-CSF receptor beta-chain develop a PAP-like syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/17\">",
"       17",
"      </a>",
"      ]. Likewise, some congenital and rare acquired forms of PAP are associated with decreased or absent function of the GM-CSF receptor beta-chain [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/2,18,19\">",
"       2,18,19",
"      </a>",
"      ]. Two separate reports of patients with familial PAP have found a genetic defect in the CSF2RA gene that results in decreased functional GM-CSF receptor alpha-chain [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. As a result, there is greatly diminished GM-CSF binding to its receptor and reduced GM-CSF receptor signaling.",
"     </li>",
"     <li>",
"      Lack of GM-CSF production does not appear to play a major role in adult PAP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/2,22\">",
"       2,22",
"      </a>",
"      ]. Instead, humoral autoimmunity may explain the functional deficiency of GM-CSF in adult patients with acquired PAP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/23-31\">",
"       23-31",
"      </a>",
"      ]. In a series of 248 patients with a pathologic diagnosis of PAP, serum autoantibodies to GM-CSF were found in 223 patients (90 percent) classified as autoimmune PAP; of the remaining 25 with negative anti-GM-CSF antibody tests, 24 (10 percent) had a disease known to cause PAP (classified as secondary PAP) and 1 (&lt;1 percent) was unclassified [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The effects of GM-CSF on surfactant clearance by alveolar macrophages are mediated, at least in part, by transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-gamma) dependent pathways. Compared to normal controls, alveolar macrophages from patients with PAP demonstrate decreased levels of PPAR-gamma and the macrophage scavenger receptor CD36, which PPAR-gamma regulates; PPAR-gamma and CD36 levels can be restored to normal following treatment with GM-CSF administered subcutaneously [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/32\">",
"       32",
"      </a>",
"      ]. The interrelationship between GM-CSF and PPAR-gamma may explain how GM-CSF deficiency could cause alveolar and macrophage accumulation of surfactant lipoprotein.",
"     </li>",
"     <li>",
"      The association of PAP with leukemia (eg, chronic myeloid leukemia) and allogeneic bone marrow transplantation may be reflective of the systemic effect of autoantibodies to GM-CSF or relative GM-CSF deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Macrophage dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings in patients and transgenic mice suggest that impaired processing of surfactant by alveolar macrophages contributes to the pathogenesis of PAP. Evidence that macrophage dysfunction (either primary or acquired) plays an important role in the initiation and propagation of disease includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alveolar macrophage and type II cell clearance mechanisms are progressively overwhelmed by the accumulation of the surfactant-rich material, resulting in impaired phagocytosis and phagolysosome fusion [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. Alveolar macrophages themselves, upon dying, may further contribute to the amorphous material [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deficiency of surfactant protein B due to a frameshift mutation in its gene, usually accompanied by qualitative and quantitative abnormalities in surfactant proteins A and C, has been found in some neonates with PAP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/35-37\">",
"       35-37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alveolar macrophages obtained from patients with PAP after therapeutic whole lung lavage have greater migratory response to in vitro stimuli compared with macrophages from the same patients prior to the lavage [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other causes of acquired macrophage dysfunction, such as immunosuppressive drug therapy or hematologic malignancies, may explain the occasional finding of PAP associated with these disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/8,39\">",
"       8,39",
"      </a>",
"      ]. As an example, lysinuric protein intolerance, a rare autosomal recessive disorder that results in defective transport of cationic amino acids, is associated with both macrophage dysfunction and PAP [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/39-43\">",
"       39-43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among adults, the typical age at presentation of a patient with PAP is 30 to 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/44\">",
"     44",
"    </a>",
"    ]. There is a male to female ratio of 2:1. The clinical presentation is usually the insidious onset of dyspnea; however, approximately one-third of affected patients are asymptomatic despite infiltration of the alveolar air spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small number of patients also have other connective tissue diseases, including hemolytic anemia, polymyalgia rheumatica, ulcerative colitis, and granulomatosis with polyangiitis (Wegener&rsquo;s) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major symptoms of PAP are progressive dyspnea on exertion, cough, fatigue, weight loss, and low-grade fever [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29,45\">",
"     29,45",
"    </a>",
"    ]. Dyspnea, the most common presenting symptom, is reported by approximately 55 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29,44\">",
"     29,44",
"    </a>",
"    ]. A non-productive cough is common, and expectoration of \"chunky\" gelatinous material may occasionally occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is often normal; clubbing and cyanosis are present in about 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29\">",
"     29",
"    </a>",
"    ]. Crackles are present in approximately 50 percent of patients, but can be absent despite marked alveolar filling on radiographs, presumably because gas movement is absent in the completely fluid-filled distal airspaces [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Associated infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PAP have an increased risk of superinfection with opportunistic organisms such as Nocardia, mycobacteria, and various endemic or opportunistic fungi, due to impaired macrophage and neutrophil function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/8,29,30,46,47\">",
"     8,29,30,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical laboratory abnormalities include polycythemia, hypergammaglobulinemia, and increased LDH levels [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/48\">",
"     48",
"    </a>",
"    ]. The value of measuring serum anti-GM-CSF titers in idiopathic PAP is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis and treatment of pulmonary alveolar proteinosis in adults\", section on 'Anti-GM-CSF titer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated levels of lung surfactant proteins A and D (SP-A and SP-D) and several tumor markers (carcinoembryonic antigen [CEA], carbohydrate antigens sialyl Lewis-a [CA 19-9], and sialyl SSEA-1 [SLX]), have also been found in BAL and serum from patients with PAP, but have unclear diagnostic utility [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/49-55\">",
"     49-55",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Bronchoalveolar lavage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several serum biomarkers appear to correlate with disease severity, including LDH, SP-A, SP-D, Kerbs von Lungren 6 antigen (KL-6), and CEA; the strongest correlations were found with the latter two [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sputum examination may suggest PAP in the correct clinical setting, based on the identification of PAS-positive material in macrophages; increased surfactant apoprotein-A (SP-A) in sputum has also been reported, although the latter test is not specific [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;On chest radiography, bilateral symmetric alveolar opacities located centrally in mid and lower lung zones are typical, often in a \"bat wing\" distribution (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62269 \" href=\"UTD.htm?9/10/9379\">",
"     image 1",
"    </a>",
"    ). Additional findings include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymmetric, unilateral, or nodular patterns may be present [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Despite the process being alveolar in distribution, air bronchograms are rare.",
"     </li>",
"     <li>",
"      A thin lucent band may sharply outline the diaphragm and the heart, consistent with sparing of the lung immediately adjacent to these structures.",
"     </li>",
"     <li>",
"      Segmental atelectasis can occur due to bronchiolar obstruction by thick lipoproteinaceous material [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Incomplete alveolar filling may result in an interstitial pattern observed radiographically despite the predominant filling of alveoli observed pathologically [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In chronic cases, focal areas of fibrosis and even extensive pulmonary fibrosis leading to respiratory insufficiency have been rarely reported [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     High resolution CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;High resolution CT scanning (HRCT) reveals ground-glass opacification, predominantly in a homogeneous distribution. There may also be thickened intralobular structures and interlobular septa in typical polygonal shapes, referred to as \"crazy-paving\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/56,61\">",
"     56,61",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58662 \" href=\"UTD.htm?40/17/41232\">",
"     image 2",
"    </a>",
"    ). In a series of 42 patients, a patchy, geographic pattern with crazy-paving was common among patients with autoimmune PAP, whereas a pattern of diffuse ground glass opacity without crazy-paving was more common among patients with secondary PAP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Crazy-paving is not specific for PAP and can also be observed in patients with the acute respiratory distress syndrome, lipoid pneumonia, acute interstitial pneumonia, drug-related hypersensitivity reactions, and diffuse alveolar damage superimposed on usual interstitial pneumonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pulmonary function tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function tests show a restrictive ventilatory defect or sometimes an isolated decrease in DLCO [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29,63\">",
"     29,63",
"    </a>",
"    ]. When present, the decrement in DLCO is often out of proportion to the degree of reduced lung volume and correlates well with other measures of disease severity, such as symptoms and reduction in PaO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/29\">",
"     29",
"    </a>",
"    ]. Varying degrees of hypoxemia and compensated respiratory alkalosis are also common and frequently worsen with exercise. An elevated right-to-left shunt fraction is usually present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic bronchoalveolar lavage (BAL) findings of PAP include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An opaque or milky appearance due to the abundant lipoproteinaceous material, which may settle upon standing",
"     </li>",
"     <li>",
"      Alveolar macrophages that are engorged with the PAS-positive material",
"     </li>",
"     <li>",
"      Large acellular eosinophilic bodies in a background of eosinophilic granules (",
"      <a class=\"graphic graphic_picture graphicRef80205 \" href=\"UTD.htm?17/20/17731\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      PAS staining of proteinaceous material (",
"      <a class=\"graphic graphic_picture graphicRef78010 \" href=\"UTD.htm?16/33/16927\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Elevated SP-A levels",
"     </li>",
"     <li>",
"      Globules in Papanicolaou-stained smears of bronchoalveolar lavage fluid are suggestive of the diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/64\">",
"       64",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 15 patients with PAP compared to control patients with other interstitial lung diseases, BAL levels of chemokine (C-C) motif ligand 2 (CCL2), Kerbs von Lungren 6 antigen (KL-6), and surfactant protein D were increased [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/65\">",
"     65",
"    </a>",
"    ]. Blood samples also revealed higher KL-6 levels in patients with PAP compared to control patients with other lung diseases. Higher levels of KL-6 in both the BAL fluid and blood correlated significantly with higher serum LDH levels, lower PaO2, and a higher alveolar-arterial oxygen gradient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/65\">",
"     65",
"    </a>",
"    ]. Further studies are needed to determine the clinical utility of these tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon histologic examination, the normal alveolar architecture is generally preserved, although the alveolar septa may be slightly thickened due to type II epithelial cell hyperplasia. There is typically little or no inflammatory cell infiltration. The terminal bronchioles and alveoli are filled with a flocculent and granular lipoproteinaceous material that stains pink with PAS stain (",
"    <a class=\"graphic graphic_picture graphicRef80653 \" href=\"UTD.htm?24/16/24840\">",
"     picture 3",
"    </a>",
"    ). Within this lipoproteinaceous material, there are PAS-positive macrophages and scattered clefts of cholesterol crystals that may elicit a histiocytic giant-cell reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8168/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electron microscopy of BAL fluid or lung tissue shows concentrically laminated structures called lamellar bodies. These bodies are comprised of phospholipids and are probably derived from the type II alveolar epithelial cells. Lamellar bodies may be found free in the alveolar airspaces, within alveolar macrophages, and in type II cells. A related ultrastructural finding of irregular concentric whorls (called tubular myelin) may represent the extracellular storage form or a breakdown product of surfactant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary alveolar proteinosis (PAP), also known as pulmonary alveolar phospholipoproteinosis, is a diffuse lung disease characterized by the accumulation of amorphous, periodic acid-Schiff (PAS)-positive lipoproteinaceous material in the distal air spaces. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Altered granulocyte macrophage-colony stimulating factor (GM-CSF) function appears to play a key role in PAP. Autoantibodies to GM-CSF are identified in most adults with PAP and reduced or absent function of the GM-CSF receptor beta-chain on mononuclear cells has been noted in some children with PAP. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alveolar macrophage dysfunction also plays a role in PAP and is likely a consequence of altered GM-CSF function. Both impaired secretion of surfactant transport vesicles and impaired phagocytosis and phagolysosome fusion have been described. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chest radiographs show bilateral symmetric alveolar opacities located centrally in mid and lower lung zones, sometimes resulting in a \"bat wing\" distribution. High resolution CT scanning (HRCT) reveals ground-glass opacification that typically spares the periphery and may have a \"crazy paving\" appearance. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical bronchoalveolar lavage fluid has an opaque or milky appearance due to abundant lipoproteinaceous material. Cytologic examination of BAL reveals alveolar macrophages engorged with PAS-positive material. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bronchoalveolar lavage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transbronchial or video-assisted transthoracic lung biopsy reveals filling of the terminal bronchioles and alveoli with flocculent and granular lipoproteinaceous material that stains pink with PAS stain. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/1\">",
"      ROSEN SH, CASTLEMAN B, LIEBOW AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/2\">",
"      Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003; 349:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/3\">",
"      Presneill JJ, Nakata K, Inoue Y, Seymour JF. Pulmonary alveolar proteinosis. Clin Chest Med 2004; 25:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/4\">",
"      Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 2010; 135:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/5\">",
"      Buechner HA, Ansari A. Acute silico-proteinosis. A new pathologic variant of acute silicosis in sandblasters, characterized by histologic features resembling alveolar proteinosis. Dis Chest 1969; 55:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/6\">",
"      Miller RR, Churg AM, Hutcheon M, Lom S. Pulmonary alveolar proteinosis and aluminum dust exposure. Am Rev Respir Dis 1984; 130:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/7\">",
"      Keller CA, Frost A, Cagle PT, Abraham JL. Pulmonary alveolar proteinosis in a painter with elevated pulmonary concentrations of titanium. Chest 1995; 108:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/8\">",
"      Prakash UB, Barham SS, Carpenter HA, et al. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc 1987; 62:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/9\">",
"      Cordonnier C, Fleury-Feith J, Escudier E, et al. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 1994; 149:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/10\">",
"      Tsushima K, Koyama S, Saitou H, et al. Pulmonary alveolar proteinosis in a patient with chronic myelogenous leukemia. Respiration 1999; 66:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/11\">",
"      McDonald JW, Alvarez F, Keller CA. Pulmonary alveolar proteinosis in association with household exposure to fibrous insulation material. Chest 2000; 117:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/12\">",
"      Cummings KJ, Donat WE, Ettensohn DB, et al. Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med 2010; 181:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/13\">",
"      Cummings KJ, Nakano M, Omae K, et al. Indium lung disease. Chest 2012; 141:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/14\">",
"      Dranoff G, Crawford AD, Sadelain M, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/15\">",
"      Huffman JA, Hull WM, Dranoff G, et al. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 1996; 97:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/16\">",
"      Reed JA, Ikegami M, Cianciolo ER, et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999; 276:L556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/17\">",
"      Nishinakamura R, Nakayama N, Hirabayashi Y, et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/18\">",
"      Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997; 100:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/19\">",
"      Bewig B, Wang XD, Kirsten D, et al. GM-CSF and GM-CSF beta c receptor in adult patients with pulmonary alveolar proteinosis. Eur Respir J 2000; 15:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/20\">",
"      Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205:2711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/21\">",
"      Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/22\">",
"      Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/23\">",
"      Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/24\">",
"      Uchida K, Nakata K, Trapnell BC, et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004; 103:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/25\">",
"      Kitamura T, Uchida K, Tanaka N, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 162:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/26\">",
"      Bonfield TL, Russell D, Burgess S, et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/27\">",
"      Latzin P, Tredano M, W&uuml;st Y, et al. Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis. Thorax 2005; 60:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/28\">",
"      Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001; 163:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/29\">",
"      Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/30\">",
"      Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007; 356:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/31\">",
"      Doerschuk CM. Pulmonary alveolar proteinosis--is host defense awry? N Engl J Med 2007; 356:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/32\">",
"      Bonfield TL, Farver CF, Barna BP, et al. Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003; 29:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/33\">",
"      Alberti A, Luisetti M, Braschi A, et al. Bronchoalveolar lavage fluid composition in alveolar proteinosis. Early changes after therapeutic lavage. Am J Respir Crit Care Med 1996; 154:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/34\">",
"      Gonzalez-Rothi RJ, Harris JO. Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages. Chest 1986; 90:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/35\">",
"      Brasch F, Birzele J, Ochs M, et al. Surfactant proteins in pulmonary alveolar proteinosis in adults. Eur Respir J 2004; 24:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/36\">",
"      Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/37\">",
"      Mildenberger E, deMello DE, Lin Z, et al. Focal congenital alveolar proteinosis associated with abnormal surfactant protein B messenger RNA. Chest 2001; 119:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/38\">",
"      Hoffman RM, Dauber JH, Rogers RM. Improvement in alveolar macrophage migration after therapeutic whole lung lavage in pulmonary alveolar proteinosis. Am Rev Respir Dis 1989; 139:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/39\">",
"      Poletti V, Costabel U, Casoni GL, et al. Rare infiltrative lung diseases: a challenge for clinicians. Respiration 2004; 71:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/40\">",
"      Santamaria F, Brancaccio G, Parenti G, et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 2004; 145:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/41\">",
"      Palac&iacute;n M, Borsani G, Sebastio G. The molecular bases of cystinuria and lysinuric protein intolerance. Curr Opin Genet Dev 2001; 11:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/42\">",
"      Parto K, M&auml;ki J, Pelliniemi LJ, Simell O. Abnormal pulmonary macrophages in lysinuric protein intolerance. Ultrastructural, morphometric, and x-ray microanalytic study. Arch Pathol Lab Med 1994; 118:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/43\">",
"      Parto K, Kallajoki M, Aho H, Simell O. Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients. Hum Pathol 1994; 25:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/44\">",
"      Goldstein LS, Kavuru MS, Curtis-McCarthy P, et al. Pulmonary alveolar proteinosis: clinical features and outcomes. Chest 1998; 114:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/45\">",
"      Shah PL, Hansell D, Lawson PR, et al. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000; 55:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/46\">",
"      Bedrossian CW, Luna MA, Conklin RH, Miller WC. Alveolar proteinosis as a consequence of immunosuppression. A hypothesis based on clinical and pathologic observations. Hum Pathol 1980; 11:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/47\">",
"      Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 1994; 73:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/48\">",
"      Martin RJ, Rogers RM, Myers NM. PUlmonary alveolar proteinosis: shunt fraction and lactic acid dehydrogenase concentration as aids to diagnosis. Am Rev Respir Dis 1978; 117:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/49\">",
"      Honda Y, Takahashi H, Shijubo N, et al. Surfactant protein-A concentration in bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Chest 1993; 103:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/50\">",
"      Kuroki Y, Tsutahara S, Shijubo N, et al. Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am Rev Respir Dis 1993; 147:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/51\">",
"      Honda Y, Kuroki Y, Shijubo N, et al. Aberrant appearance of lung surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance. Respiration 1995; 62:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/52\">",
"      Honda Y, Kuroki Y, Matsuura E, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/53\">",
"      Hirakata Y, Kobayashi J, Sugama Y, Kitamura S. Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. Eur Respir J 1995; 8:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/54\">",
"      Fujishima T, Honda Y, Shijubo N, et al. Increased carcinoembryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Respiration 1995; 62:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/55\">",
"      Usui Y, Takayama S, Nakayama M, et al. Interstitial lattice shadow and mediastinal lymphadenopathy with an elevation of carcinoembryonic antigen in severe pulmonary alveolar proteinosis. Intern Med 1992; 31:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/56\">",
"      Holbert JM, Costello P, Li W, et al. CT features of pulmonary alveolar proteinosis. AJR Am J Roentgenol 2001; 176:1287.",
"     </a>",
"    </li>",
"    <li>",
"     Wasserman K, Mason GR. Pulmonary alveolar proteinosis. In: Textbook of Respiratory Medicine, 2nd ed, Murray JF, Nadel JA (Eds), WB Saunders Co, Philadelphia 1994. p.1933.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/58\">",
"      Claypool WD, Rogers RM, Matuschak GM. Update on the clinical diagnosis, management, and pathogenesis of pulmonary alveolar proteinosis (phospholipidosis). Chest 1984; 85:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/59\">",
"      Miller PA, Ravin CE, Smith GJ, Osborne DR. Pulmonary alveolar proteinosis with interstitial involvement. AJR Am J Roentgenol 1981; 137:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/60\">",
"      Hudson AR, Halprin GM, Miller JA, Kilburn KH. Pulmonary interstitial fibrosis following alveolar proteinosis. Chest 1974; 65:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/61\">",
"      Ishii H, Trapnell BC, Tazawa R, et al. Comparative study of high-resolution CT findings between autoimmune and secondary pulmonary alveolar proteinosis. Chest 2009; 136:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/62\">",
"      Johkoh T, Itoh H, M&uuml;ller NL, et al. Crazy-paving appearance at thin-section CT: spectrum of disease and pathologic findings. Radiology 1999; 211:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/63\">",
"      Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/64\">",
"      Chou CW, Lin FC, Tung SM, et al. Diagnosis of pulmonary alveolar proteinosis: usefulness of papanicolaou-stained smears of bronchoalveolar lavage fluid. Arch Intern Med 2001; 161:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8168/abstract/65\">",
"      Lin FC, Chen YC, Chang SC. Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis. Mayo Clin Proc 2008; 83:1344.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4373 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-6BDFF69EB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8168=[""].join("\n");
var outline_f7_62_8168=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Role of GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Macrophage dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Associated infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - High resolution CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pulmonary function tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4373\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4373|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/10/9379\" title=\"diagnostic image 1\">",
"      Alveolar proteinosis chest xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/17/41232\" title=\"diagnostic image 2\">",
"      Alveolar proteinosis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4373|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/20/17731\" title=\"picture 1\">",
"      BAL in alveolar proteinosis with eosinophilic bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/33/16927\" title=\"picture 2\">",
"      PAS stain of BAL fluid in alveolar proteinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/16/24840\" title=\"picture 3\">",
"      Histopathology of pulmonary alveolar proteinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4373|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/8/14475\" title=\"table 1\">",
"      Causes alveolar proteinosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18759?source=related_link\">",
"      Diagnosis and treatment of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/360?source=related_link\">",
"      Pulmonary alveolar proteinosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40106?source=related_link\">",
"      Pulmonary complications after allogeneic hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33145?source=related_link\">",
"      Silicosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8169="Musculoskeletal injury in the young athlete: Overview of rehabilitation for nonoperative injuries";
var content_f7_62_8169=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Musculoskeletal injury in the young athlete: Overview of rehabilitation for nonoperative injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8169/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8169/contributors\">",
"     Gabriel P Brooks, PT, DPT, MSPT, MTC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8169/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8169/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8169/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8169/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8169/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/62/8169/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic reviews the phases of musculoskeletal injury rehabilitation as they relate to the phases of healing, the transition from one phase to the next, the maintenance of cardiovascular fitness during rehabilitation, and the progression of goals that must be met before return to sports participation. The treatment principles and modalities are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44775?source=see_link\">",
"     \"Musculoskeletal injury in the young athlete: Overview of treatment principles for nonoperative injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper prescription of physical therapy is vital to the completion of healing and a timely return to sports participation. The phases of rehabilitation correspond to the phases of healing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammatory phase (0 to 72 hours after injury)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Reparative/fibroblastic",
"      </span>",
"      phase (72 hours to 3 weeks after injury)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Maturation/remodeling",
"      </span>",
"      phase (3 weeks to 2 years after injury)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    How and when a modality, manipulation, or exercise is deployed is guided by the type of injury and tissue response to physiologic demand and by the signs and symptoms of the stages of the healing process (",
"    <a class=\"graphic graphic_table graphicRef65458 \" href=\"UTD.htm?42/36/43596\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The discussion that follows assumes that fractures and joint instability have been excluded. The evaluation of musculoskeletal trauma and the management of fractures and unstable joints are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INFLAMMATORY PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management during the inflammatory phase (0 to 72 hours after injury) focuses on PRICE:",
"    <strong>",
"     P",
"    </strong>",
"    rotection of the injured area,",
"    <strong>",
"     R",
"    </strong>",
"    elative rest, and decreasing swelling through",
"    <strong>",
"     I",
"    </strong>",
"    ce,",
"    <strong>",
"     C",
"    </strong>",
"    ompression, and",
"    <strong>",
"     E",
"    </strong>",
"    levation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/1\">",
"     1",
"    </a>",
"    ]. Some of these modalities also may be necessary during subsequent phases of rehabilitation, particularly if pain and swelling increase during therapeutic exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection of the injured area prevents further tissue damage. Examples of protective modalities include crutches, padding, shock-absorbing insoles, and external supports (eg, air stirrup brace) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In addition, protection includes a graduated return to play progression to help reduce the risk of reinjury due to tissue overload that exceeds the rate of tissue repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Relative rest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative, rather than complete, rest is prescribed during the inflammatory phase. Immobilization of the injured joint or musculotendinous unit should be local and of short duration. Properly dosed exercise and activities of daily living can protect ligaments and joint soft tissues as long as the force is not too great and does not result in swelling or pain at the affected site. Pain and swelling are the body's response to overloading a tissue's ability to accommodate a particular load. Sudden return to high-level training without adequate proprioceptive training increases the likelihood of ligament injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immobility is deleterious because it causes a net shift in ligament cell metabolism from homeostasis to a catabolic state. Immobilization results in bone resorption and focal weakening at the insertion sites of ligaments and tendons, with concomitant decreased strength and stiffness of connective tissue. After six to nine weeks of immobilization, the connective tissues lose one-half of their previous strength and stiffness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. Disuse of tendons leads to loss of tissue volume and formation of cross-links [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. The resulting tissue is weak and fails at &le;60 percent of its previous strain-to-failure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cold therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cold therapy is commonly used during the inflammatory phase to decrease swelling and pain. The benefits of cold therapy have been demonstrated with magnetic resonance imaging of the perfusion of muscle tissue and diffusion of water molecules following cryotherapy wherein tissue temperature and perfusion were both noted to be significantly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/10\">",
"     10",
"    </a>",
"    ]. Cryotherapy has been demonstrated to have effects on acute injury including decreased pain, decreased swelling, and increased range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the early observational studies demonstrating the benefit of cryotherapy in patients with ankle sprain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/11-13\">",
"     11-13",
"    </a>",
"    ] were of limited methodological rigor and it remains unclear if cryotherapy improves functional outcomes significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to explain correct usage of cold therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/14\">",
"     14",
"    </a>",
"    ]. Ice application should begin immediately postinjury. Ice packs (crushed ice and water in a plastic bag) should be applied directly to the skin for 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/15\">",
"     15",
"    </a>",
"    ]. Three to four times per day is considered sufficient, but cold therapy can be performed every hour; the more frequent the application, the greater the chance of effectively reducing the inflammatory process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44775?source=see_link&amp;anchor=H13#H13\">",
"     \"Musculoskeletal injury in the young athlete: Overview of treatment principles for nonoperative injuries\", section on 'Cold therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Contraindications to cold therapy include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Raynaud phenomenon (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peripheral vascular disease (eg, diabetes)",
"     </li>",
"     <li>",
"      Impaired sensation",
"     </li>",
"     <li>",
"      Cold",
"      <span class=\"nowrap\">",
"       allergy/hypersensitivity",
"      </span>",
"     </li>",
"     <li>",
"      Severe cold-induced urticaria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link\">",
"       \"Cold urticaria\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cryoglobulinemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=see_link\">",
"       \"Overview of cryoglobulins and cryoglobulinemia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Paroxysmal cold hemoglobinuria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=see_link\">",
"       \"Paroxysmal cold hemoglobinuria\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Compression and elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression is traditionally paired with elevation to provide an increase in hydrostatic gradients and to promote venous return [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/16\">",
"     16",
"    </a>",
"    ]. The addition of pain-free range of motion (ROM) may increase lymphatic drainage 5 to 15 times the resting level, hastening restoration of fluid balance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/16\">",
"     16",
"    </a>",
"    ]. The combination of compression and ice is more effective in controlling edema than is compression alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of compression were demonstrated in a trial in which noninjured subjects were randomly assigned to use or not use an elbow sleeve after eccentric muscle exercise (exercise that opposes gravity and acts to lengthen muscles) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/19\">",
"     19",
"    </a>",
"    ]. Use of the compression sleeve was associated with reduced delayed-onset muscle soreness, decreased loss of strength, decreased swelling, improved resting joint angle, increased ability to perform daily tasks, decreased perception of soreness, and decreased levels of serum creatine kinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Therapies to avoid",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Heat",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that heat therapy be avoided during the inflammatory phase of rehabilitation. Heat increases local swelling, inflammation, vasodilation, and blood flow, all of which are detrimental in the inflammatory phase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/11\">",
"     11",
"    </a>",
"    ]. In observational studies of patients with ankle sprain, application of heat was associated with delayed recovery compared with application of cold [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     PT Prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;When writing a prescription for physical therapy for a patient in the inflammatory phase, the prescription should reflect the principles described above (ie, protection of the injured area, properly dosed exercise, and application of various modalities to reduce edema) (",
"    <a class=\"graphic graphic_table graphicRef65458 \" href=\"UTD.htm?42/36/43596\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     REPARATIVE PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reparative phase (approximately three days to three weeks after injury) of rehabilitation begins after inflammation is controlled, when swelling and spasms decrease or subside and the injured area can be moved with little to no pain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example of a patient in the reparative phase is a boy who presents one week after an ankle sprain and has mild discomfort, but whose overall pain is improved. He still has pain with activities of daily living, walks with a small limp, and, subjectively, cannot return to exercise or sports. He may recruit the muscles about the ankle but does so with a delay that does not protect the joint from injurious forces encountered during sports and does not permit cutting or pivoting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reparative goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of physical therapy during the reparative phase are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continued protection of the injured structures (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Protection'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Full range of motion (ROM) of the affected joints and soft tissues",
"     </li>",
"     <li>",
"      Reestablished proprioception",
"     </li>",
"     <li>",
"      Progression from basic voluntary uniplanar muscular firing patterns to more complex, coordinated muscular strength, endurance, power, and functional tasks (",
"      <a class=\"graphic graphic_table graphicRef59348 \" href=\"UTD.htm?36/0/36876\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If pain and swelling increase during the reparative phase of therapy, it may be necessary to add the modalities used during the inflammatory phase (eg, ice and compression); reduction of the intensity and duration of therapeutic exercises is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     ROM and flexibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexibility and full ROM must be restored to the injured muscles and joints in order to adequately distribute force inherent in daily activities and sports. In setting goals for physical therapy, it is useful to know the ROM requirements for various activities. As an example, the knee ROM requirements for walking, stairs, cycling, and jogging are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Walking without a limp &mdash; Flexion of 75&ordm;",
"     </li>",
"     <li>",
"      Stair climbing and cycling &mdash; Flexion of 90&ordm;",
"     </li>",
"     <li>",
"      Jogging or running &mdash; Flexion of 105 to 120&ordm;",
"     </li>",
"     <li>",
"      Sprinting &mdash; Flexion of 140&ordm;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is necessary to have 5 to 10 more degrees of static flexion than listed above to achieve the smooth function of dynamic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with soft-tissue adhesions or contracture of muscles or joints, myofascial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    joint manipulation is required to regain full ROM, including osteokinematic (gross movements of bones at joints, such as",
"    <span class=\"nowrap\">",
"     flexion/extension)",
"    </span>",
"    and arthrokinematic (movements of joint surfaces, such as gliding) motion. Arthrokinematics must be normalized before osteokinematics can be addressed.",
"   </p>",
"   <p>",
"    Myofascial and joint manipulation (increasing myofascial length and joint accessory mobility) is an essential component of the reparative physical therapy regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Restricted joint motion decreases the working surface area of the joint, increasing the force per unit area and contributing to greater wear and early fatigue failure of structures in and about the affected joint. Myofascial length can be increased with static or dynamic flexibility activities.",
"   </p>",
"   <p>",
"    Static flexibility is the actual muscle length that allows ROM about a joint assuming normal arthrokinematics. To achieve static flexibility, static stretching is conducted by placing the affected muscle-tendon unit in an anatomically lengthened position. Low-load, long-duration (ie, 20- to 30-second) stretches are preferred to fast stretches for lengthening myofascial structures according to known tissue mechanical properties [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/20,24-26\">",
"     20,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dynamic flexibility is the ability to use the full ROM of a joint by overcoming resistance during performance of an activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. Dynamic flexibility may be gained with dynamic drills in addition to static stretching methods [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improvement in flexibility can be gained through a progressive velocity flexibility program (PVFP). PVFP facilitates motor learning response as the muscle stretches at higher velocities over time, simulating movement and integrating functional activities. Days or weeks of PVFP may be necessary to achieve the desired freedom of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A PVFP consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Static stretching",
"     </li>",
"     <li>",
"      Slow short-end range stretching",
"     </li>",
"     <li>",
"      Slow full-range stretching",
"     </li>",
"     <li>",
"      Fast short-end range stretching",
"     </li>",
"     <li>",
"      Fast full-range stretching",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Adjunctive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat therapy and cold therapy may be used as adjuncts to stretching exercises. Warming the muscles before stretching (eg, with warm-up exercises or passive heating modalities) enhances the beneficial effects of stretching exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]. Applying ice to a tissue in a lengthened position results in lengthened tissue and increased range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/16,28\">",
"     16,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Proprioception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to sports activity requires proprioception, as well as ROM and flexibility [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. Injury disrupts the proprioceptive feedback loop when the nerve ending is stretched or torn [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5,29\">",
"     5,29",
"    </a>",
"    ]. The goal of therapy is to reduce the time between the neural stimulus and the desired muscular response, thus reducing stress on the injured joint [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/30\">",
"     30",
"    </a>",
"    ]. Proprioceptive drills can be progressed from weight-bearing exercises on two limbs, to one limb, and finally, on compliant surfaces such as mini-trampolines and balance boards [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. Physical therapy treatment of a joint with a ligament sprain improves proprioception, function, pain, and disability scores [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/2,30-33\">",
"     2,30-33",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Retraining methods to improve proprioception of the affected segment include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Taping or bracing to aid joint alignment and increase sensory input",
"     </li>",
"     <li>",
"      Progressive static balance exercises moving from a firm surface to a compliant surface",
"     </li>",
"     <li>",
"      Increasing difficulty by increasing the speed of the task or performing the task without looking at the affected limb",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of an elastic bandage (or neoprene sleeve) improves proprioception during open-chain activities (eg, those in which the distal extremity is free to move, such as knee extension in the seated position) in uninjured knees; the greater the initial impairment in proprioception, the more wrapping improved performance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In contrast, the use of an elastic bandage (or neoprene sleeve) does not appear to objectively improve proprioception during closed-chain (eg, those in which the distal extremity is fixed, such as squats) activities, perhaps because of the inherent increased proprioceptive input at the plantar surface, ankle, and hop during closed-chain tasks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     PT prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescriptions for PT during the reparative phase should request a program emphasizing normalizing ROM, flexibility, functional stability, and proprioception (",
"    <a class=\"graphic graphic_table graphicRef65458 \" href=\"UTD.htm?42/36/43596\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/2,30-33\">",
"     2,30-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TRANSITION TO MATURATION PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the athlete begins the transition from the reparative to the maturation phase, it is important to establish clinical and functional rehabilitation goals that must be met before the athlete can return to sports activity. This planning spans the reparative and maturation phases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A goal-oriented approach allows the athlete to return to play when he or she is ready. The physical therapy regimen should establish step-by-step goals so progress can be evaluated. When setting goals, it is important to involve the athlete so that he or she is invested in the process, and to provide objective measures of goal attainment.",
"   </p>",
"   <p>",
"    Clinical goals should be established for flexibility, proprioception, voluntary muscle firing patterns, strength, endurance, and cardiovascular fitness. Functional goals should be established for power, speed, agility, and sport-specific skills [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. Each of these areas is discussed in greater detail below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Maturation phase'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example, sequential goals for a running athlete with knee pain would include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal ROM about the knee",
"     </li>",
"     <li>",
"      Ability to activate the quadriceps correctly in isolation",
"     </li>",
"     <li>",
"      Ability to activate the quadriceps during concentric phase contraction",
"     </li>",
"     <li>",
"      Single-limb, load-bearing balance with the concentric phase contraction",
"     </li>",
"     <li>",
"      Eccentric phase step-down with control of speed, angles, and balance",
"     </li>",
"     <li>",
"      Dynamic drills such as hopping, figure-eights, shuttle runs, or cutting drills, depending upon the athlete's sport, to further load the knee",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With such a program, the athlete progresses from easier to harder skills and from lesser to greater demand. Interval return to sports programs can be used to advance the throwing athlete, golfer, tennis, or running athlete from the injury rehabilitation phase to sports-ready condition [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     PT prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prescription for physical therapy during this transition should include activities starting in the reparative phase and progressing through the end of the maturation phase, allowing the physical therapist to select the best phase-dependent choice for neuromotor recovery (",
"    <a class=\"graphic graphic_table graphicRef65458 \" href=\"UTD.htm?42/36/43596\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MATURATION PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the",
"    <span class=\"nowrap\">",
"     maturation/remodeling",
"    </span>",
"    phase (approximately three weeks to two years after injury), new collagen and bone matrix fibers that were deposited during the reparative phase increase their strength and organization. The application of excessive force during this phase will disrupt the immature tissue. On the other hand, if insufficient force is applied, the tissue will not organize along lines of stress and will fail during the application of strong force as the athlete returns to sports activity.",
"   </p>",
"   <p>",
"    Properly dosed exercise can protect ligaments and joint soft tissues as long as the force is not too great and does not result in swelling or pain at the affected site. Low, cyclic loads increase collagen proliferation and material remodeling, making the tissue stronger and stiffer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5,16,25\">",
"     5,16,25",
"    </a>",
"    ]. The challenge for the physical therapist is to use sufficient motion to stimulate maturation without exceeding the tissue's load tolerance. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Load tolerance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Maturation goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and functional goals that begin during the reparative phase and continue into the maturation phase relate to [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flexibility",
"     </li>",
"     <li>",
"      Proprioception",
"     </li>",
"     <li>",
"      Progression from basic voluntary muscular firing patterns to muscular strength, endurance, and power (",
"      <a class=\"graphic graphic_table graphicRef59348 \" href=\"UTD.htm?36/0/36876\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiovascular endurance",
"     </li>",
"     <li>",
"      Power",
"     </li>",
"     <li>",
"      Speed",
"     </li>",
"     <li>",
"      Agility",
"     </li>",
"     <li>",
"      Sport-specific skills",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Flexibility and proprioception are discussed above. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'ROM and flexibility'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H15\">",
"     'Proprioception'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    During the maturation phase, there should be little need for physical modalities, but protection (eg, braces, taping, protective equipment) may still be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/20\">",
"     20",
"    </a>",
"    ]. Flexibility and joint motion should be normal, but ongoing maintenance is necessary to retain earlier gains. Therapeutic exercise may focus on higher speeds of contraction, enhancing power and endurance, and restoration of proprioception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Load tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major goal of therapy during the maturation phase is to identify the load tolerance of the maturing tissue and apply sufficient force to allow the tissue to get stronger without exceeding its threshold; cyclic loading has been demonstrated to alter collagen in a manner consistent with the goals of physical therapy for improving collagen synthesis and resistance to loading [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/37\">",
"     37",
"    </a>",
"    ]. The load must match the strain tolerance of healing collagen without disrupting the immature fiber matrix. Pain is a sign that the load is excessive and must be reduced.",
"   </p>",
"   <p>",
"    In a patient with a partial thickness tear of the Achilles' tendon, for example, if pain occurs with single-limb load-bearing exercise, double-limb load-bearing exercise can be used. If there is pain on two legs, the load can be reduced through a variable inclined plane or aquatic exercise. These adaptations enable the patient to exercise as little as 3 percent to &ge;70 percent of body weight. Over the course of weeks, the plantar flexion load is progressively increased until the activity demand is met by the healing tissue, permitting a pain-free return to sports activity.",
"   </p>",
"   <p>",
"    Identification of appropriate load is accomplished by selecting exercises that are specific to the injured muscle tendon unit and allowing the patient to reach fatigue between 20 and 30 repetitions of the exercise without pain provocation. Each phase of the progression adds a degree of challenge to the maturing tissue when it has met the previous stage's goal.",
"   </p>",
"   <p>",
"    Progressive loading can be done by increasing the percentage of body weight for which the patient is responsible, increasing the resistance applied, or speeding up the movement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, an athlete who begins at a load tolerance of 50 percent of his body weight before provocation of familiar pain may be progressed to 60 percent when sets of 30 or more repetitions can be performed at 50 percent of body weight without pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;The redevelopment of strength is a primary step in rehabilitation. Strengthening exercises should be as functional or sport-specific as possible and should be progressed from general strength to specific strength [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. However, to achieve the premorbid sports level, core strengthening of the lumbo-pelvic muscular stabilizers also may be necessary.",
"   </p>",
"   <p>",
"    In the progression of strengthening exercises, it is important to involve concentric and eccentric strengthening, isometrics, isotonics, proprioceptive neuromuscular facilitation, and stretch-shortening cycle activities (",
"    <a class=\"graphic graphic_table graphicRef66164 \" href=\"UTD.htm?33/34/34348\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. Closed-chain exercises are an excellent way to include all these phases of strengthening. Closed-chain exercises are performed with the distal segment of an extremity fixed and with motion occurring at the proximal segments. Examples of closed-chain exercises for the lower extremity include partial squats, leg presses, single leg load bearing balance with or without perturbation, step-ups, lunges, stair climbers, lateral slide boards, treadmills, the use of a biomechanical ankle platform system (BAPS) board, mini-trampolines, and Dyna Discs.",
"   </p>",
"   <p>",
"    Working in closed-chain contexts provides functional deceleration training for large lower-extremity muscle groups and enhances speed, balance, and coordination. Closed-chain exercises increase joint stability through a larger ROM and enhanced muscle action around the joint. However, closed kinetic chain exercises should be augmented by open chain exercises where deemed appropriate by the treating therapist because the addition of open kinetic chain exercise to a closed kinetic chain regimen improves outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Muscular endurance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscular endurance is the capacity of muscle to perform repetitive contractions against a load [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. Endurance is compromised after injury and immobilization because there is a preferential loss of type I muscle fibers (also known as slow-twitch, red, or oxidative endurance-biased muscle fibers) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/39\">",
"     39",
"    </a>",
"    ]. During rehabilitation, it takes longer to regain muscular endurance than muscular strength.",
"   </p>",
"   <p>",
"    Endurance can be obtained via high-repetition, low-load exercises. A level of muscular discomfort but not familiar pain should be reached at 20 repetitions of the assigned weight. The speed of movement or the load should be decreased if muscular discomfort is felt before 20 repetitions. The speed or load should be increased if the muscle is not taxed by 30 repetitions in one set.",
"   </p>",
"   <p>",
"    Exercises should be performed daily with progression until symptoms are gone and full load bearing is achieved with sport-specific weight. It may take 2 to 16 weeks to achieve this goal (average six weeks). Reasons for failure or delay include incorrect diagnosis, external factors (eg,",
"    <span class=\"nowrap\">",
"     environmental/ergonomic),",
"    </span>",
"    noncompliance, or improperly paced progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     CV endurance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The athlete's cardiovascular fitness should be maintained during rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. Maintaining cardiovascular endurance helps to minimize the time away from sport. The athlete may return to sports without delay when the rehabilitation goals for the injured tissue have been met if cardiovascular endurance is maintained during rehabilitation.",
"   </p>",
"   <p>",
"    Cardiovascular endurance can be maintained via cross-training (eg, aqua jogging, upper-extremity bikes, gait-unloading devices). Runners can maintain maximum oxygen consumption (VO2 max) and two-mile run performance similar to that achieved with running through cycling or aqua jogging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Power",
"    </span>",
"    &nbsp;&mdash;&nbsp;Power is the ability of muscle to exert a large amount of force at a fast rate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5,41,42\">",
"     5,41,42",
"    </a>",
"    ]. Increased power requires increased strength or rate of muscle shortening.",
"   </p>",
"   <p>",
"    To improve power with training, exercise should occur at 30 to 60 percent of maximum voluntary contraction (MVC). Training at 30 to 60 percent MVC increases both force and velocity (and thus power), whereas training at 100 percent MVC improves force, but not velocity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plyometric activities, which use the stretch-shortening cycle to get a greater force of contraction, increase power by requiring the muscle to change from eccentric to concentric action quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. They also may help develop reciprocal reflexes to help prevent injuries. A plyometric program should be performed two to three times per week to allow for soft-tissue repair but should be discontinued if pain or swelling occurs.",
"   </p>",
"   <p>",
"    Practical examples of plyometric activities for lower- and upper-extremity injuries include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower-extremity injuries &mdash; Pilates machine (supine rebounder), mini-trampoline, platform-floor-platform jumping (4-inch platform increased 2 to 4 inches per week, up to 10 inches)",
"     </li>",
"     <li>",
"      Upper-extremity injuries &mdash; Plyoballs or medicine balls",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The training consists of three to five sets of 15 to 20 repetitions. The intensity may be increased by turning 90&ordm; to 180&ordm; in the air, including a slant board, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Speed",
"    </span>",
"    &nbsp;&mdash;&nbsp;The well-designed physical therapy regimen includes a progression of strength and endurance superimposed on a progression of speed. Speed is important for return to sports; it is one of the elements that compose agility. Muscular recruitment is specific by angle and speed, so training that occurs in a rehabilitation gym at 30 to",
"    <span class=\"nowrap\">",
"     60&ordm;/s",
"    </span>",
"    will not prepare an athlete who performs his sport at",
"    <span class=\"nowrap\">",
"     &ge;300&ordm;/second",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/44\">",
"     44",
"    </a>",
"    ]. Performing drills to regain coordination and muscle recruitment required for sport-specific speed should be included [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Agility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agility is the ability to change directions of the body and its parts quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ]. It is a combination of reaction time, speed, coordination, power, and strength. Agility allows the athlete to avoid obstacles or contact with other players and thus to avoid injury.",
"   </p>",
"   <p>",
"    Agility can be trained using figure-eight running, zigzag running, shuttle runs (repetitions of running back and forth between markers), carioca (running sideways with the legs crossing each other), retro-running (running backwards), and cross-over cutting. It is possible to progress the degree of difficulty by going from half speed to full speed and increasing the cutting angle from 45 to 90&ordm;.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Sport-specific activities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression to sport-specific activities requires the athlete to possess power, speed, and agility [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5,41,42\">",
"     5,41,42",
"    </a>",
"    ]. The goal is to reacquire sport-specific motor memory patterns learned by thousands of repetitions. The regimen of sport-specific activities uses all the skills the athlete has gained in physical therapy to make the transition from clinical wellness to game readiness.",
"   </p>",
"   <p>",
"    The criteria for the sport-specific activities phase include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjective assessment from therapist or trainer that the athlete is able to use the injured extremity well.",
"     </li>",
"     <li>",
"      Athlete's demonstration of self-confidence to participate fully in sport-specific activities without experiencing pain, swelling, or giving way.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific tests can be used to assess the quality of performance, such as a slow descent from an 18- to 24-inch stair on the involved leg or separately performing a hop stress test (triangle of spots jumping back, forward, and side to side) for an ankle or knee injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Sport-specific drills",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final phase of an athlete's physical therapy in order to return to sports is performance of sport-specific drills. These drills are akin to a practice regimen. There are several specific programs available for certain sports, such as throwing, tennis, and golf [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/16\">",
"     16",
"    </a>",
"    ]. At this point in the rehabilitation, the athlete makes a return to unrestricted activities that should follow as a natural progression from functional rehabilitation, with the final step mimicking competition or performance conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     DISCHARGE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discharge from the functional rehabilitation physical therapy program, the athlete must meet certain criteria, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete resolution of acute signs and symptoms related to injury; the strength and motion of the injured extremity must be the same as those in the uninjured extremity [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8169/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Full, dynamic ROM of all joints, with adequate strength and proprioception to perform expected skills successfully",
"     </li>",
"     <li>",
"      No alteration of athlete's normal mechanics, which might predispose to subsequent injury",
"     </li>",
"     <li>",
"      Performance of sport-specific activities at or above pre-injury level",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Post-rehab goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the athlete has met the criteria for each phase, has met the discharge criteria, and is formally discharged from care, the treating practitioner should define the specifics of the sports program, such as number of exercise bouts per day or week, intensity level,",
"    <span class=\"nowrap\">",
"     repetitions/distance,",
"    </span>",
"    and amount of rest. With the completion of a comprehensive, phase-dependent physical therapy regimen, the athlete can return to sports with confidence and yield excellent performance with minimal chance for reinjury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proper prescription of physical therapy is vital to the completion of healing and a timely return to sports participation. The phases of rehabilitation correspond to the phases of healing: inflammatory (0 to 72 hours after injury), reparative (72 hours to 3 weeks after injury), and maturation (3 weeks to 2 years after injury). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management during the inflammatory phase focuses on PRICE:",
"      <strong>",
"       P",
"      </strong>",
"      rotection of the injured area,",
"      <strong>",
"       R",
"      </strong>",
"      elative rest, and decreasing swelling through",
"      <strong>",
"       I",
"      </strong>",
"      ce,",
"      <strong>",
"       C",
"      </strong>",
"      ompression, and",
"      <strong>",
"       E",
"      </strong>",
"      levation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Inflammatory phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest cold therapy during the inflammatory phase of sports injuries (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ice application should begin immediately postinjury. Ice packs (1 kg of ice and water in a plastic bag) should be applied directly to the skin for 20 minutes at least three times per day. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Cold therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not applying heat to injuries during the inflammatory phase of sports injury (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Heat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of physical therapy during the reparative phase are continued protection of the injured structures, full range of motion (ROM) of the affected joints and soft tissues, reestablished proprioception, and progression from basic voluntary muscular firing patterns to muscular strength, endurance, and power (",
"      <a class=\"graphic graphic_table graphicRef59348 \" href=\"UTD.htm?36/0/36876\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Reparative phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the athlete begins the transition from the reparative to the maturation phase, it is important to establish clinical and functional rehabilitation goals that must be met before the athlete can return to sports activity. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Transition to maturation phase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical and functional goals that begin during the reparative phase and continue into the maturation phase relate to flexibility; proprioception; progression from basic voluntary muscular firing patterns to muscular strength, endurance, and power; cardiovascular endurance; speed; agility; and sport-specific skills (",
"      <a class=\"graphic graphic_table graphicRef59348 \" href=\"UTD.htm?36/0/36876\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Maturation goals'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Criteria for discharge from functional rehabilitation include complete resolution of acute signs and symptoms related to injury; full, dynamic ROM of all joints, with adequate strength and proprioception to perform expected skills successfully; return to athlete's normal mechanics; and performance of sport-specific activities at or above pre-injury level. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Discharge criteria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     ACKNOWLEDGMENT",
"    </strong>",
"    &nbsp;&mdash;&nbsp;The authors and editorial staff at UpToDate, Inc. would like to acknowledge Dr. Jeffrey Cline and Dr. Dana Fitzgerald, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/1\">",
"      Hubbard TJ, Denegar CR. Does Cryotherapy Improve Outcomes With Soft Tissue Injury? J Athl Train 2004; 39:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/2\">",
"      Seah R, Mani-Babu S. Managing ankle sprains in primary care: what is best practice? A systematic review of the last 10 years of evidence. Br Med Bull 2011; 97:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/3\">",
"      Boyce SH, Quigley MA, Campbell S. Management of ankle sprains: a randomised controlled trial of the treatment of inversion injuries using an elastic support bandage or an Aircast ankle brace. Br J Sports Med 2005; 39:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/4\">",
"      Mohammadi F. Comparison of 3 preventive methods to reduce the recurrence of ankle inversion sprains in male soccer players. Am J Sports Med 2007; 35:922.",
"     </a>",
"    </li>",
"    <li>",
"     Magee DJ, Quillen WS, Zachazewski JE. Athletic Injuries and Rehabilitation, 1st ed, Saunders, Philadelphiai 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/6\">",
"      Akeson WH, Amiel D, Abel MF, et al. Effects of immobilization on joints. Clin Orthop Relat Res 1987; :28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/7\">",
"      Akeson WH, Amiel D, Woo SL. Immobility effects on synovial joints the pathomechanics of joint contracture. Biorheology 1980; 17:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/8\">",
"      Noyes FR. Functional properties of knee ligaments and alterations induced by immobilization: a correlative biomechanical and histological study in primates. Clin Orthop Relat Res 1977; :210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/9\">",
"      Woo SL, Gomez MA, Sites TJ, et al. The biomechanical and morphological changes in the medial collateral ligament of the rabbit after immobilization and remobilization. J Bone Joint Surg Am 1987; 69:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/10\">",
"      Yanagisawa O, Fukubayashi T. Diffusion-weighted magnetic resonance imaging reveals the effects of different cooling temperatures on the diffusion of water molecules and perfusion within human skeletal muscle. Clin Radiol 2010; 65:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/11\">",
"      McLean DA. The use of cold and superficial heat in the treatment of soft tissue injuries. Br J Sports Med 1989; 23:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/12\">",
"      Hocutt JE Jr, Jaffe R, Rylander CR, Beebe JK. Cryotherapy in ankle sprains. Am J Sports Med 1982; 10:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/13\">",
"      Knight KL. Ankle rehabilitation with cryotherapy. Phys Sportsmed 1979; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/14\">",
"      Hergenroeder A. Acute shoulder, knee, and ankle injuries part 2: Rehabilitation. Adolescent Health Update 1996; 8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/15\">",
"      Dykstra JH, Hill HM, Miller MG, et al. Comparisons of cubed ice, crushed ice, and wetted ice on intramuscular and surface temperature changes. J Athl Train 2009; 44:136.",
"     </a>",
"    </li>",
"    <li>",
"     Reid DC. Sports Injury Assessment and Rehabilitation, Churchill Livingstone, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/17\">",
"      Sloan JP, Gidding P, Hain R. Effects of cold and compression on edema. Phys Sportsmed 1988; 16:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/18\">",
"      Tomchuk D, Rubley MD, Holcomb WR, et al. The magnitude of tissue cooling during cryotherapy with varied types of compression. J Athl Train 2010; 45:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/19\">",
"      Kraemer WJ, Bush JA, Wickham RB, et al. Influence of compression therapy on symptoms following soft tissue injury from maximal eccentric exercise. J Orthop Sports Phys Ther 2001; 31:282.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson SJ. Principles of rehabilitation. In: Care of the Young Athlete, 1st ed, Sullivan JA, Anderson SJ (Eds), American Academy of Orthopedic Surgeons, American Academy of Pediatrics, Oklahoma City 2000. p.267.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/21\">",
"      Passmore SR, Burke JR, Good C, et al. Spinal manipulation impacts cervical spine movement and fitts' task performance: a single-blind randomized before-after trial. J Manipulative Physiol Ther 2010; 33:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/22\">",
"      Gonz&aacute;lez-Iglesias J, Fern&aacute;ndez-de-las-Pe&ntilde;as C, Cleland JA, et al. Inclusion of thoracic spine thrust manipulation into an electro-therapy/thermal program for the management of patients with acute mechanical neck pain: a randomized clinical trial. Man Ther 2009; 14:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/23\">",
"      Gross AR, Hoving JL, Haines TA, et al. A Cochrane review of manipulation and mobilization for mechanical neck disorders. Spine (Phila Pa 1976) 2004; 29:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/24\">",
"      Light KE, Nuzik S, Personius W, Barstrom A. Low-load prolonged stretch vs. high-load brief stretch in treating knee contractures. Phys Ther 1984; 64:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/25\">",
"      Zhao H, Wu YN, Hwang M, et al. Changes of calf muscle-tendon biomechanical properties induced by passive-stretching and active-movement training in children with cerebral palsy. J Appl Physiol 2011; 111:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/26\">",
"      Fasen JM, O'Connor AM, Schwartz SL, et al. A randomized controlled trial of hamstring stretching: comparison of four techniques. J Strength Cond Res 2009; 23:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/27\">",
"      Lentell G, Hetherington T, Eagan J, Morgan M. The use of thermal agents to influence the effectiveness of a low-load prolonged stretch. J Orthop Sports Phys Ther 1992; 16:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/28\">",
"      Brodowicz GR, Welsh R, Wallis J. Comparison of stretching with ice, stretching with heat, or stretching alone on hamstring flexibility. J Athl Train 1996; 31:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/29\">",
"      Holmes A, Delahunt E. Treatment of common deficits associated with chronic ankle instability. Sports Med 2009; 39:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/30\">",
"      Hale SA, Hertel J, Olmsted-Kramer LC. The effect of a 4-week comprehensive rehabilitation program on postural control and lower extremity function in individuals with chronic ankle instability. J Orthop Sports Phys Ther 2007; 37:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/31\">",
"      Holme E, Magnusson SP, Becher K, et al. The effect of supervised rehabilitation on strength, postural sway, position sense and re-injury risk after acute ankle ligament sprain. Scand J Med Sci Sports 1999; 9:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/32\">",
"      Barkler EH, Magnusson SP, Becher K, et al. [The effect of supervised rehabilitation on ankle joint function and the risk of recurrence after acute ankle distortion]. Ugeskr Laeger 2001; 163:3223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/33\">",
"      Wikstrom EA, Naik S, Lodha N, Cauraugh JH. Bilateral balance impairments after lateral ankle trauma: a systematic review and meta-analysis. Gait Posture 2010; 31:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/34\">",
"      Geffen SJ. 3: Rehabilitation principles for treating chronic musculoskeletal injuries. Med J Aust 2003; 178:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/35\">",
"      Perlau R, Frank C, Fick G. The effect of elastic bandages on human knee proprioception in the uninjured population. Am J Sports Med 1995; 23:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/36\">",
"      Birmingham TB, Inglis JT, Kramer JF, Vandervoort AA. Effect of a neoprene sleeve on knee joint kinesthesis: influence of different testing procedures. Med Sci Sports Exerc 2000; 32:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/37\">",
"      Kjaer M. Role of extracellular matrix in adaptation of tendon and skeletal muscle to mechanical loading. Physiol Rev 2004; 84:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/38\">",
"      Glass R, Waddell J, Hoogenboom B. The Effects of Open versus Closed Kinetic Chain Exercises on Patients with ACL Deficient or Reconstructed Knees: A Systematic Review. N Am J Sports Phys Ther 2010; 5:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/39\">",
"      Tomanek RJ, Lund DD. Degeneration of different types of skeletal muscle fibres. II. Immobilization. J Anat 1974; 118:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/40\">",
"      Eyestone ED, Fellingham G, George J, Fisher AG. Effect of water running and cycling on maximum oxygen consumption and 2-mile run performance. Am J Sports Med 1993; 21:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/41\">",
"      Markovic G, Mikulic P. Neuro-musculoskeletal and performance adaptations to lower-extremity plyometric training. Sports Med 2010; 40:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/42\">",
"      Cormie P, McGuigan MR, Newton RU. Developing maximal neuromuscular power: Part 1--biological basis of maximal power production. Sports Med 2011; 41:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/43\">",
"      Cormie P, McGuigan MR, Newton RU. Developing maximal neuromuscular power: part 2 - training considerations for improving maximal power production. Sports Med 2011; 41:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8169/abstract/44\">",
"      Tanimoto M, Arakawa H, Sanada K, et al. Changes in muscle activation and force generation patterns during cycling movements because of low-intensity squat training with slow movement and tonic force generation. J Strength Cond Res 2009; 23:2367.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6471 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8169=[""].join("\n");
var outline_f7_62_8169=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INFLAMMATORY PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Relative rest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cold therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Compression and elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Therapies to avoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Heat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PT Prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      REPARATIVE PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reparative goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ROM and flexibility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Proprioception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PT prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TRANSITION TO MATURATION PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PT prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MATURATION PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Maturation goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Load tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Muscular endurance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CV endurance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Power",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Speed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Agility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Sport-specific activities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Sport-specific drills",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      DISCHARGE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Post-rehab goals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/36/43596\" title=\"table 1\">",
"      Sample PT prescriptions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/0/36876\" title=\"table 2\">",
"      Sports rehab progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/34/34348\" title=\"table 3\">",
"      Therapeutic exercise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=related_link\">",
"      Cold urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44775?source=related_link\">",
"      Musculoskeletal injury in the young athlete: Overview of treatment principles for nonoperative injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22522?source=related_link\">",
"      Overview of cryoglobulins and cryoglobulinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=related_link\">",
"      Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8170="Thromboangiitis obliterans (Buerger's disease)";
var content_f7_62_8170=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thromboangiitis obliterans (Buerger's disease)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8170/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8170/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8170/contributors\">",
"     Jeffrey W Olin, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8170/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8170/contributors\">",
"     Gene G Hunder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8170/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8170/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/62/8170/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/62/8170/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/62/8170/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboangiitis obliterans, also called Buerger's disease, is a nonatherosclerotic, segmental, inflammatory disease that most commonly affects the small to medium-sized arteries and veins of the extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Thromboangiitis obliterans is characterized by highly cellular and inflammatory occlusive thrombus with relative sparing of the blood vessel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients are young smokers who present with distal extremity ischemia, ischemic digit ulcers or digit gangrene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/4\">",
"     4",
"    </a>",
"    ]. The disease is strongly associated with the use of tobacco products and smoking cessation is important to decrease the risk for amputation. The epidemiology, clinical manifestations, diagnosis, and treatment of thromboangiitis obliterans are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboangiitis obliterans is more common in countries where tobacco is heavily used, especially among people who make homemade cigarettes from raw tobacco [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/5\">",
"     5",
"    </a>",
"    ]. As such, thromboangiitis obliterans is most prevalent in the Mediterranean, Middle East and Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In North America, the prevalence of thromboangiitis obliterans has declined in the past 30 years due to a decline in smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In other parts of the world, the prevalence of this disease among patients with arterial occlusive disease varies widely, ranging from 0.5 to 5.6 percent in Western Europe to as high as 45 to 63 percent in India. [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men are more commonly affected than women and the typical age of onset is 40 to 45 years. Of patients diagnosed with thromboangiitis obliterans, 70 to 91 percent are male and 11 to 30 percent are female [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/11\">",
"     11",
"    </a>",
"    ]. However, there are reports of increasing prevalence of disease in women, possibly due to the increasing use of cigarettes among women [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/4,9,11-17\">",
"     4,9,11-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of tobacco is essential for the initiation and progression of thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Most patients are heavy cigarette smokers. In one study, patients diagnosed with thromboangiitis obliterans smoked an average of 23 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/21\">",
"     21",
"    </a>",
"    ]. Thromboangiitis obliterans has also been reported in cigar smokers, marijuana users and those who use smokeless tobacco such as chewing tobacco and snuff [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/3,4,22-25\">",
"     3,4,22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic anaerobic periodontal infection may also play a role in the development of thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Nearly two-thirds of patients with thromboangiitis obliterans have severe periodontal disease. In one study, DNA fragments associated with anaerobic bacteria were found within both the arterial lesions and oral cavities of patients with thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the prevalence of periodontal disease in smokers without thromboangiitis obliterans is similarly high and thus the association may be confounded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514794264\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboangiitis obliterans is a segmental inflammatory, nonatherosclerotic, occlusive vascular disease that affects the small and medium-sized arteries and veins. Pathologically, the condition is distinguished from other forms of vasculitis by a highly cellular, inflammatory intraluminal thrombus with relative sparing of the vessel wall and, more specifically, sparing of the internal elastic lamina [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/28\">",
"     28",
"    </a>",
"    ]. Although the disease was recognized and the pathology described over 100 years ago, its pathogenesis is poorly understood [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three pathologic phases are described (",
"    <a class=\"graphic graphic_picture graphicRef59478 \" href=\"UTD.htm?1/13/1240\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the acute phase, inflammatory thrombi develop in the arteries and veins, typically of the distal extremities. The thrombus is occlusive and polymorphonuclear leukocytes, micro-abscesses, and multinucleated giant cells may be present, but there is no evidence of fibrinoid necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/28,31\">",
"       28,31",
"      </a>",
"      ]. Although the external elastic lamina may show some disruption, the internal elastic lamina is intact. Biopsy of an involved superficial vein that demonstrates acute thrombophlebitis will likely show the characteristic acute phase lesion and is diagnostic of the disease. (See",
"      <a class=\"local\" href=\"#H461453879\">",
"       'Biopsy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The intermediate (subacute) phase is characterized by progressive organization of the thrombus in the small to medium-sized arteries and veins. (A prominent inflammatory infiltrate is still present within the thrombus but is less in the vessel wall.)",
"     </li>",
"     <li>",
"      In the chronic phase, inflammation is no longer present and only organized thrombus and vascular fibrosis remain. The pathological appearance in the chronic phase is indistinguishable from all other types of arterial disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although smoking tobacco is central to the initiation, continuation and recurrence of disease, the specific role of smoking in the pathogenesis of thromboangiitis is unknown. It is postulated that smoking may cause a delayed type of hypersensitivity or toxic angiitis. Immunohistochemical analyses indicate an inflammatory and immunologic pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/19,32-36\">",
"     19,32-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial dysfunction may also be involved in the pathogenesis of thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. High titers of antiendothelial antibodies have been detected in patients with this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/37\">",
"     37",
"    </a>",
"    ]. Vascular invasion of not only tunica intima but also the tunica media in affected vessels is clearly demonstrated using endothelial cell-specific antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/40\">",
"     40",
"    </a>",
"    ]. There also appears to be impairment of endothelium-dependent vasodilation in angiographically normal limbs of patients diagnosed with thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/41\">",
"     41",
"    </a>",
"    ]. Abnormalities in endothelin may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=see_link\">",
"     \"Endothelial dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prothrombotic factors may also play a role in the pathogenesis of thromboangiitis obliterans. The prothrombin gene mutation 20210 and the presence of anticardiolipin antibodies are associated with an increased risk and severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboangiitis obliterans typically presents in young smokers less than 40 to 45 years of age. Vascular involvement in thromboangiitis obliterans usually begins with the distal arteries and veins, followed by more proximal arterial occlusive disease. Two or more extremities are usually involved [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/3,16\">",
"     3,16",
"    </a>",
"    ]. A seasonal variation has also been reported with patients more likely to present in the winter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/6,21\">",
"     6,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Superficial thrombophlebitis can occur as a very early disease manifestation even before symptoms and signs, such as extremity pain or digit ischemia, become clinically evident. The presence of superficial phlebitis distinguishes this disorder from other occlusive vascular diseases, though phlebitis may also be observed in Behcet&rsquo;s disease (",
"    <a class=\"graphic graphic_table graphicRef68663 \" href=\"UTD.htm?31/12/31948\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The migratory phlebitis consists of tender nodules that follow a venous distribution, and frequently parallel arterial disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/12,45\">",
"     12,45",
"    </a>",
"    ]. When superficial nodules are present, they should be biopsied to establish a histologic diagnosis. (See",
"    <a class=\"local\" href=\"#H461453879\">",
"     'Biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Digit (toe, finger) ischemia is the most common presentation of thromboangiitis obliterans. One report of 112 patients found that 66 percent had ischemic ulcerations at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients usually note pain and subsequently discoloration of the digits, which can progress to ischemic ulcerations in the upper or lower extremity with accompanying ischemic pain or gangrene of the fingers or toes (",
"    <a class=\"graphic graphic_picture graphicRef80866 \" href=\"UTD.htm?4/42/4769\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower extremity ulcers occurred in 46 percent, upper extremity ulcers in 28 percent and ulcers in both upper and lower extremities in 26 percent in one series [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/46\">",
"       46",
"      </a>",
"      ].&nbsp;",
"     </li>",
"     <li>",
"      Another group reported that two limbs were affected in 16 percent of patients, three limbs in 41 percent and all four limbs in 43 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combined upper and lower extremity disease occurred in 20 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Raynaud phenomenon occurs in approximately 40 percent of patients and may be asymmetric. However, the frequency of Raynaud&rsquo;s may depend upon the population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As the disease progresses, it may involve more proximal arteries. Large artery involvement is unusual and rarely occurs in the absence of small vessel occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/16\">",
"     16",
"    </a>",
"    ]. If vessels proximal to the wrist or ankle become involved, the patient may complain of claudication of the feet, calves, thighs, hands, or arms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/3\">",
"     3",
"    </a>",
"    ]. Symptoms of claudication due to thromboangiitis obliterans may be indistinguishable from those due to other vascular occlusive diseases. Foot claudication is often mistaken for an orthopedic problem. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a minority of patients, joint complaints may be the first indication of clinical disease. In one study, arthralgias and arthritis were reported in 12.5 percent of patients, typically in the preocclusive phase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/45\">",
"     45",
"    </a>",
"    ]. The most commonly affected joints were the wrists and knees. The duration of joint symptoms prior to the digit ischemia can be months to years. The joint manifestations of thromboangiitis obliterans do not lead to erosive arthritis and are frequently episodic, generally resolving within two weeks.",
"   </p>",
"   <p>",
"    Although thromboangiitis obliterans most commonly affects the small and medium arteries of the extremities, the pathologic findings have been reported in cerebral, coronary, internal thoracic, renal and mesenteric arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Symptoms from intestinal or multi-organ involvement are rare but have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Involvement of large vessels, such as the aorta and iliac arteries, is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/16\">",
"     16",
"    </a>",
"    ]. Occlusive disease of these vessels is more likely to be due to peripheral artery disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H514794398\">",
"    <span class=\"h1\">",
"     CLINICAL AND LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87000089\">",
"    <span class=\"h2\">",
"     Vascular evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should have a thorough history and detailed vascular examination. The extremities should be inspected for superficial venous nodules and cords, and the hands and feet examined for evidence of ischemia. Neurologic examination may document peripheral nerve involvement with sensory abnormalities in up to 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/3\">",
"     3",
"    </a>",
"    ]. The physical examination alone cannot distinguish arterial occlusive disease due to thromboangiitis obliterans from other etiologies (",
"    <a class=\"graphic graphic_table graphicRef68663 \" href=\"UTD.htm?31/12/31948\">",
"     table 1",
"    </a>",
"    ). Given that smoking is a common risk factor, it is not surprising that peripheral artery disease and thromboangiitis obliterans are often superimposed.",
"   </p>",
"   <p>",
"    For patients with lower extremity signs and symptoms, an ankle brachial-index (ABI) should be performed. A normal ABI does not exclude thromboangiitis obliterans, because disease may be limited to the distal vasculature. For patients with upper extremity involvement, a wrist-brachial index should be performed. As with the ankle-brachial index, a normal value may not exclude disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58549402#H58549402\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Wrist-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An Allen test should also be performed (",
"    <a class=\"graphic graphic_picture graphicRef79685 \" href=\"UTD.htm?39/52/40771\">",
"     picture 3",
"    </a>",
"    ). A positive Allen test at the wrist in a young smoker with lower extremity digit ischemia is suggestive of thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Patients suspected of having arterial occlusive disease due to thromboangiitis obliterans but who have abnormal ABIs should be referred to the vascular laboratory for additional studies (eg, segmental pressures, pulse volume recordings) to identify patients with proximal vascular disease who may benefit from intervention (stent, bypass).",
"   </p>",
"   <p>",
"    The distal circulation can be evaluated using digital plethysmography which may demonstrate one or more flattened digit waveforms supporting the diagnosis. However, digital plethysmography cannot distinguish disease due to thromboangiitis obliterans from other vasculitides that affect the digital arteries (eg, scleroderma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H86998053#H86998053\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Digit waveforms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific laboratory tests to diagnose thromboangiitis obliterans. The purpose of laboratory studies is to exclude other entities that cause occlusive vascular disease such as diabetes, the vasculitides (eg, lupus, mixed connective tissue disease, scleroderma, CREST syndrome) and thrombophilias (",
"    <a class=\"graphic graphic_table graphicRef68663 \" href=\"UTD.htm?31/12/31948\">",
"     table 1",
"    </a>",
"    ). The laboratory evaluation of vasculitis and thrombophilia is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link&amp;anchor=H24#H24\">",
"     \"Classification of and approach to the vasculitides in adults\", section on 'Laboratory tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H25#H25\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Choice of coagulation tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should undergo a complete blood count with differential, a chemistry panel including fasting blood sugar, liver enzymes, renal function, urinalysis and a serologic profile which includes the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute phase reactants &ndash; Westergren sedimentation rate (ESR), C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Immunologic panel &ndash; antinuclear antibody (ANA), rheumatoid factor (RF), complement measurements, anticentromere antibody and SCL70 (markers for scleroderma and CREST [calcinosis, Raynaud&rsquo;s, esophageal dysmotility, sclerodactyly, telangiectasias] syndrome)",
"     </li>",
"     <li>",
"      Complete hypercoagulability screen &ndash; coagulation tests, antiphospholipid antibodies, anticardiolipin antibodies, protein C, protein S, antithrombin III, factor V Leiden and prothrombin gene mutation &nbsp;",
"     </li>",
"     <li>",
"      Toxicology panel &ndash; cocaine, amphetamines, cannabis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These tests are normal or negative in patients with thromboangiitis obliterans. However, anticardiolipin antibodies may be present in some patients with thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical examination along with testing to exclude other conditions usually suffices to establish the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/11,56,57\">",
"     11,56,57",
"    </a>",
"    ]. However, for patients with arterial disease established on noninvasive vascular studies who have clinical symptoms and signs consistent with but not definitive for thromboangiitis obliterans, an arteriogram may be obtained to look for typical findings and identify the nature and extent of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although gadolinium-enhanced magnetic resonance angiography (MRA) or multidetector computed tomographic angiography (CTA) can be used to image the vasculature, these modalities may still not provide sufficient spatial resolution to provide adequate anatomic detail of the vasculature of the hands and feet.",
"   </p>",
"   <p>",
"    When arteriogram is obtained, we prefer to obtain an arteriogram of the upper and lower extremities including the aorta (thoracic and abdominal), even in patients who present with clinical involvement of only one extremity, because of the high prevalence of disease in multiple limbs. Angiographic abnormalities consistent with thromboangiitis obliterans can be seen in limbs that are not yet clinically involved. Arteriographic features suggestive of thromboangiitis obliterans include (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64278 \" href=\"UTD.htm?8/17/8467\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/2,58,59\">",
"     2,58,59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No evidence of atherosclerosis",
"     </li>",
"     <li>",
"      No source for thromboembolism (eg, aneurysmal disease)",
"     </li>",
"     <li>",
"      Involvement of small and medium-sized vessels such as the plantar, tibial, peroneal, palmar, radial, and ulnar arteries",
"     </li>",
"     <li>",
"      Segmental occlusion with diseased segments interspersed between normal appearing segments",
"     </li>",
"     <li>",
"      Collateralization around areas of occlusion (ie, corkscrew collaterals).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the angiographic findings given above, including the presence of corkscrew collaterals, are suggestive, they are not pathognomonic for thromboangiitis obliterans since they may be found in patients with other causes of small vessel occlusive disease.",
"   </p>",
"   <p>",
"    The arteriographic findings in patients with cocaine, amphetamine or cannabis ingestion, including the presence of corkscrew collaterals, may also mimic those of thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/23,24,60,61\">",
"     23,24,60,61",
"    </a>",
"    ]. Therefore, in patients who present with manifestations of thromboangiitis obliterans but deny using tobacco, it is advisable to obtain a toxicology screen for cocaine, amphetamine and cannabis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Laboratory tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A cardiac source of thromboembolism should also be ruled out. The diagnosis of cardiac embolic sources is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If surgical revascularization is planned, and if preoperative testing suggests the presence of concomitant ischemic heart disease that requires subsequent cardiac catheterization, then consideration should be given to performing arteriography of the internal thoracic arteries. As noted above, involvement of these arteries may occasionally occur in thromboangiitis obliterans, and planning for coronary bypass surgery is facilitated if their patency is assessed prior to heart surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Revascularization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86999828\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboangiitis obliterans is a predominantly clinical diagnosis that should be suspected in young male patients who smoke and who present with ischemia of the hands",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    feet. However, the diagnosis of thromboangiitis obliterans may be a diagnosis of exclusion after ruling out other more common entities which may produce similar clinical symptoms. Biopsy provides a definitive diagnosis, but subcutaneous nodules are not always present. A clinical diagnosis can be established based upon a scoring system using clinical, angiographic, histopathological, and exclusionary criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/4,62\">",
"     4,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thromboangiitis obliterans is differentiated from other entities that cause vascular occlusive disease (",
"    <a class=\"graphic graphic_table graphicRef68663 \" href=\"UTD.htm?31/12/31948\">",
"     table 1",
"    </a>",
"    ), the most common of which are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peripheral artery disease &ndash; The distal nature of thromboangiitis obliterans and involvement of the lower and upper extremities helps to distinguish the disorder from atherosclerosis. Other risk factors for peripheral artery disease, such as hypertension and hypercholesterolemia, may be absent. In the absence of a histological diagnosis of the acute phase lesion, a diagnosis of diabetes mellitus excludes thromboangiitis obliterans.",
"     </li>",
"     <li>",
"      Thromboembolic disease &ndash; Patients with thromboangiitis obliterans will not have a proximal source for embolism (cardiac, aneurysmal disease) or laboratory evidence of a thrombophilia, though anticardiolipin antibodies may be present.",
"     </li>",
"     <li>",
"      Vasculitis &ndash; Although distal vessel involvement causes distal ischemia in other vasculitides, serologic markers are negative in thromboangiitis obliterans.",
"     </li>",
"     <li>",
"      Repetitive trauma &ndash; These patients have an occupational history (eg, jackhammer operator) to suggest the mechanism of small vessel disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86999781\">",
"    <span class=\"h2\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical diagnosis can be established with the following commonly used criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age less than 45 years",
"     </li>",
"     <li>",
"      Current or recent history of tobacco use",
"     </li>",
"     <li>",
"      Distal extremity ischemia (objectively noted on vascular testing) (See",
"      <a class=\"local\" href=\"#H87000089\">",
"       'Vascular evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical arteriographic findings of thromboangiitis obliterans (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exclusion of autoimmune disease, thrombophilia, diabetes, and proximal embolic sources (",
"      <a class=\"graphic graphic_table graphicRef68663 \" href=\"UTD.htm?31/12/31948\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461453879\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy is rarely needed but is the only means to establish a definitive diagnosis. Patients with subcutaneous nodules or superficial thrombophlebitis should undergo biopsy. Biopsy is suggested if the patient presents with unusual characteristics such as large artery involvement, age &gt;45 years or the presence of elevated anticardiolipin antibodies. Patients with antiphospholipid syndrome exhibit thrombus without inflammation ruling out a diagnosis of thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there are no nodules and the patient fulfills the above criteria, a biopsy of an artery or examination of the vein or arteries in an amputated digit or limb may provide a diagnosis; however, this is rarely done. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking cessation is the only definitive therapy for patients diagnosed with thromboangiitis obliterans. Although a number of other therapies have been investigated, these should be considered palliative.",
"   </p>",
"   <p>",
"    Digit ulcerations are managed as with other ischemic wounds, debridement and moist dressing. Negative pressure wound therapy is becoming popular for the management of open wounds and has been used in the management of open wounds associated with thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/40/19078?source=see_link\">",
"     \"Clinical assessment of wounds\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients discontinue cigarette smoking or the use of tobacco in any form because it is the only effective strategy for managing thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/64\">",
"     64",
"    </a>",
"    ]. Complete abstinence from tobacco products is the only way to halt the progression of thromboangiitis obliterans and to avoid future amputations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/3\">",
"     3",
"    </a>",
"    ]. The disease may be activated by smoking as little as one or two cigarettes a day. Transdermal nicotine patches and nicotine chewing gum should be avoided because they may also keep the disease active, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    can be used as smoking cessation aids. The correlation between smoking and disease activity is so strong that measurement of urinary nicotine and cotinine (a byproduct of nicotine) should be performed if the disease is active despite patient claims of tobacco cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients can be reassured that if they are able to discontinue tobacco use, the disease will remit and the need for amputation is low provided critical limb ischemia (gangrene and tissue loss) has not already occurred. However, the patient may continue to experience intermittent claudication or Raynaud&rsquo;s phenomenon. (See",
"    <a class=\"local\" href=\"#H87000741\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unfortunately, only about half of patients are able to maintain smoking cessation long term [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/12,66\">",
"     12,66",
"    </a>",
"    ]. In one series of 110 patients, only 41 (37 percent) were able to discontinue smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/66\">",
"     66",
"    </a>",
"    ]. Inpatient nicotine dependence treatment is an alternative for recidivist smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268457206\">",
"    <span class=\"h2\">",
"     Iloprost",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     Iloprost",
"    </a>",
"    is a prostaglandin analog used to manage pain associated with thromboangiitis obliterans. Intravenous iloprost is more effective than the oral formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/68\">",
"     68",
"    </a>",
"    ]. The major benefit of iloprost may be in helping patients with critical limb ischemia get through the period of initial smoking cessation. Two randomized trials have evaluated its effectiveness.",
"   </p>",
"   <p>",
"    In one trial, 152 patients were randomly assigned to a six-hour daily intravenous infusion of the drug versus low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/69\">",
"     69",
"    </a>",
"    ]. Total relief of pain at rest and complete healing of all trophic changes were the primary outcome measures. At 28 days and at six months there was a significant improvement in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    -treated group compared with the aspirin group, with 6 percent of patients in the iloprost group requiring amputation compared with 18 percent of those receiving aspirin.",
"   </p>",
"   <p>",
"    In another trial, 200 patients were randomly assigned to lumbar sympathectomy or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/70\">",
"     70",
"    </a>",
"    ]. Rates of ulcer healing were significantly higher in the iloprost group compared with the lumbar sympathectomy group (62 versus 41 percent). Analgesic requirements were less and pain scores lower with iloprost treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268457398\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium channel blockers are frequently used to manage vasospasm associated with the Raynaud phenomenon. When significant vasospasm is present in patients with thromboangiitis obliterans, calcium channel blocking agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    may similarly be used [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/3\">",
"     3",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=see_link&amp;anchor=H188847417#H188847417\">",
"     \"Initial treatment of the Raynaud phenomenon\", section on 'Calcium channel blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268457455\">",
"    <span class=\"h2\">",
"     Intermittent pneumatic compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Application of intermittent pneumatic compression (IPC) to the foot and calf augments popliteal artery flow through a sharp decrease in peripheral arterial resistance manifested by increases in peak systolic and end diastolic flow velocities on Doppler ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intermittent pneumatic compression enhances calf inflow in patients with intermittent claudication or critical limb ischemia. In one study, complete healing of ischemic ulcers was demonstrated in patients with small vessel occlusive diseases such as scleroderma, CREST and thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/72\">",
"     72",
"    </a>",
"    ]. We utilize this therapy in patients with painful ulcerations when there is no viable revascularization option. It is useful in decreasing pain even before complete ulcer healing occurs. While there are limited studies, specifically in thromboangiitis obliterans, studies have demonstrated efficacy in small vessel occlusive disease of many etiologies. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Revascularization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H268457277\">",
"    <span class=\"h2\">",
"     Experimental therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of additional therapies have been studied or are under active clinical investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/46,73\">",
"     46,73",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapeutic angiogenesis has been evaluated for treatment of peripheral artery disease and this therapy may improve the ischemic manifestations of thromboangiitis obliterans. Short-term results of therapeutic angiogenesis using growth factors or autologous bone marrow have been promising, but longer term studies are needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one trial of six patients with nonhealing wounds (&gt;1 month), intramuscular vascular endothelial growth factor (VEGF) 165 was injected into seven affected limbs [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/74\">",
"       74",
"      </a>",
"      ]. Ulcers completely healed in three of five limbs. In the other two patients, nocturnal rest pain was relieved, although both continued to have claudication. In all seven limbs, perfusion was improved on magnetic resonance imaging and newly visible collateral vessels were seen on contrast angiography.",
"     </li>",
"     <li>",
"      A second phase one trial tested the safety of intramuscular gene transfer by using naked plasmid DNA encoding the gene for VEGF in seven patients with thromboangiitis obliterans [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/75\">",
"       75",
"      </a>",
"      ]. Ischemic pain in the affected limb was relieved or improved markedly in six of seven patients, and ischemic ulcers healed or improved in four of six patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell-based therapy with autologous bone marrow mononuclear cell implantation has also been used with some degree of success. A meta-analysis indicates that intramuscular autologous bone marrow cell therapy is a feasible, relatively safe and potentially effective therapeutic strategy for patients with severe peripheral artery disease who are not candidates for traditional revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/76\">",
"       76",
"      </a>",
"      ]. The therapeutic angiogenesis by cell transplantation (TACT) trial, which included patients with thromboangiitis obliterans, randomly assigned patients to autologous bone marrow mononuclear cell injection versus placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/77\">",
"       77",
"      </a>",
"      ]. Significant improvements were seen in leg pain scale, ulcer size and pain-free walking distance that were maintained at two years after therapy. Other available small nonrandomized studies have shown similar short-term improvements [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/78-81\">",
"       78-81",
"      </a>",
"      ]. A confounding factor for many of these studies is the fact that, in addition to receiving therapy, many of the patients stopped smoking.",
"     </li>",
"     <li>",
"      Another method of stimulating angiogenesis using a Kirschner wire placed in the medullary canal of the tibia was used in six patients with thromboangiitis obliterans [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/82\">",
"       82",
"      </a>",
"      ]. At a mean follow-up of 19 months, significant improvements were seen in symptoms with reduced rest pain, increased pain-free walking distance and ulcer healing. Most studies have not reported significant adverse events to angiogenic therapy; however, in one study, four of eight patients suffered significant clinical events underscoring the need for long-term monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/83\">",
"       83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38502?source=see_link\">",
"       Cilostazol",
"      </a>",
"      is a phosphodiesterase inhibitor that suppresses platelet aggregation and is a direct arterial vasodilator [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/84\">",
"       84",
"      </a>",
"      ]. It is often used in the treatment of peripheral artery disease. In one small study, flow improvements measured in response to reactive hyperemia were significantly increased after two weeks of cilostazol therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/85\">",
"       85",
"      </a>",
"      ]. Case reports treating patients with digital ischemia with cilostazol have reported improvements in digit pain and ulceration [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234644233\">",
"    <span class=\"h1\">",
"     INTERVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical revascularization is usually not indicated due to the distal nature of occlusive disease and because most patients do well with smoking cessation. It has been our experience that surgery is rarely needed if the patient is able to stop smoking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bypass surgery may be considered in select patients with severe ischemia and suitable distal target vessels. Surgical bypass with autologous vein [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/87,88\">",
"     87,88",
"    </a>",
"    ] or even omental graft may facilitate limb salvage [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Although the long-term vein graft patency is less than that seen with peripheral artery disease, limb salvage rates are reasonable and generally greater than 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/7,92,93\">",
"     7,92,93",
"    </a>",
"    ]. A possible explanation is that patent grafts, even over a short period of time, are sufficient to allow healing of ulcers in patients with thromboangiitis obliterans. Ulcers are not likely to develop or recur provided the patient is compliant with smoking cessation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 71 bypasses performed on patients with thromboangiitis obliterans, primary and secondary patency rates were 50 and 63 percent at 5 years, and 43 and 56 percent at 10 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/88\">",
"       88",
"      </a>",
"      ]. The 10-year patency rates of the postoperative non-smoking group were significantly higher than that of the smoking group (67 versus 35 percent).",
"     </li>",
"     <li>",
"      In another study, revascularization was performed in 19 patients and the cumulative secondary patency rate was 58 percent at a mean of 5.4 years follow up [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/87\">",
"       87",
"      </a>",
"      ]. The limb salvage rate was 96 percent with seven major and 36 minor amputations performed. These authors noted that, although the long-term patency of the bypass grafts was low, short-term patency was sufficient to allow healing of ischemic lesion.",
"     </li>",
"     <li>",
"      Similarly, in another study of 27 patients with thromboangiitis obliterans who underwent revascularization, patency rates at 12, 24, and 36 months were 59, 48, and 33 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/7\">",
"       7",
"      </a>",
"      ]. The limb salvage rate, however, was 93 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Sympathectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar or thoracic sympathectomy improves pain control in other vascular occlusive diseases, but its role in the treatment of patients with thromboangiitis remains unclear. There have been several reports demonstrating that sympathectomy can be safely and effectively used in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/15,94,95\">",
"     15,94,95",
"    </a>",
"    ]. Laparoscopic sympathectomy in the lower [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/96,97\">",
"     96,97",
"    </a>",
"    ] and upper extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/98,99\">",
"     98,99",
"    </a>",
"    ] has been performed. Although sympathectomy anecdotally benefits some individuals, there are no data to guide patient choice. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87009583\">",
"    <span class=\"h2\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other forms of chronic critical limb ischemia, spinal cord stimulation has been used to manage pain in patients with thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/100-103\">",
"     100-103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=see_link&amp;anchor=H31#H31\">",
"     \"Treatment of chronic lower extremity critical limb ischemia\", section on 'Spinal cord stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombolytic therapy has undergone limited investigation in patients with thromboangiitis obliterans. In one study of 11 patients with longstanding disease who had gangrene or pregangrenous lesions of the toes or feet, treatment with low dose intraarterial streptokinase resulted in avoidance or alteration in the level of amputation in 58 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/104\">",
"     104",
"    </a>",
"    ]. However, further study is required before the precise role of thrombolytic therapy can be defined. In our experience, thrombolytic therapy is rarely used because of its limited benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87000741\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have evaluated the long-term outcomes, including rates for major and minor amputations and survival in patients with thromboangiitis obliterans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/13,66\">",
"     13,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study followed 110 patients with thromboangiitis obliterans for a mean of 10.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/66\">",
"     66",
"    </a>",
"    ]. The cumulative survival rate was 84 percent up to 25 years after the initial consultation. The rate for any kind of amputation (upper or lower limb) was 43 percent with 12 percent being major amputations. Forty-one patients who stopped smoking did not undergo major amputation and of 69 patients who continued smoking, 19 percent required major amputation. No ischemic ulcers occurred or recurred in patients older than 60 years.",
"   </p>",
"   <p>",
"    Another study followed 111 patients with proven thromboangiitis obliterans for a mean of 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/13\">",
"     13",
"    </a>",
"    ]. The risk of major amputation was 11 percent at 5 years, 21 percent at 10 years and 23 percent at 20 years. As in virtually every other study published, tobacco abstinence was associated with a good prognosis. In this study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of amputation in former smokers was eliminated by 8 years after smoking cessation",
"     </li>",
"     <li>",
"      The risk of amputation continued in patients who continued to smoke",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study, however, found reduced life-expectancy in patients with thromboangiitis obliterans compared with the remainder of the population in the United States. The average age of death was 52 years. Older age at time of diagnosis was associated with an increased risk of death. Patients with anticardiolipin antibodies have a younger age of onset and an increased rate of major amputations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/62/8170/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234644142\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thromboangiitis obliterans is a vasculitis that affects medium and small arteries, veins and nerves in the extremities, with rare involvement of visceral and cerebral vessels. Patients are predominantly young smokers who present with distal extremity ischemia, ischemic digit ulcers, or digit gangrene. The disease is strongly associated with the use of tobacco products. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The disease is characterized by segmental inflammatory thrombotic vessel occlusions. It is distinguished pathologically from other forms of vasculitis by a highly cellular, inflammatory intraluminal thrombus with relative sparing of the vessel wall and, more specifically, sparing of the internal elastic lamina. Although smoking is important to the pathogenesis, the specific etiologic mechanism remains unknown. Inflammatory, immunologic, and endothelial factors play a role. (See",
"      <a class=\"local\" href=\"#H514794264\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of thromboangiitis obliterans consists of history and physical examination, vascular evaluation, and laboratory examination to serologically rule out other etiologies that can cause small and medium vessel occlusive arterial disease. (See",
"      <a class=\"local\" href=\"#H514794398\">",
"       'Clinical and laboratory evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical diagnosis can be established with the following commonly used criteria:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age less than 45 years",
"     </li>",
"     <li>",
"      Current or recent history of tobacco use",
"     </li>",
"     <li>",
"      Distal extremity ischemia (objectively noted on vascular testing) (See",
"      <a class=\"local\" href=\"#H87000089\">",
"       'Vascular evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical arteriographic findings of thromboangiitis obliterans (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exclusion of autoimmune disease, thrombophilia, diabetes, and proximal embolic sources (",
"      <a class=\"graphic graphic_table graphicRef68663 \" href=\"UTD.htm?31/12/31948\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Imaging studies are not necessary to establish a diagnosis but may be performed in patients whose clinical features are not definitive. When imaging is performed, features suggestive of thromboangiitis obliterans include lack of atherosclerosis, no proximal source for embolism, the involvement of small and medium-sized vessels, segmental vascular occlusion, and collateralization around areas of occlusion (ie, corkscrew collaterals). However, the finding of corkscrew collaterals is nonspecific. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biopsy of a subcutaneous nodule or superficial thrombophlebitis showing typical acute phase changes provides a definitive diagnosis, but biopsy is not usually needed. (See",
"      <a class=\"local\" href=\"#H461453879\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients diagnosed with thromboangiitis obliterans, we recommend smoking cessation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Smoking cessation reduces symptoms and decreases the risk for major amputation. Continued smoking is associated with an overall amputation rate of 40 to 50 percent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Smoking cessation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other treatments used to manage pain associated with critical ischemia include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      infusion, sympathectomy and spinal cord stimulation. Calcium channel blockers and intermittent pneumatic compression indirectly improve pain by increasing blood flow. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Medical management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H87009583\">",
"       'Other interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical revascularization is usually not indicated due to the distal nature of occlusive disease and because most patients do well with smoking cessation. Bypass surgery may be considered in select patients with severe ischemia and suitable distal target vessels. Although the long&ndash;term patency rates are inferior to those seen with peripheral artery disease due to atherosclerosis, limb salvage rates are generally greater than 90 percent and may be more correlated to smoking cessation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Revascularization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/1\">",
"      Buerger L. Landmark publication from the American Journal of the Medical Sciences, 'Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene'. 1908. Am J Med Sci 2009; 337:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/2\">",
"      Piazza G, Creager MA. Thromboangiitis obliterans. Circulation 2010; 121:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/3\">",
"      Olin JW. Thromboangiitis obliterans (Buerger's disease). N Engl J Med 2000; 343:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/4\">",
"      Mills JL, Porter JM. Buerger's disease: a review and update. Semin Vasc Surg 1993; 6:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/5\">",
"      Grove WJ, Stansby GP. Buerger's disease and cigarette smoking in Bangladesh. Ann R Coll Surg Engl 1992; 74:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/6\">",
"      Laohapensang K, Rerkasem K, Kattipattanapong V. Seasonal variation of Buerger's disease in Northern part of Thailand. Eur J Vasc Endovasc Surg 2004; 28:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/7\">",
"      Dilege S, Aksoy M, Kayabali M, et al. Vascular reconstruction in Buerger's disease: is it feasible? Surg Today 2002; 32:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/8\">",
"      Lie JT. The rise and fall and resurgence of thromboangiitis obliterans (Buerger's disease). Acta Pathol Jpn 1989; 39:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/9\">",
"      Lie JT. Thromboangiitis obliterans (Buerger's disease) in women. Medicine (Baltimore) 1987; 66:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/10\">",
"      Arkkila PE. Thromboangiitis obliterans (Buerger's disease). Orphanet J Rare Dis 2006; 1:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/11\">",
"      Mills JL, Taylor LM Jr, Porter JM. Buerger's disease in the modern era. Am J Surg 1987; 154:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/12\">",
"      Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 1990; 82:IV3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/13\">",
"      Cooper LT, Tse TS, Mikhail MA, et al. Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease). J Am Coll Cardiol 2004; 44:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/14\">",
"      Ehrenfeld M, Adar R. Rheumatic manifestations in patients with thromboangiitis obliterans (Buerger's disease). J Rheumatol 2000; 27:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/15\">",
"      Lau H, Cheng SW. Buerger's disease in Hong Kong: a review of 89 cases. Aust N Z J Surg 1997; 67:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/16\">",
"      Shionoya S, Ban I, Nakata Y, et al. Involvement of the iliac artery in Buerger's disease (pathogenesis and arterial reconstruction). J Cardiovasc Surg (Torino) 1978; 19:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/17\">",
"      Sasaki S, Sakuma M, Yasuda K. Current status of thromboangiitis obliterans (Buerger's disease) in Japan. Int J Cardiol 2000; 75 Suppl 1:S175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/18\">",
"      Mills JL, Porter JM. Buerger's disease (thromboangiitis obliterans). Ann Vasc Surg 1991; 5:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/19\">",
"      Papa M, Bass A, Adar R, et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex. Surgery 1992; 111:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/20\">",
"      Salimi J, Tavakkoli H, Salimzadeh A, et al. Clinical characteristics of Buerger's disease in Iran. J Coll Physicians Surg Pak 2008; 18:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/21\">",
"      Tavakoli H, Rezaii J, Esfandiari K, et al. Buerger's disease: a 10-year experience in Tehran, Iran. Clin Rheumatol 2008; 27:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/22\">",
"      Lie JT. Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum 1988; 31:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/23\">",
"      Combemale P, Consort T, Denis-Thelis L, et al. Cannabis arteritis. Br J Dermatol 2005; 152:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/24\">",
"      Disdier P, Granel B, Serratrice J, et al. Cannabis arteritis revisited--ten new case reports. Angiology 2001; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/25\">",
"      Joyce JW. Buerger's disease (thromboangiitis obliterans). Rheum Dis Clin North Am 1990; 16:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/26\">",
"      Iwai T, Inoue Y, Umeda M, et al. Oral bacteria in the occluded arteries of patients with Buerger disease. J Vasc Surg 2005; 42:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/27\">",
"      Chen YW, Nagasawa T, Wara-Aswapati N, et al. Association between periodontitis and anti-cardiolipin antibodies in Buerger disease. J Clin Periodontol 2009; 36:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/28\">",
"      Lie JT. Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes. Rheum Dis Clin North Am 1990; 16:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/29\">",
"      Maecki R, Zdrojowy K, Adamiec R. Thromboangiitis obliterans in the 21st century--a new face of disease. Atherosclerosis 2009; 206:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/30\">",
"      Leu HJ. Early inflammatory changes in thromboangiitis obliterans. Pathol Microbiol (Basel) 1975; 43:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/31\">",
"      Lie JT. Thromboangiitis obliterans (Buerger's disease) revisited. Pathol Annu 1988; 23 Pt 2:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/32\">",
"      Adar R, Papa MZ, Halpern Z, et al. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983; 308:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/33\">",
"      Lee T, Seo JW, Sumpio BE, Kim SJ. Immunobiologic analysis of arterial tissue in Buerger's disease. Eur J Vasc Endovasc Surg 2003; 25:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/34\">",
"      Kobayashi M, Ito M, Nakagawa A, et al. Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vasc Surg 1999; 29:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/35\">",
"      Guzel E, Topal E, Yildirim A, et al. Targeting novel antigens in the arterial wall in thromboangiitis obliterans. Folia Histochem Cytobiol 2010; 48:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/36\">",
"      Edo N, Miyai K, Ogata S, et al. Thromboangiitis obliterans with multiple large vessel involvement: case report and analysis of immunophenotypes. Cardiovasc Pathol 2010; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/37\">",
"      Eichhorn J, Sima D, Lindschau C, et al. Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci 1998; 315:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/38\">",
"      Azizi M, Boutouyrie P, Bura-Rivi&egrave;re A, et al. Thromboangiitis obliterans and endothelial function. Eur J Clin Invest 2010; 40:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/39\">",
"      Joras M, Poredos P, Fras Z. Endothelial dysfunction in Buerger's disease and its relation to markers of inflammation. Eur J Clin Invest 2006; 36:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/40\">",
"      Subhashree AR, Gopalan R, Krishnan KB, Shekar N. Buerger's disease: clinical and histomorphological study. Indian J Pathol Microbiol 2006; 49:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/41\">",
"      Makita S, Nakamura M, Murakami H, et al. Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation 1996; 94:II211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/42\">",
"      Czarnacki M, Gacka M, Adamiec R. [A role of endothelin 1 in the pathogenesis of thromboangiitis obliterans (initital news)]. Przegl Lek 2004; 61:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/43\">",
"      Avcu F, Akar E, Demirkili&ccedil; U, et al. The role of prothrombotic mutations in patients with Buerger's disease. Thromb Res 2000; 100:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/44\">",
"      Maslowski L, McBane R, Alexewicz P, Wysokinski WE. Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 2002; 7:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/45\">",
"      Pu&eacute;chal X, Fiessinger JN. Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist. Rheumatology (Oxford) 2007; 46:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/46\">",
"      Olin JW, Shih A. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006; 18:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/47\">",
"      Donatelli F, Triggiani M, Nascimbene S, et al. Thromboangiitis obliterans of coronary and internal thoracic arteries in a young woman. J Thorac Cardiovasc Surg 1997; 113:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/48\">",
"      Lie JT. Visceral intestinal Buerger's disease. Int J Cardiol 1998; 66 Suppl 1:S249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/49\">",
"      Hoppe B, Lu JT, Thistlewaite P, et al. Beyond peripheral arteries in Buerger's disease: angiographic considerations in thromboangiitis obliterans. Catheter Cardiovasc Interv 2002; 57:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/50\">",
"      Kurata A, Nonaka T, Arimura Y, et al. Multiple ulcers with perforation of the small intestine in buerger's disease: a case report. Gastroenterology 2003; 125:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/51\">",
"      Cakmak A, Gyedu A, Akyol C, et al. Occlusion of the celiac trunk, the inferior mesenteric artery and stenosis of the superior mesenteric artery in peripheral thrombangiitis obliterans. Vasa 2009; 38:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/52\">",
"      Turkbey B, Eldem G, Akpinar E. Mesenteric ischemia in a patient with Buerger's disease: MDCT findings. JBR-BTR 2009; 92:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/53\">",
"      Harten P, M&uuml;ller-Huelsbeck S, Regensburger D, Loeffler H. Multiple organ manifestations in thromboangiitis obliterans (Buerger's disease). A case report. Angiology 1996; 47:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/54\">",
"      Michail PO, Filis KA, Delladetsima JK, et al. Thromboangiitis obliterans (Buerger's disease) in visceral vessels confirmed by angiographic and histological findings. Eur J Vasc Endovasc Surg 1998; 16:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/55\">",
"      Pereira de Godoy JM, Braile DM. Buerger's disease and anticardiolipin antibodies. J Cardiovasc Med (Hagerstown) 2009; 10:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/56\">",
"      Shionoya S. Diagnostic criteria of Buerger's disease. Int J Cardiol 1998; 66 Suppl 1:S243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/57\">",
"      Shionoya S. What is Buerger's disease? World J Surg 1983; 7:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/58\">",
"      Lambeth JT, Yong NK. Arteriographic findings in thromboangiitis obliterans with emphasis on femoropopliteal involvement. Am J Roentgenol Radium Ther Nucl Med 1970; 109:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/59\">",
"      Yoshimuta T, Akutsu K, Okajima T, et al. Corkscrew collaterals in Buerger's disease. Can J Cardiol 2009; 25:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/60\">",
"      Marder VJ, Mellinghoff IK. Cocaine and Buerger disease: is there a pathogenetic association? Arch Intern Med 2000; 160:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/61\">",
"      No&euml;l B. Cocaine and arsenic-induced Raynaud's phenomenon. Clin Rheumatol 2002; 21:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/62\">",
"      Papa MZ, Rabi I, Adar R. A point scoring system for the clinical diagnosis of Buerger's disease. Eur J Vasc Endovasc Surg 1996; 11:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/63\">",
"      Canter HI, Isci E, Erk Y. Vacuum-assisted wound closure for the management of a foot ulcer due to Buerger's disease. J Plast Reconstr Aesthet Surg 2009; 62:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/64\">",
"      Corelli F. Buerger's disease: cigarette smoker disease may always be cured by medical therapy alone. Uselessness of operative treatment. J Cardiovasc Surg (Torino) 1973; 14:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/65\">",
"      Hurt RD, Hays JT. Urinary tobacco alkaloid measurement in patients having thromboangiitis obliterans. Mayo Clin Proc 2008; 83:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/66\">",
"      Ohta T, Ishioashi H, Hosaka M, Sugimoto I. Clinical and social consequences of Buerger disease. J Vasc Surg 2004; 39:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/67\">",
"      Hooten WM, Bruns HK, Hays JT. Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease). Mayo Clin Proc 1998; 73:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/68\">",
"      Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. The European TAO Study Group. Eur J Vasc Endovasc Surg 1998; 15:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/69\">",
"      Fiessinger JN, Sch&auml;fer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet 1990; 335:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/70\">",
"      Bozkurt AK, K&ouml;ksal C, Demirbas MY, et al. A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease. Int Angiol 2006; 25:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/71\">",
"      Labropoulos N, Watson WC, Mansour MA, et al. Acute effects of intermittent pneumatic compression on popliteal artery blood flow. Arch Surg 1998; 133:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/72\">",
"      Montori VM, Kavros SJ, Walsh EE, Rooke TW. Intermittent compression pump for nonhealing wounds in patients with limb ischemia. The Mayo Clinic experience (1998-2000). Int Angiol 2002; 21:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/73\">",
"      Paraskevas KI, Liapis CD, Briana DD, Mikhailidis DP. Thromboangiitis obliterans (Buerger's disease): searching for a therapeutic strategy. Angiology 2007; 58:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/74\">",
"      Isner JM, Baumgartner I, Rauh G, et al. Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 1998; 28:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/75\">",
"      Kim HJ, Jang SY, Park JI, et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 2004; 36:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/76\">",
"      Fadini GP, Agostini C, Avogaro A. Autologous stem cell therapy for peripheral arterial disease meta-analysis and systematic review of the literature. Atherosclerosis 2010; 209:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/77\">",
"      Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008; 156:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/78\">",
"      Motukuru V, Suresh KR, Vivekanand V, et al. Therapeutic angiogenesis in Buerger's disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J Vasc Surg 2008; 48:53S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/79\">",
"      Saito S, Nishikawa K, Obata H, Goto F. Autologous bone marrow transplantation and hyperbaric oxygen therapy for patients with thromboangiitis obliterans. Angiology 2007; 58:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/80\">",
"      Durdu S, Akar AR, Arat M, et al. Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg 2006; 44:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/81\">",
"      Boda Z, Udvardy M, R&aacute;zs&oacute; K, et al. Stem cell therapy: a promising and prospective approach in the treatment of patients with severe Buerger's disease. Clin Appl Thromb Hemost 2009; 15:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/82\">",
"      Inan M, Alat I, Kutlu R, et al. Successful treatment of Buerger's Disease with intramedullary K-wire: the results of the first 11 extremities. Eur J Vasc Endovasc Surg 2005; 29:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/83\">",
"      Miyamoto K, Nishigami K, Nagaya N, et al. Unblinded pilot study of autologous transplantation of bone marrow mononuclear cells in patients with thromboangiitis obliterans. Circulation 2006; 114:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/84\">",
"      Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/85\">",
"      Yasuda K, Sakuma M, Tanabe T. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Arzneimittelforschung 1985; 35:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/86\">",
"      Dean SM, Satiani B. Three cases of digital ischemia successfully treated with cilostazol. Vasc Med 2001; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/87\">",
"      Sayin A, Bozkurt AK, T&uuml;z&uuml;n H, et al. Surgical treatment of Buerger's disease: experience with 216 patients. Cardiovasc Surg 1993; 1:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/88\">",
"      Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg 1997; 13:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/89\">",
"      Singh I, Ramteke VK. The role of omental transfer in Buerger's disease: New Delhi's experience. Aust N Z J Surg 1996; 66:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/90\">",
"      Talwar S, Jain S, Porwal R, et al. Free versus pedicled omental grafts for limb salvage in Buerger's disease. Aust N Z J Surg 1998; 68:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/91\">",
"      Agarwal VK. Long-term results of omental transplantation in chronic occlusive arterial disease (Buerger's disease) and retinal avascular diseases (retinitis pigmentosa). Int Surg 2007; 92:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/92\">",
"      Nishikimi N. Fate of limbs with failed vascular reconstruction in Buerger's disease patients. Int J Cardiol 2000; 75 Suppl 1:S183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/93\">",
"      Lazarides MK, Georgiadis GS, Papas TT, Nikolopoulos ES. Diagnostic criteria and treatment of Buerger's disease: a review. Int J Low Extrem Wounds 2006; 5:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/94\">",
"      Durai R, Hoque H. Chemical sympatholysis: indications, technique and complications. Br J Hosp Med (Lond) 2008; 69:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/95\">",
"      Ates A, Yekeler I, Ceviz M, et al. One of the most frequent vascular diseases in northeastern of Turkey: Thromboangiitis obliterans or Buerger's disease (experience with 344 cases). Int J Cardiol 2006; 111:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/96\">",
"      Chander J, Singh L, Lal P, et al. Retroperitoneoscopic lumbar sympathectomy for buerger's disease: a novel technique. JSLS 2004; 8:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/97\">",
"      Watarida S, Shiraishi S, Fujimura M, et al. Laparoscopic lumbar sympathectomy for lower-limb disease. Surg Endosc 2002; 16:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/98\">",
"      De Giacomo T, Rendina EA, Venuta F, et al. Thoracoscopic sympathectomy for symptomatic arterial obstruction of the upper extremities. Ann Thorac Surg 2002; 74:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/99\">",
"      Rizzo M, Balderson SS, Harpole DH, Levin LS. Thoracoscopic sympathectomy in the management of vasomotor disturbances and complex regional pain syndrome of the hand. Orthopedics 2004; 27:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/100\">",
"      Swigris JJ, Olin JW, Mekhail NA. Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger's disease). J Vasc Surg 1999; 29:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/101\">",
"      Chierichetti F, Mambrini S, Bagliani A, Odero A. Treatment of Buerger's disease with electrical spinal cord stimulation--review of three cases. Angiology 2002; 53:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/102\">",
"      Pace AV, Saratzis N, Karokis D, et al. Spinal cord stimulation in Buerger's disease. Ann Rheum Dis 2002; 61:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/103\">",
"      Donas KP, Schulte S, Ktenidis K, Horsch S. The role of epidural spinal cord stimulation in the treatment of Buerger's disease. J Vasc Surg 2005; 41:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/62/8170/abstract/104\">",
"      Hussein EA, el Dorri A. Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials. Int Surg 1993; 78:54.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8205 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8170=[""].join("\n");
var outline_f7_62_8170=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H234644142\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H514794264\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H514794398\">",
"      CLINICAL AND LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87000089\">",
"      Vascular evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H86999828\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86999781\">",
"      Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H461453879\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268457206\">",
"      Iloprost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268457398\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268457455\">",
"      Intermittent pneumatic compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H268457277\">",
"      Experimental therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234644233\">",
"      INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Revascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Sympathectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87009583\">",
"      Other interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87000741\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234644142\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8205|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/17/8467\" title=\"diagnostic image 1\">",
"      Hand arteriogram in thromboangiitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8205|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/13/1240\" title=\"picture 1\">",
"      Histologic changes in thromboangiitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/42/4769\" title=\"picture 2\">",
"      Ulcerations and gangrene in thromboangiitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/52/40771\" title=\"picture 3\">",
"      The Allen test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8205|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/12/31948\" title=\"table 1\">",
"      Differential diagnosis of thromboangiitis obliterans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/40/19078?source=related_link\">",
"      Clinical assessment of wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/39/23162?source=related_link\">",
"      Endothelial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28200?source=related_link\">",
"      Initial treatment of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19370?source=related_link\">",
"      Treatment of chronic lower extremity critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_62_8171="Antiadrenal antibodies";
var content_f7_62_8171=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of antiadrenal antibodies in patients with autoimmune disease of other endocrine glands",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Autoimmune endocrine disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence of antiadrenal antibodies, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoparathyroidism",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Goitrous autoimmune thyroiditis",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atrophic autoimmune thyroiditis",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperthyroidism",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pernicious anemia",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8171=[""].join("\n");
var outline_f7_62_8171=null;
var title_f7_62_8172="Key questions for tired patient";
var content_f7_62_8172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F86812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F86812&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Key questions in evaluating the tired patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Key questions in the evaluation of a patient who complains of sleepiness, tiredness, fatigue, or low energy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Questions about sleep and sleepiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Do you feel sleepy during the day?",
"        </p>",
"        <p>",
"         Is daytime sleepiness a problem for you?",
"        </p>",
"        <p>",
"         Is it difficult to keep your eyes open at times during the day?",
"        </p>",
"        <p>",
"         Do you struggle to stay awake during the day?",
"        </p>",
"        <p>",
"         Do you take naps?",
"        </p>",
"        <p>",
"         How often and how long do you nap during the day?",
"        </p>",
"        <p>",
"         Do you fall asleep at times you do not want to (ie, watching a movie, reading a book, or on long drives)?",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Questions about tiredness, fatigue, and low energy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Do you lack the energy to go about your daily activities?",
"        </p>",
"        <p>",
"         Do you tire easily, or sooner than others, when you are active?",
"        </p>",
"        <p>",
"         Do you feel physically or mentally exhausted?",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Questions to differentiate sleepiness from related complaints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Does your problem bother you more if you sit to read for an hour, or if you go out shopping for an hour?",
"        </p>",
"        <p>",
"         Which of the following is the single most important problem for you: sleepiness, tiredness, fatigue, or lack of energy?",
"        </p>",
"        <p>",
"         Which of the following most interferes with your ability to accomplish what you would like to: sleepiness, tiredness, fatigue, or lack of energy?",
"        </p>",
"        <p>",
"         Which of the following is the one problem you would most like to address effectively: sleepiness, tiredness, fatigue, or lack of energy?",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bodkin CL, Manchanda S. Office evaluation of the \"tired\" or \"sleepy\" patient. Semin Neurol 2011; 31:42.",
"      </li>",
"      <li>",
"       Chervin RD. Sleepiness, fatigue, tiredness, and lack of energy in obstructive sleep apnea. Chest 2000; 118:372.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8172=[""].join("\n");
var outline_f7_62_8172=null;
var title_f7_62_8173="Decisions regarding daily HD options";
var content_f7_62_8173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F87704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F87704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm of decisions regarding daily hemodialysis options",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 242px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Golper TA, Clark JA, Majors DS, et al. Practical Aspects of Hybrid Dialysis Techniques. In: Critical Care Nephrology, 2nd ed, Ronco C, Bellomo R, Kellum J (Eds), Saunders Elsevier, Philadelphia, 2009. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8173=[""].join("\n");
var outline_f7_62_8173=null;
var title_f7_62_8174="Dosing schedules immunotherapy";
var content_f7_62_8174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing schedules for fire ant immunotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Schedule 1",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Schedule 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Dose number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Concentration (weight/volume)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose number",
"       </td>",
"       <td class=\"subtitle2\">",
"        Concentration (weight/volume)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.05 mL",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.10 mL",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.15 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.20 mL",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.25 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.30 mL",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.50 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.40 mL",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        1:100,000",
"       </td>",
"       <td>",
"        0.50 mL",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.05 mL",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.10 mL",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.30 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.20 mL",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.30 mL",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.50 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.40 mL",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        1:10,000",
"       </td>",
"       <td>",
"        0.50 mL",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.05 mL",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.10 mL",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.30 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.20 mL",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.30 mL",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.50 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.40 mL",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.05 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        1:1000",
"       </td>",
"       <td>",
"        0.50 mL",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.07 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.05 mL",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.10 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.10 mL",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.15 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.15 mL",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.20 mL",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.25 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.25 mL",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.30 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.30 mL",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.40 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.35 mL",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.50 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.40 mL",
"       </td>",
"       <td colspan=\"3\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.45 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        1:100",
"       </td>",
"       <td>",
"        0.50 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moffitt JE, Golden DB, Reisman RE, et al. Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol 2004; 114:869. Copyright &copy; 2004 The American Academy of Allergy, Asthma, and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8174=[""].join("\n");
var outline_f7_62_8174=null;
var title_f7_62_8175="Otorrhea inflammation";
var content_f7_62_8175=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Otorrhea with external auditory canal inflammation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 438px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TM: tympanic membrane.",
"     <br>",
"      * Reexamine the ear after foreign body removal to ensure no tympanic membrane perforation or concurrent ear disease.",
"      <br>",
"       &bull; Concurrent tympanostomy tube drainage or acute otitis media may be present.",
"       <br>",
"        &Delta; Often thin brown otorrhea with pruritis.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_62_8175=[""].join("\n");
var outline_f7_62_8175=null;
